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Abstract	
	
Endogenous	 retroviruses	 (ERVs)	 have	 accumulated	 in	 vertebrate	 genomes	 and	
contribute	 to	 the	 complexity	of	 gene	 regulation.	 ERVs	are	beneficial	 to	 their	hosts	
because	their	promoters	can	drive	temporal	and	spatial	expression	of	cellular	genes.	
Aberrantly	 activated	 ERVs,	 however,	 can	 be	 detrimental.	 ERV	 transcription	 is	
therefore	controlled	by	multiple	epigenetic	modifiers.	One	ERV	repression	pathway	
involves	 KAP1	 and	 Krüppel-associated	 box	 domain-zinc	 finger	 proteins	 (KZNFs),	
which	 recruit	 KAP1	 to	 ERVs	 and	 other	 repetitive	 sequences	 early	 in	 development.	
Little	 is	 known,	 in	 contrast,	 about	 the	 regulation	 of	 ERVs	 in	 differentiated	 cells,	
particularly	 in	 humans.	 In	 this	 thesis,	 we	 aimed	 firstly	 to	 address	 the	 question	 of	
whether	 KAP1	 and	 related	 epigenetic	 factors	 are	 necessary	 to	 repress	 ERVs	 in	
differentiated	 human	 cells.	 Secondly,	 we	 sought	 to	 assess	 the	 impact	 of	 ERV	
reactivation	on	 the	 innate	 immune	system.	We	 found	 through	KAP1	knockout	and	
mRNA-sequencing	 analyses	 that	 KAP1	 represses	 ERVs	 and	 ZNFs,	 both	 of	 which	
overlap	with	 KAP1	 binding	 sites	 and	 silent	 chromatin	marks	 in	multiple	 cell	 types.	
Furthermore,	 this	 pathway	 is	 functionally	 conserved	 in	 primary	 human	 peripheral	
blood	mononuclear	cells	 (PBMCs).	We	show	that	cytosine	methylation	that	acts	on	
KAP1-regulated	 loci	 is	 necessary	 to	 prevent	 immune	 reactivity	 of	 ERVs	 and	 other	
retrotransposons	 that	 can	mimic	 viruses	 by	 producing	 immunostimulatory	 nucleic	
acids.	While	KAP1	depletion	alone	leads	to	activation	of	several	chemokines,	it	is	not	
sufficient	 for	 global	 induction	 of	 interferon-stimulated	 genes.	 Therefore,	 we	
depleted	key	epigenetic	complexes	that	KAP1	collaborates	with	including	the	HUSH	
complex	 comprising	 MPP8,	 Periphilin	 and	 Tasor.	 We	 identified	 MPP8	 to	 play	 a	
dominant	role	 in	preventing	aberrant	 immune	activation	 in	human	cells.	MPP8	 is	a	
chromodomain	protein	 implicated	 in	the	spread	of	heterochromatin.	 In	sum,	these	
data	indicate	that	the	KAP1-KZNF	pathway	and	MPP8	are	central	to	genome	stability	
and	the	control	of	viral	mimicry	in	differentiated	human	cells.			
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Abbreviations	
5-Aza	 5-Aza-2’-deoxycytidine	
Ago	 Argonaute	
AIM2	 Absent	In	Melanoma	2	
ALS	 Amyotrophic	Lateral	Sclerosis	
Alu	 Arthrobacter	luteus		
ALV	 Avian	Leucosis	Virus	
ATRX	
Β2M	
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CD	 Cluster	of	Differentiation	
cGAMP	 2’3’	cyclic-AMP-GMP	
cGAS	 cyclic	GMP-AMP	Synthase	
DAI	 DNA-dependent	Activator	of	IFN	regulatory	factor	
DAMP	 Danger-Associated	Molecular	Pattern	
DAXX	 Death-domain-Associated	protein	
DLBCL	 Diffuse	Large	B	Cell	Lymphoma	
DNMT		 DNA	Methyltransferase	
dNTP	 deoxynucleotide	
dsRNA	 double	stranded	RNA	
EBP1	 ErbB3-Binding	Protein	1	
ENV	 Envelope	
eRNA	 enhancer	RNA	
ERV	 Endogenous	Retrovirus	
ESC	 Embryonic	Stem	Cell	
ETn	 Early	Transposable	element	
GAG	 Group-specific	Antigen	
H3K27ac	 acetylation	of	Histone	3	at	Lysine	27	
H3K27me3	 trimethylation	of	Histone	3	at	Lysine	27	
H3K4me1	 monomethylation	of	Histone	3	at	Lysine	4	
H3K9me3	 trimethylation	of	Histone	3	at	Lysine	9	
H4K20me3	 trimethylation	of	Histone	4	at	Lysine	20	
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HDAC	 Histone	Deacetylase	
HEK293	 Human	Embryonic	Kidney	293	cells	
HEK293T	 Human	Embryonic	Kidney	293	cells	with	T-antigen	
HERV	 Human	Endogenous	Retrovirus	
HIV	 Human	Immunodeficiency	Virus	
HL	 Hodgkin’s	Lymphoma	
HMTase	 Histone	Methyltransferase	
HP1	 Heterochromatin	Protein	1	
HSP90	 Heat	Shock	Protein	90	
HUSH	 Human	Silencing	Hub		
IAP	 Intracisternal A Particle 
IDDM	 Insulin-Dependent	Diabetes	Mellitus	
IFI16	 IFN-γ-inducible	protein	16	
IFN	 Interferon	
IL	 Interleukin	
iPSC	 induced	Pluripotent	Stem	Cell	
IRF5	
ISG	
Interferon	Regulatory	Factor	5	
Interferon-stimulated	gene	
ISRE	 IFN-Stimulated	Regulatory	Element	
JSRV	 Jaagsiekte	Sheep	Retrovirus	
KAP1	 KRAB-Associated	Protein	1	
KRAB	 Krüppel-associated	box	
kb	 kilo	base	pairs	
KD	 Knockdown		
KO		 Knockout		
KZNF	 KRAB	Zinc	Finger	Protein	
LINE	 Long	Interspersed	Nuclear	Element		
lncRNA		 long	non-coding	RNA	
LSD1	 Lysine	Specific	Demethylase	1A	
LSH1	 Lymphoid-Specific	Helicase	1	
LTR	 Long	Terminal	Repeat	
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LTR	 Long	Terminal	Repeat	
MaLR	 Mammalian	apparent	LTR	Retrotransposon	
MDA5	 Melanoma	Differentiation-Associated	gene	5	
MeCP2	 Methyl-CpG-binding	Protein	2	
MERV-L	 Murine	ERV-L	
miRNA	 microRNA	
MLV	 Murine	Leukemia	Virus	
MMTV	 Mouse	Mammary	Tumour	Virus	
MPP8	 MPHOSPH8		
mRNA	 messenger	RNA	
MS	 Multiple	Sclerosis	
MyD88	 Myeloid	Differentiation	factor	88	
NPC	 Neural	Progenitor	Cells	
ORF	 Open	Reading	Frame	
ORF1p	 Open	Reading	Frame	I	product	
ORF2p	 Open	Reading	Frame	II	product	
PAMP	 Pathogen-Associated	Molecular	Patterns	
PBMC	 Peripheral	Blood	Mononuclear	Cell	
PBS	 Primer	Binding	Site	
PHD	 Plant	Homeodomain	
piRNA	 Piwi-interacting	RNA	
POL	 Polymerase	
Pol	II	 RNA	Polymerase	II	
Pol	III		 RNA	Polymerase	III	
Poly-A	 Polyadenylation	
pri-miRNA	 primary	miRNA	transcript	
PRR	 Pattern	Recognition	Receptor	
RA		 Rheumatoid	Arthritis	
RBCC	 RING-B-box-Coiled-coil	
RIG-I	 Retinoic	acid-Inducible	Gene	I	
RISC	 RNA-Induced	Silencing	Complex	
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RLP	 Retroviral	Like	Particle	
RLR	 RIG-I	Like	Receptor	
RNP	 Ribonucleoprotein	
RT	 Reverse	transcriptase	
SINE	 Short	Interspersed	Nuclear	Element		
siRNA	 short	/	small	interfering	RNA	
SLE	 Systemic	Lupus	Erythematosus	
ssDNA	 single	stranded	DNA	
STING	 Stimulator	of	IFN	genes	
SVA	 SINE-VNTR-Alu	
TE	 Transposable	Element	
TFIIB	 Transcription	Factor	II	B	
TFIIC	 Transcription	Factor	II	C	
TFRC	 Transferrin	Receptor	
Th1	 Type	1	T	helper	cell	
TIR	 Toll-IL-1-Resistance	
TLR	 Toll-Like	Receptor	
TM	 Transmembrane	
TNF	 Tumour	Necrosis	Factor	
TPRT	 Target	site	Primed	Reverse	Transcription	
tRNA	 transfer	RNA	
TSA	 Trichostatin	A	
TSD	 Target	Site	Duplication	
UTR	 Untranslated	Region	
VLP	 Virus	Like	Particle	
VSV	 Vesicular	stomatitis	virus	
VNTR	 Variable	Number	of	Tandem	Repeat		
XRV	 Exogenous	Retrovirus	
ZFP	 Zinc	Finger	Protein	
ZNF	 Zinc	Finger	Protein	
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Chapter	1:	Introduction	
1.1	What	are	transposable	elements	(TEs)?	
When	Barbara	McClintock	 first	 discovered	 a	 ‘controlling	 element’	 in	 the	maize	
genome	 in	 the	1950s,	 the	 idea	of	 transposon-mediated	gene	 regulation	was	novel	
and	controversial	(McClintock,	1956).	This	new	paradigm	was	further	developed	by	
Britten	 and	 Davidson	 and	 they	 subsequently	 postulated	 a	 model	 in	 which	 repeat	
families	 could	 amplify	 a	 set	 of	 regulatory	 elements	 resulting	 in	 complex	 gene	
regulatory	networks	(Britten	and	Davidson,	1971).	Despite	so,	repetitive	DNA	is	still	
often	 referred	 to	 as	 “selfish-DNA”	 or	 “junk	DNA”.	 TEs	 remain	 understudied	 (Orgel	
and	 Crick,	 1980)	 but	 with	 the	 advancement	 of	 genome	 sequencing	 and	
bioinformatics	 tools,	 scientists	are	 starting	 to	comprehend	 the	proportion	of	 these	
‘controlling	elements’	 in	mammalian	genomes	(Lander	et	al.,	2001).	Their	 identities	
and	functions	are	also	starting	to	be	revealed.	
TEs	refer	to	a	stretch	of	DNA	sequence	that	is	mobile.	TEs	can	be	divided	into	
two	 classes	 namely	 retrotransposons	 and	 DNA	 transposons.	 Retrotransposons	 are	
capable	of	replicating	themselves	via	the	copy-and-paste	mechanism	through	a	RNA	
intermediate	reminiscent	to	the	replication	mechanism	used	by	retroviruses	like	HIV.	
Retrotransposons	 are	 successful	 in	 colonising	 our	 genome	 and	 they	 have	
accumulated	to	at	least	50%	of	the	human	genome	(de	Koning	et	al.,	2011;	Goodier	
and	Kazazian,	2008;	Rebollo	et	al.,	 2012).	Retrotransposons	 can	be	 further	divided	
into	 long	 terminal	 repeats	 (LTR)	 retrotransposons	 and	 non-LTR	 retrotransposons	
(Figure	1).	
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Figure	1	Types	of	transposable	elements	(TEs)	in	the	human	genome.		
The	 majority	 of	 transposon-derived	 repeats	 in	 the	 human	 genome	 are	 retrotransposons,	 which	
represent	50%	of	our	genome.	TEs	can	be	categorised	based	on	the	presence	of	LTRs	and	on	whether	
or	 not	 they	 can	 replicate	 autonomously.	 ERVs	 and	 LINEs	 are	 autonomous	 families	while	 SINEs	 are	
non-autonomous.	
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Figure	2	Structure	of	endogenous	retroviruses	(ERVs).	
A	 canonical	 ERV	 provirus	 with	 gag,	 pol,	 and	 env	 genes	 is	 shown	 here.	 The	 identical	 long-terminal	
repeats	 (LTRs)	 comprising	 direct	 repeats	 of	 the	U5,	 R,	 and	U3	 elements	 flank	 the	 internal	 protein-
coding	genes.	A	primer-binding	site	(PBS),	which	 is	necessary	for	reverse	transcription	can	be	found	
within	the	5’-UTR	region	of	the	provirus.	
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1.1.1	ERVs		
Endogenous	 retroviruses	 (ERVs)	 are	 a	 group	 of	 autonomous	 LTR	
retrotransposons	 	 in	 the	 human	 genome.	 They	 constitute	 around	 7-8%	 of	 our	
genome	 and	 are	 believed	 to	 be	 the	 remnants	 of	 ancient	 germ-line	 retroviral	
infections	(Belshaw	et	al.,	2004;	Jern	and	Coffin,	2008;	Lander	et	al.,	2001).	
A	typical	ERV	is	made	up	of	gag,	pol,	and	env	genes	and	is	flanked	by	LTRs	at	
both	3’	and	5’	ends	(Figure	2).	However,	random	mutations	and	deletions	over	the	
evolutionary	 timeline	 has	 led	 to	 either	 inactivation	 of	 the	 proviruses	 or	 restricted	
them	to	be	intracellular	pathogens	(Ribet	et	al.,	2008).	As	a	result,	their	genomic	size	
can	 vary	 from	 around	 several	 hundred	 base	 pairs	 to	 12kb.	Many	 of	 the	 ERV	 loci,	
however,	 still	 contain	 intact	 regulatory	 elements	 and	 can	be	 transmitted	 vertically	
from	 one	 host	 generation	 to	 the	 next	 as	 a	 gene	 allele	 (Boeke	 and	 Stoye,	 1997).	
Deletions	of	the	env	gene	has	rendered	ERV	an	intracellular	pathogen	and	has	been	
proposed	 to	 have	 increased	 their	 retrotransposition	 potential	 making	 them	
‘superspreaders’	 (Magiorkinis	 et	 al.,	 2012)	 (Figure	 3).	 While	 the	 working	 model	
seems	 plausible,	 there	 are	 also	 examples	 in	 which	 ancient	 retrotransposons	 have	
captured	 an	 env	 gene	 and	 successfully	 escaped	 from	 the	 host	 (Malik	 et	 al.,	 2000;	
Song	et	al.,	1994).	As	a	result,	the	exact	origin	of	ERV	is	still	being	debated.	
In	 an	 effort	 to	understand	 the	origin	 and	 age	of	 ERVs	 in	mammals,	 several	
methods	 have	 been	 deployed	 including	 looking	 at	 the	 integration	 histories	 and	
analysing	 host-virus	 co-phylogenetic	 relationships	 (Hayward,	 2017).	 Integration	
analysis	looks	at	the	divergence	between	the	5’	and	3’	LTRs	of	a	provirus	in	order	to	
estimate	the	dates	of	ERV	integrations.	However,	this	method	is	restricted	to	recent	
integrants	because	sequence	erosion	of	the	older	copies	limits	the	usefulness	of	such		
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Figure	3	Life	cycle	of	ERVs.		
Retroviral	 infection	 involves	 the	 following	 steps:	 binding	 to	 a	 specific	 receptor	 on	 the	 target	 cell	
surface;	 membrane	 fusion	 or	 receptor-mediated	 endocytosis;	 release	 of	 the	 viral	 core;	 reverse	
transcription;	 transit	 through	 the	cytoplasm	and	nuclear	entry;	and	 integration	 into	cellular	DNA	to	
give	rise	to	a	provirus.	In	the	case	of	ERVs,	deletion	of	the	env	gene	means	that	the	transcription	(Pol	
II	mediated)	and	 translation	of	 the	viral	 capsid	and	enzyme	proteins	 fuel	 the	next	 round	of	 reverse	
transcription	and	integration	(known	as	retrotransposition)	within	the	same	host	without	the	budding	
stage.	
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method.	 The	 alternative	 approach	 involves	 screening	 the	 host	 genome	 for	
orthologous	ERVs.	A	shared	ERV	locus	is	strong	indication	of	a	common	ancestor	in	
which	 the	 integration	 event	 occurred.	 Using	 this	 approach,	 ERV-L	 elements	 have	
been	found	to	be	widespread	among	placental	mammals	and	are	estimated	to	have	
integrated	into	the	genome	~104-110	million	years	ago	(Lee	et	al.,	2013a).	The	third	
method	 involves	 looking	 at	 the	 host-virus	 co-evolutionary	 relationships	 but	 this	
approach	is	restricted	to	retroviruses	with	relatively	few	cross-species	transmissions	
such	as	spumaretroviruses	(foamy	viruses)	(Switzer	et	al.,	2005).	
	
1.1.1.1	Life	cycle	of	ERVs	
Retroviruses	 such	 as	 human	 immunodeficiency	 virus	 (HIV)	 and	 murine	
leukaemia	virus	 (MLV)	are	capable	of	 reverse	 transcribing	 their	positive-sense	RNA	
genomes	 into	 DNA	 with	 the	 help	 of	 the	 reverse	 transcriptase	 enzyme	 (Hu	 and	
Hughes,	2012).	The	DNA	is	then	integrated	into	the	host	genome	with	the	help	of	a	
virally-encoded	integrase	enzyme	(Craigie	and	Bushman,	2012).	Once	integrated	into	
the	germline,	the	provirus	stays	 in	the	host	and	the	sequence	can	be	passed	down	
vertically.	The	viral	genes	can	 then	be	 transcribed	and	 translated,	with	 the	help	of	
host	cellular	machinery,	producing	proteins	required	for	the	assembly	of	new	virus	
particles	 for	 as	 long	 as	 the	 infected	 cell	 is	 alive	 (Sundquist	 and	 Kräusslich,	 2012).	
ERVs	 have	 a	 similar	 life	 cycle	 to	 their	 exogenous	 counterparts	 except	 for	 the	
extracellular	steps	potentially	due	to	the	deletion	of	env	gene	(Figure	3).		
1.1.1.2	Classification	
The	 lack	 of	 a	 clear	 classification	 and	 consensus	 nomenclature	 for	 ERVs	 has	
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complicated	 their	 study.	 Several	 methods	 have	 been	 used	 to	 classify	 ERVs.	
Historically,	 it	 was	 common	 to	 name	 a	 newly	 discovered	 ERV	 based	 on	 the	 RT	
sequence	similarity	 to	 its	exogenous	counterpart.	Under	 such	a	 system,	ERVs	have	
been	 divided	 into	 three	 classes	 named	 Class	 I	 to	 III	 for	 Gammaretrovirus-like,	
Betaretrovirus-like	 and	 Spumaretrovirus-like	 elements,	 respectively	 (Jern	 et	 al.,	
2005).	 This	 method	 later	 proved	 to	 be	 over	 simplistic	 following	 the	 discovery	 of	
additional	ERVs	(Gifford	et	al.,	2008;	Katzourakis	et	al.,	2007b).	A	second	strategy	has	
been	to	classify	ERVs	based	on	their	primer	binding	site	(PBS)	sequences	within	their	
5’	untranslated	regions	(UTRs).	The	PBS	sequence	dictates	the	specific	tRNA	used	by	
the	 virus	 for	 priming	 the	 reverse	 transcription	 of	 its	 RNA.	 Previously	 identified	
Betaretrovirus-like	 ERV	 groups,	 due	 to	 their	 similarity	 to	 MMTV,	 were	 then	
regrouped	 into	 the	 HERV-K	 super-group	 under	 the	 PBS	 classification	 method	
(Blomberg	et	al.,	2009).	This	was	later	proved	to	be	misleading	with	the	availability	
of	 larger	 sequence	datasets	 as	not	 all	 elements	under	 the	HERV-K	 group	have	 the	
same	 PBS	 sequence	 (Gifford	 and	 Tristem,	 2003;	 Lavie	 et	 al.,	 2004).	 In	 addition	 to	
that,	 because	 ERV	 sequences	 are	 part	 of	 the	 genome,	 they	 can	 also	 be	 named	 as	
genetic	loci.	However,	this	has	led	to	much	confusion	as	they	were	named	based	on	
multiple	criteria,	for	instance	on	their	flanking	sequence,	chromosomal	band	or	even	
the	probe	used	for	their	cloning.		
Sequence	similarity	between	individual	ERVs	is	another	widely	used	method	
for	 grouping	 ERVs.	 In	 this	 case,	 the	more	 conserved	 coding	 domain	 such	 as	 Pol	 is	
used	 as	 a	 template	 because	 it	 makes	 sequence	 recognition	 and	 alignment	 easier	
(Fitch,	1987).	The	same	strategy	can	also	be	extended	to	include	protein	alignments	
using	 the	 same	 region.	 Alternatively,	 LTR	 sequences	 can	 also	 be	 useful	 to	 classify	
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ERVs	 including	solo	LTRs	or	copies	devoid	of	Pol	 (Jern	and	Coffin,	2008;	 Jern	et	al.,	
2005).	 This	 is	 done	 by	 comparing	 a	 new	 LTR	 sequence	 to	 the	 database	 (such	 as	
Repbase)	 but	 it	 can	 get	 tricky	 when	 grouping	 recombined	 LTR	 sequences	
(Katzourakis	et	al.,	2007a).	Both	methods	essentially	divide	ERV	sequences	into	LTR	
and	internal	sequences	for	analysis.	
1.1.2	LINEs		
LINEs	 are	 a	 group	 of	 autonomous	 non-LTR	 retrotransposons	 ubiquitously	
found	 in	 the	human	genome.	While	 this	 class	 is	made	up	of	 LINE1	 (L1),	 LINE2	 (L2)	
and	LINE3	(L3)	elements,	L1	is	the	only	group	that	is	still	active	today	(Lander	et	al.,	
2001).	 L1	 is	 also	 the	 most	 successful	 TE	 in	 the	 human	 genome	 by	 mass	 and	 it	
constitutes	 approximately	 17%	 of	 our	 genome	 resulting	 from	 its	 activities	 for	 the	
past	150	million	years	(Lander	et	al.,	2001).	
A	 canonical,	 full	 length	 human	 L1	 is	 around	 6kb	 in	 length.	 The	 element	 is	
comprised	of	an	internal	RNA	polymerase	II	(Pol	II)	promoter	at	the	5’-untranslated	
region,	two	non-overlapping	open	reading	frames	(ORF1	and	ORF2)	separated	by	a	
short	 inter-ORF	 spacer	 and	 a	 3’	 UTR	 containing	 a	 polyadenylation	 (poly-A)	 signal	
ending	with	 an	oligo	dA-rich	 tail	 of	 variable	 length	 (Babushok	 and	Kazazian,	 2007)	
(Figure	4).	ORF1	encodes	a	40kDa	RNA-binding	protein	(ORF1p)	that	shares	little	to	
no	 homology	 with	 known	 proteins,	 leaving	 its	 origins	 and	 its	 role	 in	
retrotransposition	 unknown.	 ORF2	 encodes	 a	 150kDa	 protein	 (ORF2p)	 with	
endonuclease	 (Feng	 et	 al.,	 1996)	 and	 reverse	 transcriptase	 (Mathias	 et	 al.,	 1991)	
activities	 (Babushok	 and	 Kazazian,	 2007).	 The	 poly-A	 signal	 (AATAAA)	 within	 L1	 is	
commonly	read	through	during	transcription	resulting	in	‘chimeric’	L1	transcripts		
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Figure	4	Structure	of	a	LINE1	(L1)	element.	
During	integration,	L1	elements	induce	target	site	duplications	at	both	5’	and	3’	ends.	Abbreviations:	
An,	poly-A.	
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composed	of	3’	flanking	sequences	and	L1	sequences	(Holmes	et	al.,	1994;	Moran	et	
al.,	1999;	Moran	et	al.,	1996).	
1.1.2.1	Life	cycle	of	LINE1	
Out	of	 the	>500,000	 L1	elements	 inserted	 in	 the	human	genome,	 less	 than	
100	 copies	 (<0.1%)	 are	 intact	 due	 to	 5’	 truncations,	 internal	 rearrangements	 and	
mutations	 (Grimaldi	et	al.,	 1984;	 Lander	et	al.,	 2001;	Ostertag	and	Kazazian,	2001;	
Szak	et	al.,	2002).	Most	retrotransposition	in	the	human	population	is	believed	to	be	
the	 result	 of	 a	 number	 of	 highly	 active	 L1	 loci	 (Brouha	 et	 al.,	 2003).	 The	
retrotransposition	of	L1	starts	with	the	transcription	at	the	internal	Pol	 II	promoter	
within	the	5’	UTR	(Swergold,	1990).	The	L1’s	5’	UTR	promoter	is	bidirectional	and	it	
can	 direct	 transcription	 in	 sense	 as	 well	 as	 antisense	 direction	 resulting	 in	 the	
production	of	chimeric	transcripts	containing	both	L1	5’	UTR	and	genomic	sequences	
upstream	 of	 the	 5’	 end	 of	 that	 L1	 locus	 (Nigumann	 et	 al.,	 2002;	 Speek,	 2001).	
Translated	ORF1p	and	ORF2p	preferentially	bind	to	the	mRNAs	from	which	they	are	
derived,	a	phenomenon	known	as	cis-preference	(Kulpa	and	Moran,	2006;	Wei	et	al.,	
2001)	 and	 this	 results	 in	 the	 formation	 of	 L1	 ribonucleoprotein	 (RNP)	 particle	
(Hohjoh	and	Singer,	1996;	Kulpa	and	Moran,	2005;	Martin,	1991).	The	RNP	particle	
then	 enters	 the	 nucleus	 (Kubo	 et	 al.,	 2006)	 where	 L1	 target-site	 primed	 reverse	
transcription	 (TPRT)	 takes	 place	 (Cost	 et	 al.,	 2002;	 Feng	 et	 al.,	 1996;	 Luan	 et	 al.,	
1993).	
During	 TPRT,	ORF2p	 generates	 a	 single	 strand	endonucleolytic	 break	 in	 the	
genomic	DNA	via	its	endonuclease	activity	to	expose	a	3’-OH	(Feng	et	al.,	1996).	The	
liberated	3’-OH	is	then	utilised	as	a	primer	by	the	reverse	transcriptase	to	initiate	
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Figure	5	L1	retrotransposition	mechansim.	
Inactive	L1	is	either	dead	due	to	mutations	or	under	the	regulation	of	transcription	factors	in	a	tissue-
specific	manner.	Factors	such	as	MeCP2	and	Sox2	have	been	demonstrated	to	regulate	L1	in	neuronal	
cell	 types.	 For	 L1	 to	 retrotranspose,	 L1	 RNA	 is	 first	 transcribed	 by	 RNA	 polymerase	 II	 and	 then	
translated.	 This	will	 give	 rise	 to	multiple	 copies	 of	 ORF1p	 and	 as	 few	 as	 one	 copy	 of	 ORF2p.	 Both	
proteins	associate	with	 their	encoding	RNA	 to	assemble	 the	L1	 ribonucleoprotein	particle.	The	RNP	
then	enters	the	nucleus,	where	the	L1	endonuclease	activity	nicks	the	genomic	DNA	at	the	consensus	
5	-TTTT/A-3	to	 liberate	a	3-hydroxyl	(3’-OH)	residue.	The	3’-OH	serves	as	the	target	site	at	which	L1	
reverse	transcriptase	initiates	reverse	transcription	of	its	associated	L1	mRNA.	This	process,	known	as	
target-site-primed	reverse	transcription,	generates	a	new,	frequently	5	truncated	L1	insertion.	
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cDNA	synthesis	using	the	L1	mRNA	as	a	template	(Cost	et	al.,	2002;	Feng	et	al.,	1996;	
Kulpa	 and	 Moran,	 2006).	 The	 process	 generates	 a	 new	 L1	 copy	 that	 is	 generally	
flanked	by	7-20-bp	target	site	duplications	(TSDs)	(Kazazian	and	Moran,	1998)	(Figure	
5).	The	molecular	details	behind	TPRT	have	not	been	fully	elucidated.		
1.1.2.2	Classification	
The	replication	mechanism	adopted	by	L1	is	not	very	efficient	and	results	in	
defective	 copies	 with	 a	 truncation	 at	 their	 5’	 end	 due	 to	 its	 inefficient	 reverse	
transcriptase	but	exact	reason	behind	such	strategy	 is	unknown.	 In	addition	to	this	
region,	 the	 first	 third	 of	 ORF1	 and	 the	 3’	 UTR	 evolve	much	 faster	 than	 the	 other	
regions	 that	 presumably	 are	 crucial	 for	 L1’s	 biochemical	 function.	 The	 rapidly	
evolving	regions	may	either	encode	structures	that	are	secondary	for	L1	replication	
or	 they	 need	 to	 be	 adapted	 for	 different	 host	 species	 (Furano	 et	 al.,	 2006).		
Therefore,	the	highly	variable	non-coding	3’-UTR,	both	in	 length	and	sequence,	has	
been	used	in	many	of	the	diagnostic	differences	between	L1	families	within	a	species	
(Furano	et	al.,	2006;	Smit	et	al.,	1995).	The	L1	elements	also	accumulate	mutations	
at	 a	 neutral	 rate	 because	 the	 majority	 of	 L1	 inserts	 are	 pseudogenes	 and	 as	 a	
consequence	 older	 families	 become	 more	 divergent	 than	 the	 younger	 ones	
(Boissinot	et	al.,	2000;	Hardies	et	al.,	1986;	Pascale	et	al.,	1993;	Voliva	et	al.,	1984).	
This	can	be	verified	through	the	analysis	on	L1	families	revealing	that	a	single	lineage	
of	 L1	 families	 can	 amplify	 and	 evolve	 to	 replace	 its	 predecessor	 as	 the	 dominant	
family.	This	mode	of	evolution	can	be	observed	in	human	L1	families	over	the	last	25	
million	years	(Boissinot	and	Furano,	2001;	Smit	et	al.,	1995)	(Figure	6).		
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Figure	6	Evolution	of	L1.	
Phylogenetic	analyses	of	L1	in	primates	over	the	past	30	million	years	has	shown	the	continuous	demise	
of	 activity	 from	 the	 preceding	 L1	 family	 that	 coincides	 with	 the	 arrival	 of	 a	 new	 L1	 family.	 The	
nomenclature	of	L1	families	depends	on	the	species	the	family	is	present	in,	the	global	3’-UTR	sequence	
structure,	a	number	to	show	the	timing	of	 the	source	gene	within	 the	group,	and	occasionally	another	
lower	case	letter	indicating	that	the	family	forms	a	side	branch	within	the	main	lineage.	
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1.1.3	SINEs	
SINE	is	a	collective	term	referring	to	short	interspersed	nuclear	elements	and	
they	are	non-autonomous	and	non-LTR	retrotransposons.	They	are	highly	repetitive	
elements	of	typically	100-500	bps	in	length	(Singer,	1982)	and	the	largest	SINE	family		
within	the	human	genome	is	Alu.	There	are	over	a	million	copies	of	Alu	in	the	human	
genome	making	 up	 >10%	 of	 the	 total	 genomic	 sequence	 and	 these	 elements	 are	
usually	 found	 in	 gene-rich	 regions	 (Consortium,	 2005;	 Lander	 et	 al.,	 2001).	 Alu	
elements	are	typically	~300	bp	in	length	and	can	be	traced	back	at	least	~65	million	
years	(Batzer	and	Deininger,	2002).	
1.1.3.1	Life	cycle	of	SINEs	
SINEs	 are	 frequently	 found	 within	 cellular	 genes	 and	 their	 defining	 feature	 is	
their	 transcription	 by	 Pol	 III	 from	 an	 internal	 promoter	 (Okada,	 1991).	 In	 general,	
SINEs	 consist	 of	 two	 or	 more	 modules	 namely	 head,	 body	 and	 tail.	 The	 5’-	 head	
originates	from	the	cellular	RNAs	synthesised	by	Pol	III.	While	most	SINEs	like	mouse	
B2	has	a	head	of	 tRNA	origin	 (Daniels	and	Deininger,	1985),	a	 few	families	such	as	
human	Alu	have	 that	 of	 7SL	 RNA	 (Ullu	 and	 Tschudi,	 1984;	Weiner,	 1980),	 an	 RNA	
component	of	signal	recognition	particles	or	5S	ribosomal	RNA	(Kapitonov	and	Jurka,	
2003).	 The	 origin	 of	 their	 body	 is	 usually	 unknown	 but	 some	 are	 derived	 from	 a	
partner	LINE	and	mimic	LINE	RNA	to	hijack	the	reverse	transcriptase	for	their	cDNA	
synthesis	 (Okada	 et	 al.,	 1997).	 The	 SINE	 3’-tail	 is	 a	 sequence	 of	 variable	 length	
consisting	of	simple	repeats	(Figure	7).	To	date,	around	70	SINE	families	have	been	
identified	 (Vassetzky	 and	 Kramerov,	 2013)	 and	 their	 classifications	 are	 vastly	
dependent	on	the	origin	of	their	‘head’	modules	(Kramerov	and	Vassetzky,	2011).		
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	 SINEs	do	not	encode	proteins	necessary	 for	 autonomous	 retrotransposition	
and	are	reliant	on	the	reverse	transcriptase	and	nuclease	from	LINEs	(Moran	et	al.,	
1996).	Their	genetic	constituents	only	contain	an	A-,	a	B-	box	sequence	as	well	as	a	
short	sequence	homologous	to	the	3’	portion	of	their	partner	LINE	within	the	same	
genome	(Figure	3).	The	life	cycle	of	SINEs	starts	with	the	transcription	of	its	genome	
by	Pol	 III.	This	 is	 initiated	by	the	recognition	of	the	A-	and	B-boxes	by	a	six-subunit	
protein	 complex	 known	as	 TFIIIC.	 This	protein-nucleotide	 interaction	 then	 leads	 to	
the	 binding	 of	 the	 TFIIIB	 complex,	 which	 then	 recruits	 the	 Pol	 III	 polymerase.	
Transcription	 starts	 from	 the	upstream	of	A-box	 through	 the	promoter	 region	and	
continues	 to	 the	site	of	 the	 termination	signal,	which	 is	a	 simple	 run	of	4	or	more	
thymidines	 (Ichiyanagi,	 2013).	 In	 contrast,	 Alu	 elements	 possess	 no	 termination	
signals	for	Pol	III,	therefore,	the	transcription	of	Alu	can	extend	downstream	into	the	
flanking	sequence	until	a	terminator	is	reached	(Comeaux	et	al.,	2009;	Shaikh	et	al.,	
1997).		
	 The	 homology	 between	 the	 3’	 portion	 of	 the	 SINE	 structure	 and	 its	 LINE	
partner	allows	LINE	reverse	transcriptase	to	recognise	the	SINE	RNA	and	initiate	the	
target-primed	reverse	transcription	(Luan	et	al.,	1993)	using	the	target	genomic	site	
cleaved	by	the	LINE	nuclease	as	a	primer	(Figure	8).	For	instance,	human	Alu	RNA	has	
a	 poly-A	 3’	 sequence	 and	 this	 can	 be	 mobilised	 by	 the	 L1	 reverse	 transcriptase,	
which	recognises	the	poly-A	region	in	the	L1	RNA	(Dewannieux	et	al.,	2003).	Despite	
the	fact	that	L1’s	ORF1	and	ORF2	proteins	have	a	strong	cis-preference	for	L1	RNA,	
Alu	 can	 hijack	 these	 proteins	 which	 are	 thus	 known	 as	 ‘the	 parasite’s	 parasite’	
(Weiner,	2002).	The	preservation	of	A-	and	B-	boxes	in	SINEs	allows	them	to	retain	
their	promoter	sequence	and	capability	of	making	another	‘jump’.		
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Figure	7	Structure	of	Alu	and	SVA	elements.	
Both	Alu	and	SVA	elements	hijack	L1	machinery	in	order	to	retrotranspose.	A	full	length	Alu	exhibits	a	
dimeric	 structure	 formed	 by	 the	 fusion	 of	 two	 monomers	 originating	 from	 the	 signal	 recognition	
article	 7SL	 RNA	 gene,	 sandwiching	 an	 A-rich	 linker	 region.	 A-	 and	 B-	 boxes	 harbour	 the	 internal	
promoter	 for	 RNA	 Pol	 III.	 Alu	 elements	 do	 not	 have	 a	 Pol	 III	 termination	 site,	 allowing	 for	 read-
through	 transcription	 into	 the	 flanking	 sequence.	 Full-length	 SINE-VNTR-Alu	 (SVA)	 elements	 are	 a	
composite	of	multiple	repeats,	a	CCCTCT	repeat,	two	Alu-like	sequences,	a	VNTR	and	a	SINE-R	region,	
which	 is	homologous	to	 the	env	and	LTR	sequences	of	an	extinct	HERV-K10.	The	 lack	of	an	 internal	
promoter	within	the	SVA	elements	means	that	they	are	reliant	on	flanking	cellular	promoters	for	their	
transcription.	The	3’	end	of	the	element	is	a	stretch	of	poly-A	sequence. 
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Figure	8	L1-mediated	SINE	retrotransposition	mechanism.	
To	retrotranspose,	SINE	elements	first	produce	a	transcript	through	TFIIIC	binding	to	their	A-	and	B-
boxes	which	 then	 recruits	 TFIIIB	 and	Pol	 III.	 Transcription	 stops	 at	 a	downstream	 terminator,	 TTTT,	
occurring	 by	 chance.	 In	 parallel,	 a	 partner	 LINE	 encodes	 a	 protein	 with	 reverse	 transcriptase	 and	
endonuclease	activities.	The	LINE	protein	cleaves	the	target	DNA	and	initiates	reverse	transcription	of	
SINE	RNA	in-trans.	Recognition	of	the	RNA	template	is	mediated	via	the	LINE	homology	region	present	
in	the	3’	region	of	the	SINE.	SVA	follows	a	similar	pathway	with	the	difference	that	 its	 transcription	
depends	on	Pol	II	and	requires	an	upstream	cellular	promoter.	
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1.1.3.2	SVAs	
Another	 member	 of	 the	 non-autonomous	 retrotransposon	 group	 is	 the	 SINE-
VNTR-Alu	(SVA)	elements.	There	are	approximately	3,000	SVA	elements	resulting		
from	 their	 continued	 activities	 throughout	 the	 25	 million	 years	 of	 hominoid	
evolution	(Ostertag	et	al.,	2003;	Wang	et	al.,	2005).	SVA	elements	are	specific	to	the	
primate	 lineage	 (Cordaux	and	Batzer,	 2009).	Unlike	a	 typical	 SINE,	 full-length	SVAs	
are	much	larger	in	size	and	typically	2kb	in	length.	SVA	elements	contain	an	hexamer	
repeat	 region,	 an	 Alu-like	 region,	 a	 variable	 number	 of	 tandem	 repeats	 region	
(VNTR),	 a	 HERV-K10-like	 region	 and	 a	 poly-A	 ending	 with	 an	 oligo	 dA-rich	 tail	 of	
variable	 length	 (Ostertag	et	 al.,	 2003;	Wang	et	 al.,	 2005).	 These	elements	are	also	
flanked	by	the	L1-TSDs	(Ono	et	al.,	1987)	(Figure	7).	
In	contrast	to	SINEs,	SVAs	are	likely	to	be	transcribed	by	Pol	II	and	the	resultant	
RNA	 is	 trans-mobilised	 by	 L1	 retrotransposition	 machinery.	 In	 addition,	 SVA	
elements	are	likely	to	contain	no	internal	promoter	suggesting	that	they	might	rely	
on	the	promoter	activity	of	 their	 flanking	gene	promoter	but	 this	 remains	an	open	
question	(Beck	et	al.,	2011;	Ostertag	et	al.,	2003;	Wang	et	al.,	2005)	(Figure	8).	
1.2	The	impact	of	ERVs	on	their	hosts		
1.2.1	Exaptation	of	ERVs	in	host	gene	regulation		
Despite	 their	potential	 for	 insertional	mutagenesis,	no	 replicating	ERV	has	 thus	
far	been	identified	in	the	human	genome	(Bock	and	Stoye,	2000;	McPherson	et	al.,	
2001).	Genome-wide	 studies	 have	 revealed	 ERVs	 to	be	 a	 rich	 source	of	 regulatory	
sequences	 that	 play	 a	 crucial	 role	 in	 the	 evolution	 of	 mammalian	 transcriptional	
networks		
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Figure	9	Mechanisms	of	ERV	co-option.	
A)	Spreading	of	repressive	histone	marks	at	the	site	of	a	repressed	ERV	can	impact	on	the	expression	
level	of	cellular	genes	within	the	vicinity	(Rowe	et	al.,	2013a;	Rowe	et	al.,	2013b;	Turelli	et	al.,	2014).	
B)	LTRs	with	binding	sites	for	pluripotency	transcription	factors	can	serve	as	short-range	or	long-range	
enhancers	 to	specific	host	genes	 (Suntsova	et	al.,	2013).	C)	ERV	elements	expand	the	complexity	of	
the	 ESC	 mRNA	 transcripts	 by	 functioning	 as	 alternative	 promoters	 to	 genes,	 being	 exonised	 in	
chimeric	transcripts,	providing	alternative	splice	and	acceptor	sites,	and	driving	non-AUG	translation	
in	order	to	give	novel	products	(Wang	et	al.,	2014).	D)	Host	cells	can	exploit	viral	gene	to	devise	novel	
gene	product	(Gifford	et	al.,	2013;	Mi	et	al.,	2000).	E)	lncRNA	transcribed	from	ERVs	can	interact	with	
transcription	factors	in	order	to	rewire	the	transcriptional	network	associated	with	the	ground	state	
of	ES	cells	(Lu	et	al.,	2014).	F)	Transcripts	from	ERVs	can	be	sensed	by	the	host	as	foreign	and	this	can	
elicit	a	sensing	event	and	a	downstream	signalling	cascade	that	is	crucial	for	normal	immune	function	
during	T-independent	B	cell	responses	(Zeng	et	al.,	2014).	
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(Brattas	et	al.,	2017;	Cordaux	and	Batzer,	2009;	Feschotte	and	Gilbert,	2012;	Gifford	
et	 al.,	 2013;	 Griffiths,	 2001;	 Jern	 and	 Coffin,	 2008;	 Katoh	 and	 Kurata,	 2013;	
Manghera	and	Douville,	2013;	Rebollo	et	al.,	2012;	Thompson	et	al.,	2016)	(Figure	9).	
The	current	population	of	ERVs	is	 likely	to	reflect	the	loci	that	have	been	positively	
selected	while	those	with	a	lethal	phenotype	have	been	out	selected	(Medstrand	et	
al.,	 2002).	 There	 are	 also	 an	 estimated	 577,000	 solo	 LTRs	 in	 the	 human	 genome	
(Friedli	and	Trono,	2015),	which	arise	from	recombination	between	5’	and	3’	LTRs	of	
ERVs	(Belshaw	et	al.,	2007).		
ERVs	as	alternative	promoters 
ERV	LTRs	have	 the	 intrinsic	capacity	 to	 recruit	 cellular	 transcription	 factors	and	
can	be	exapted	as	cis-regulatory	elements	with	either	activating	or	repressive	effects	
(Chuong	 et	 al.,	 2013;	 Jacques	 et	 al.,	 2013;	 Sundaram	 et	 al.,	 2014).	 For	 instance,	
KZNF/	KAP1	and	SETDB1	mediated	repression	of	intact	ERVs	and	solo	LTRs	can	result	
in	 heterochromatin	 spreading	 and	 the	 repression	 of	 nearby	 genes	 (Karimi	 et	 al.,	
2011;	Rebollo	et	al.,	2011;	Rowe	et	al.,	2013b;	Turelli	et	al.,	2014;	Wolf	et	al.,	2015)	
(Figure	 9).	 In	 contrast,	 some	 solo	 LTRs	 and	 incomplete	 ERVs	 can	 function	 as	
promoters	or	enhancers	(Ecco	et	al.,	2016;	Friedli	and	Trono,	2015).		
The	 promoter	 and	 enhancer	 functions	 of	 LTRs	 are	 often	 cell	 type	 specific.	 For	
example,	in	mice,	LTRs	of	the	MERV-L	family	(class	III	LTR	retrotransposon)	drive	the	
expression	of	a	cohort	of	stage-specific	genes	necessary	for	totipotency	(Macfarlan	
et	al.,	2012;	Peaston	et	al.,	2004).	In	comparison,	LTRs	of	MaLR	and	IAP	families	drive	
the	expression	of	oocyte-specific	transcripts	in	mice	(Peaston	et	al.,	2004;	Veselovska	
et	al.,	2015).	Similarly	in	humans,	LTR7	from	the	primate-specific	retrovirus	HERV-H	
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has	been	demonstrated	 to	drive	many	pluripotency-associated	 lncRNAs	 (Durruthy-
Durruthy	et	al.,	2016;	Lu	et	al.,	2014b;	Wang	et	al.,	2014b).	Additionally,	LTRs	with	
promoter	 functions	 such	as	LTR3B,	 LTR14B,	 LTR12C,	MLT2A1,	THE1A	and	LTR5_Hs,	
are	 all	 expressed	 at	 discrete	 stages	 of	 human	 embryo	 development	 serving	 as	
promoters	for	distinct	sets	of	gene	(Goke	et	al.,	2015).		
Many	 LTRs	 are	 sequentially	 inactivated	 beyond	 zygote	 and	 two-cell	 stage	
(Hayashi	 et	 al.,	 2016;	 Hisada	 et	 al.,	 2012;	 Ishiuchi	 et	 al.,	 2015;	 Lu	 et	 al.,	 2014a;	
Macfarlan	et	al.,	2012;	Thompson	et	al.,	2015)	but	 some	are	positively	 selected	 to	
drive	tissue-specific	genes	in	differentiated	cells	(Figure	9).		For	example,	MER39	and	
MER77	LTRs	have	been	exapted	to	drive	the	Prolactin	gene	within	endometrial	cells	
in	primates	and	rodents	respectively	(Emera	et	al.,	2012;	Romanish	et	al.,	2007).	The	
anti-apoptotic	gene,	Naip,	has	also	been	shown	to	be	driven	by	MER12C	and	MT-C	
LTRs	 in	 rodents	 and	 primates	 respectively	 (Romanish	 et	 al.,	 2007).	 Additional	
examples	 of	 ERV-driven	 genes	 include	 the	 pancreatic	 amylase	 gene	 (Meisler	 and	
Ting,	1993)	and	germ	cell-associated	p63	(Beyer	et	al.,	2011).		
ERVs	as	lncRNAs 
Genome-wide	 surveys	 have	 revealed	 that	 more	 than	 75%	 of	 the	 ~10,000	
annotated	 human	 lncRNAs	 contain	 TE	 sequences	 (Fort	 et	 al.,	 2014;	 Kannan	 et	 al.,	
2015;	Kapusta	et	al.,	2013;	Kelley	and	Rinn,	2012)	and	they	are	enriched	with	LTR-
elements	when	compared	to	other	non-LTR	elements	(Kannan	et	al.,	2015;	Kapusta	
et	al.,	2013;	Kelley	and	Rinn,	2012).	While	many	LTR	elements	are	transcribed	as	part	
of	 lncRNAs,	 some	 families	 act	 as	 promoters	 for	 lncRNAs.	 For	 instance,	 LTR7	drives	
the	 lncRNAs	 transcription	 in	 stem	 cell	 (Durruthy-Durruthy	 et	 al.,	 2016;	 Lu	 et	 al.,	
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2014b;	Wang	et	al.,	2014b)	while	HERV-H	elements	function	in	pluripotency-specific	
alternative	splicing	and	alternative	non-AUG	usage	 (Goke	et	al.,	2015;	Wang	et	al.,	
2014b).	 Transcription	 from	 LTR7	 is	 driven	 by	 the	 recruitment	 of	 pluripotency	
transcription	factors	 including	LTR	binding	protein-9	 (LBP9),	a	 transcriptional	 factor	
crucial	for	ground-state	pluripotency,	highlighting	the	role	of	LTR7	in	maintaining	the	
‘stemness’	 of	 stem	 cells	 (Ohnuki	 et	 al.,	 2014;	 Santoni	 et	 al.,	 2012;	 Wang	 et	 al.,	
2014b).	Consistent	with	this	role,	 increased	expression	of	HERV-H	lncRNA	has	been	
observed	in	induced	pluripotent	stem	cells	(iPSCs)	(Ohnuki	et	al.,	2014)	and	the	loss	
of	 this	RNA	species	compromises	 the	ability	of	embryonic	stem	cells	 (ESCs)	 to	self-
renew	(Lu	et	al.,	2014b)	(Figure	9).	Analysis	of	human	preimplantation	embryos	also	
revealed	the	expression	of	ERV1,	ERV-K,	and	ERV-L	derived	noncoding	RNAs	but	their	
functions	remain	elusive	(Goke	et	al.,	2015;	Grow	et	al.,	2015).		
ERVs	as	enhancers 
The	 enhancer	 function	 of	 ERVs	 is	 supported	 by	 the	 epigenetic	 enhancer	
signatures	 observed	 on	 these	 loci	 (Figure	 9).	 Typical	 epigenomic	 signatures	 of	 an	
active	 enhancer	 include	 H3K4me1,	 H3K27ac,	 DNase	 I	 hypersensitivity,	 DNA	
hypomethylation,	 and	 the	 lack	 of	 the	 repressive	 H3K9me3	 and	 H3K27me3	 marks	
(Chuong	et	al.,	2013;	Fort	et	al.,	2014;	 Jacques	et	al.,	2013;	Sundaram	et	al.,	2014;	
Xie	et	al.,	2013).	One	such	example	is	the	MaLR	LTR,	which	acts	as	an	enhancer	for	
~80%	 of	mammalian	Pomc	 gene	 expression	 (Lam	 et	 al.,	 2015).	 Similarly,	 LTR9	 has	
also	been	shown	to	act	as	an	enhancer	for	the	B-globin	gene	cluster	(Pi	et	al.,	2010)	
and	more	 recently,	 Chuong	 et	 al.	 have	 also	 shown	 that	MER41	 LTR	 enhances	 the	
expression	of	several	interferon	stimulated	genes	(Chuong	et	al.,	2016).	
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The	enhancer	property	of	LTRs	may	be	determined	by	using	LTR	reporter	assays	
(Rowe	 et	 al.,	 2013b)	 and	 by	 their	 ability	 to	 drive	 enhancer	 RNAs	 (eRNAs)	 through	
bidirectional	transcription	(Kim	et	al.,	2015;	Plank	and	Dean,	2014).	eRNA	production	
by	BGLII-	 and	LTR17-	derived	enhancers	has	 recently	been	 shown	 to	be	present	 in	
pluripotent	 stem	 cells	 (Fort	 et	 al.,	 2014),	 and	 LTR9/LTR16A	 act	 as	 enhancers	 in	
certain	tissues	(Dunn	et	al.,	2006).		
ERVs	as	pathogen-associated	molecular	patterns	(PAMPs) 
Beyond	 their	 genomic	 sequences,	 ERV	 transcripts	 can	 also	 play	 a	 role	 in	 T-
independent	B	cell	 responses	 (Zeng	et	al.,	2014).	When	B	cells	are	activated,	ERVs	
get	 transcribed	 into	 mRNAs,	 which	 then	 get	 reverse	 transcribed	 into	 DNA.	 Both	
double	stranded	RNA	and	DNA	are	then	sensed	as	PAMPs	by	retinoic	acid-inducible	
gene	I	(RIG-I)	and	cyclic	GMP-AMP	synthase	(cGAS)	respectively	(Zeng	et	al.,	2014).	
These	 signaling	 events	 then	 result	 in	 B	 cell	 activation,	 proliferation	 and	 antibody	
production	 (Zeng	 et	 al.,	 2014).	 A	 similar	 mechanism	 (RNA	 sensing	 of	 ERVs)	 has	
recently	 been	 shown	 to	 take	 place	 in	 cancer	 cells	 treated	 with	 the	 DNA-
demethylating	 agent,	 5-Aza-2’-deoxycytidine	 (5-Aza)	 (Chiappinelli	 et	 al.,	 2015;	
Roulois	et	al.,	2015).		
1.2.2	ERVs	and	cellular	protein	expression	
Novel	cellular	protein	expression	patterns 
Studies	in	mice	have	shown	that	the	repression	of	IAP	elements,	but	not	of	L1	
and	 the	 majority	 of	 the	 ETn/MusD	 elements,	 induces	 H3K9me3	 and	 H4K20me3	
repressive	 histone	 marks	 (Rebollo	 et	 al.,	 2011)	 and	 establishes	 a	 repressive	
chromatin	environment	in	the	vicinity	(Elsässer	et	al.,	2015;	Sadic	et	al.,	2015).	The	
resulting	 spread	 of	 heterochromatin	 has	 been	 demonstrated	 to	 impact	 on	 the	
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expression	of	cellular	genes	such	as	B3gaItI	(Rebollo	et	al.,	2011),	which	in	turn	will	
affect	the	protein	expression	profile	of	the	cell.	L1	has	also	been	shown	to	play	a	role	
in	 the	 formation	of	 facultative	heterochromatin	during	X	 chromosome	 inactivation	
(Chow	et	al.,	2016)	and	chromocenters	 (Kuznetsova	et	al.,	2016)	 in	mouse	studies,	
although	the	exact	mechanisms	for	these	processes	are	not	fully	understood.		
More	 recently,	 ERVs	 have	 been	 shown	 to	 impact	 on	 genes	 in	 neural	
progenitor	 cells	 (NPC)	 (Brattas	 et	 al.,	 2017;	 Fasching	 et	 al.,	 2015).	 These	 studies	
showed	that,	like	in	human	and	mouse	ESCs	(Rowe	et	al.,	2013b;	Turelli	et	al.,	2014),	
the	 regulation	 of	 ERVs	 consequently	 leads	 to	 the	 establishment	 of	 local	
heterochromatin	 and	 the	 repression	 of	 neighbouring	 genes.	 Incidentally,	 some	 of	
these	genes	are	involved	in	brain	development	(Brattas	et	al.,	2017).		
Beyond	 transcriptional	 regulation,	 ERVs	have	 also	been	 reported	 to	benefit	
the	host	by	providing	new	gene	products	and	one	such	example	is	the	syncytin	gene,	
which	plays	a	vital	role	in	mammalian	development	and	reproduction	(Dupressoir	et	
al.,	 2009;	Mangeney	 et	 al.,	 2007;	Mi	 et	 al.,	 2000).	 The	 syncytin	 family	 consists	 of	
Syncytin-1	and	-2	and	compelling	evidence	has	been	presented	to	show	that	they	are	
derived	 from	 the	 envelope	 glycoprotein	 gene	 of	 the	 HERV-W	 family	 and	 are	
necessary	for	the	formation	of	syncytiotrophoblasts	in	the	placenta	(Mi	et	al.,	2000).	
Considering	 the	 importance	 of	 both	 properties	 to	 mammalian	 evolution,	 it	 is	 not	
surprising	 that	 env	 gene	 was	 captured	 and	 exapted	 independently	 on	 multiple	
occasions	 throughout	 mammalian	 evolution	 (Blaise	 et	 al.,	 2003;	 Cornelis	 et	 al.,	
2015).		
There	 are	 several	 other	 examples	 of	 ERV	protein	 products	 being	 expressed	
particularly	 during	 development.	 In	 the	 mouse	 genome,	 there	 are	 16	 copies	 of	
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MERV-L	with	intact	open	reading	frames	flanked	by	identical	LTRs.	MERV-L	elements	
are	active	and	their	GAG	proteins	expressed	from	zygotic	genome	activation	at	the	
2-cell	stage	up	to	the	blastocyst	stage	(Kigami	et	al.,	2003;	Svoboda	et	al.,	2004).	By	
comparison,	IAP	transcripts	and	p73	GAG	proteins	are	detectable	first	in	the	oocyte	
and	 expressed	 until	 their	 repression	 and	 DNA	 methylation	 (Pikó	 et	 al.,	 1984;	
Poznanski	and	Calarco,	1991;	Svoboda	et	al.,	2004).	In	contrast,	MusD/ETn	elements	
are	transcribed	in	post-implantation	embryos	(Peaston	et	al.,	2004).	The	function	of	
ERV-derived	proteins	is	unclear,	except	as	antivirals	(see	below).	
ERVs	as	antiviral	agents	
Budding	of	virus	like	particles	(VLPs)	has	been	observed	in	chicken	and	mouse	
embryos	as	well	as	in	human	blastocysts	(Bieda	et	al.,	2001;	Dupressoir	et	al.,	2005;	
Grow	et	 al.,	 2015;	 Yotsuyanagi	 and	 Szollosi,	 1981).	Until	 recently,	 it	was	unclear	 if	
such	VLPs	have	a	physiological	function	in	the	cell	but	new	data	suggest	they	might	
play	 a	 role	 in	 protecting	 the	 embryos	 from	 certain	 infections.	Grow	et	 al.	 showed	
that	 the	HERV-K	 accessory	 protein,	 Rec,	 could	 influence	 cellular	mRNA	 translation	
and	upregulate	 the	classical	virus	 restriction	 factor	 IFITM1	 (Grow	et	al.,	2015).	Rec	
overexpression,	however,	has	been	suggested	to	also	have	a	role	in	the	formation	of	
germ	cell	tumours	by	derepressing	oncogenic	transcription	factors	(Kaufmann	et	al.,	
2010).	
The	antiviral	property	of	another	viral	proteins,	Env,	has	been	documented	in	
multiple	 vertebrates.	 The	 earliest	 example	 of	 such	 property	 was	 observed	 in	
domestic	chicken,	in	which	endogenous	avian	leucosis	virus	(ALV)	derived	env	genes	
were	found	to	protect	the	animal	from	the	insult	of	exogenous	ALV	by	impeding	its	
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entry	 (Payne	 and	 Chubb,	 1968;	 Robinson	 et	 al.,	 1981).	 Similar	 observations	 were	
then	 reported	 in	 domestic	 sheep	 (endogenous	 Jaagsiekte	 sheep	 retrovirus	 (JSRV),	
enJSRV56A1)	(Varela	et	al.,	2009)	and	mice	(Fv4	from	endogenous	MLV)	(Gardner	et	
al.,	 1991;	 Kozak,	 2015).	 In	 humans,	 one	 candidate	 known	 as	 Suppressyn,	 an	 Env	
protein	 from	 HERV-F	 without	 the	 TM	 domain,	 has	 been	 proposed	 to	 regulate	
Syncytin-1	activity	by	 interacting	with	 the	same	cell	 receptor,	ASCT2,	 thus	blocking	
the	binding	of	another	domesticated	env	gene	(Sugimoto	et	al.,	2013).	Several	other	
retroviruses	such	as	simian	retroviruses	1	to	5,	baboon	endogenous	virus,	and	feline	
RD114	 all	 utilise	 the	 same	 receptor	 so	 the	 protein	 can	 potentially	 restrict	 these	
viruses	in	other	species	(Sommerfelt	and	Weiss,	1990).	Another	example	in	humans	
is	the	Env	protein	derived	from	a	HERV-T	provirus,	which	has	recently	been	shown	to	
be	well	 preserved.	 A	 recent	 study	 proposed	 that	 ancient	 primates	may	 have	 used	
this	viral	Env	gene	to	restrict	HERV-T	entry	causing	extinction	of	the	same	element	
that	provided	the	restriction	factor	(Blanco-Melo	et	al.,	2017).	
1.2.3	Negative	effects	of	ERVs	
Disruption	 of	 ERV	 regulation	 can	 have	 a	 negative	 impact	 on	 cellular	 gene	
expression	 and	 can	 ultimately	 cause	 disease.	 The	 association	 between	 ERVs	 and	
cancer	 has	 long	 been	 documented	 (Babaian	 and	Mager,	 2016;	 Kassiotis,	 2014).	 In	
addition	 to	 the	 ERV	 accessory	 proteins,	 Np9	 and	 Rec,	most	 oncogenesis	 has	 been	
linked	to	the	intrinsic	regulatory	capacity	of	the	ERVs	(Chen	et	al.,	2013;	Hohn	et	al.,	
2013;	Kassiotis,	2014).	For	 instance,	 inappropriate	transcriptional	activation	of	LTRs	
have	been	 linked	 to	multiple	 cancers	 in	 a	 phenomena	 known	as	 ‘onco-exaptation’	
(Babaian	 and	 Mager,	 2016).	 Onco-exaptation	 occurs	 through	 aberrant	 promoter	
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activation	 or	 alternative	 promoter	 usage,	 which	 results	 in	 either	 ectopic	 or	
overexpression	of	an	oncogene	(Babaian	and	Mager,	2016).		
To	 give	 an	 example,	 ERV	 activity	 has	 been	 linked	 to	 solid	 cancers	 such	 as	
breast	 cancer	 (Golan	 et	 al.,	 2008;	 Wang-Johanning	 et	 al.,	 2008)	 and	 melanoma	
(Buscher	 et	 al.,	 2005;	 Schmitt	 et	 al.,	 2013).	 In	 Hodgkin’s	 Lymphoma	 (HL)	 patient	
samples,	 ectopic	 expression	 of	 the	 gene	 “colony	 stimulating	 factor	 one	 receptor”	
(CSF1R)	was	identified	to	be	a	possible	cause	of	this	cancer	(Lamprecht	et	al.,	2010).	
This	protein	is	usually	restricted	to	macrophages	of	the	myeloid	lineage	but	can	get	
ectopically	activated	and	expressed	by	a	solitary	THE1B	LTR	(MaLR-ERVL)	in	B	cells		
(Lamprecht	 et	 al.,	 2010).	 The	 survival	 of	 HL	 cells	 is	 dependent	 on	 Interferon	
Regulatory	 Factor	 5	 (IRF5)	 gene	 expression	 driven	 by	 another	 primate	 LTR,	 LOR1a	
(Kreher	 et	 al.,	 2014).	 Furthermore,	 LTR	 elements	 of	 the	 ancient	 MaLR-ERVL	 class	
have	also	been	shown	to	act	as	alternative	promoters	for	the	gene	“Erb-b2	receptor	
tyrosine	 kinase	 4”	 (ERBB4	 or	 HER4)	 and	 give	 rise	 to	 truncated	 proteins	 with	
oncogenic	properties	(Scarfo	et	al.,	2016).		
LTR7-driven	chimeric	 long	non-coding	RNAs	are	a	 characteristic	of	ESCs	but	
their	 expression	 has	 been	 linked	 to	 colon	 cancer	 (Liang	 et	 al.,	 2012;	 Pérot	 et	 al.,	
2015).	LTR7	and	the	neighbouring	MER4C	LTR	drive	the	expression	of	the	truncated	
form	of	SLCO1B3	but	 its	 role	 in	colon	cancer	 is	unclear	 for	now	(Liang	et	al.,	2012;	
Pérot	 et	 al.,	 2015).	 Additionally,	 HERV-E-mediated	 ectopic	 expression	 of	 fatty	 acid	
binding	 protein	 7	 (FABP7)	was	 found	 in	 several	 solid	 tumours	 such	 as	 aggressive	
breast	cancer	and	some	diffuse	large	B	cell	lymphoma	(DLBCL)	(Liu	et	al.,	2012;	Lock	
et	al.,	2014;	Morin	et	al.,	2011).		
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ERV-initiated	non-coding	RNAs	have	also	been	associated	with	cancers.	One	
example	of	 this	 is	 the	association	between	HOST2	 lncRNA,	which	 is	produced	from	
the	LTR2B	of	a	HERV-E	element	in	epithelial	ovarian	cancer	(Gao	et	al.,	2015;	Rangel	
et	al.,	2003).	Also,	the	5’	end	of	the	HERV-K	element	on	chromosome	22q11.23	has	
been	 shown	 to	 fuse	 to	 the	 ETV1	 gene	 via	 chromosomal	 translocation	 and	 the	
resulting	 product	 is	 highly	 expressed	 in	 prostate	 cancer	 (Goering	 et	 al.,	 2015;	
Tomlins	et	al.,	2007).	
Beyond	 cancers,	 ERVs	 have	 also	 been	 linked	with	 a	 variety	 of	 neurological	
diseases	 (Douville	 and	 Nath,	 2014).	 One	 example	 would	 be	 amyotrophic	 lateral	
sclerosis	 (ALS)	 where	 the	 patient	 brain	 tissue	 presents	 elevated	 ERV-K	 activity	
(Douville	et	al.,	2011).	Animal	models	 looking	at	motor	dysfunction	show	increased	
ERV-K	 env	 gene	 expression	 in	 cortical	 and	 spinal	 neurons	 suggesting	 a	 potential	
cause	 of	 neurodegeneration	 (Li	 et	 al.,	 2015).	 ALS	 has	 also	 been	 linked	 to	HERV-W	
gag	 and	 env	 expression,	 but	 whether	 this	 causes	 the	 disease	 remain	 debatable	
(Oluwole	et	al.,	2007).		
Multiple	sclerosis	(MS)	has	also	been	linked	to	ERV-W,	ERV-W1,	W2,	and	ERV-
H/F	 elements	 (Christensen,	 2016)	 following	 the	 observation	 of	 the	 presence	 of	
elevated	 Env	 antigen	 in	 the	 serum,	 and	 HERV-W	 DNA	 in	 peripheral	 blood	
mononuclear	 cells	 (PBMCs)	 from	 MS	 patients	 (Perron	 et	 al.,	 2012).	 Additionally,	
schizophrenia	 and	 other	 neuropsychiatric	 disorders	 have	 been	 linked	 to	 the	
hypermethylation	 of	 the	 HERV-W	 LTR	 located	 in	 the	 regulatory	 region	 of	GABBR1	
(Hegyi,	2013),	and	ERV-K	near	the	PRODH	gene	(Suntsova	et	al.,	2013).		
	 42	
The	 link	 between	 autoimmune	 diseases	 and	 ERVs	 was	 first	 established	
following	 the	 discovery	 of	 conserved	 retroviral	pol,	 with	 a	 homology	 to	 HERVs,	 in	
patient	 samples	 (Herrmann	 et	 al.,	 1998;	 Nelson	 et	 al.,	 1999).	 Since	 then,	multiple	
mechanisms	 used	 by	 ERVs	 to	 induce	 autoimmune	 diseases	 have	 been	 proposed.	
Firstly,	insertions	near	to	immune	genes	can	affect	the	expression	level	of	genes	and	
potentially	contribute	to	the	onset	of	certain	diseases	(Balada	et	al.,	2009;	Wu	et	al.,	
1993).	Secondly,	viral	proteins	 from	ERVs	could	be	recognised	by	the	host	 immune	
system	 as	 foreign,	 leading	 to	 antibody	 production.	 These	 antibodies	 might	 cross-
react	with	certain	self-proteins	 (Balada	et	al.,	2009;	Conrad	et	al.,	1997)	and	could	
contribute	to	the	pathogenesis	of	some	autoimmune	disease	in	a	process	known	as	
molecular	mimicry.	 Lastly,	 ERV	proteins	may	 also	 act	 as	 superantigens	 fuelling	 the	
expansion	of	autoreactive	T-lymphocytes	(Balada	et	al.,	2009;	Rolland	et	al.,	2006).		
The	association	between	ERVs	and	systemic	 lupus	erythematosus	 (SLE)	was	
first	 implicated	 from	 SLE	 mouse	 models.	 GP70	 (an	 endogenous	 retroviral	 Env	
protein)	is	expressed	at	high	levels	and	anti-GP70	antibodies	are	detectable	in	lupus-
prone	 mouse	 strains.	 However,	 this	 association	 was	 later	 dismissed	 with	 the	
discovery	of	non-autoimmune	strains	of	mice	with	equally	high	GP70	level.	Detection	
of	autoantibodies	in	different	populations	of	SLE	patients	has	led	to	the	proposal	of	
multiple	mechanisms	explaining	the	causality	of	SLE	 including	enhanced	expression	
of	Fas	gene	by	early	transposable	element	(ETn),	molecular	mimicry	between	HRES-1	
Gag	 protein	 and	 host	 U1snRNP	 (Banki	 et	 al.,	 1992;	 Perl	 et	 al.,	 1995)	 and	 Rab4	
proteins	(Fernandez	et	al.,	2009;	Nagy	et	al.,	2006),	immune	reactivity	against	HERV-
K	(Herve	et	al.,	2002),	HERV-H	(Naito	et	al.,	2003),	and	the	ERV-3	Env	protein	(Li	et	
al.,	1996).		
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The	 association	 between	 insulin-dependent	 diabetes	 mellitus	 (IDDM)	 and	
HERV-K18	was	first	recorded	following	the	detection	of	HERV-K	antibodies	(Herve	et	
al.,	2002)	and	HERV-K18	mRNA	(Conrad	et	al.,	1994)	in	the	PBMCs	and	inflammatory	
lesions	 of	 patients.	 This	 observation	 can	 be	 explained	 by	 the	 detection	 of	 ENV	
superantigen	encoded	by	HERVK-18	(Conrad	et	al.,	1994;	Marguerat	et	al.,	2004)	but	
ENV	expression	was	 later	proved	 to	be	non-specific	and	similar	observations	could	
also	be	made	in	healthy	participants	(Murphy	et	al.,	1998).	
Patients	 with	 rheumatoid	 arthritis	 (RA)	 have	 been	 shown	 to	 express	more	
HERV-K	mRNA	and	antibodies	(Herve	et	al.,	2002)	in	their	synovial	fluid	(Ehlhardt	et	
al.,	2006;	Sicat	et	al.,	2005).	A	different	study	has	shown	that	higher	levels	of	HERV-
K10	gag	mRNA	can	also	be	detected	in	both	peripheral	cells	and	synovial	fluid	cells	
of	RA	patients	 relative	 to	 the	healthy	 controls	 (Ejtehadi	et	al.,	 2006).	 Interestingly,	
elevated	 transcript	 levels	of	 the	HERV-K18	 superantigen	were	also	 reported	 in	 the	
synovial	fluid	mononuclear	cells	of	juvenile	RA	patients	(Sicat	et	al.,	2005)	but	HERV-
K	(HML-2)	env	mRNA	was	downregulated	in	RA	patients	(Reynier	et	al.,	2009).		
The	activity	of	ERVs	in	autoimmune	diseases	has	also	been	linked	to	systemic	
sclerosis,	autoimmune	Addison’s	disease,	alopecia	areata,	psoriasis	(Perl,	2003),	and	
even	prion	 disease	 (Lee	 et	 al.,	 2013b).	 The	question	 remains	 of	whether	 ERVs	 are	
bona	fide	causative	agents	of	these	diseases	or	merely	reflect	the	consequence	of	an	
inflammatory	 response	 in	 these	diseases.	To	address	 this,	more	studies	and	better	
experimental	 models	 are	 needed	 in	 order	 to	 clarify	 the	 role	 of	 ERVs	 in	 various	
diseases.			
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1.3	Regulation	of	ERVs		
Upon	 fertilization,	 the	 paternal	 genome	 undergoes	 active	 demethylation	while	
the	maternal	genome	is	subjected	to	passive	demethylation	(Feng	et	al.,	2010).	This	
global	 loss	 of	methylation	 is	 accompanied	 by	 a	 surge	 in	 transcriptional	 activity	 of	
certain	 ERV	 families	 (Feng	 et	 al.,	 2010;	 Oswald	 et	 al.,	 2000).	 Considering	 the	
potential	impacts	of	ERV	reactivation	on	host	cells,	 it	 is	not	surprising	that	the	host	
has	 evolved	 a	 spectrum	 of	 regulatory	 mechanisms.	 These	 strategies	 range	 from	
epigenetics,	through	to	RNA	interference	and	restriction	factors.	
1.3.1	Epigenetics	
Chromatin	regulation	and	DNA	sequence	both	play	a	role	in	cell-type	identity	
during	development.	Epigenetics	 refers	 to	modifications	on	chromatin,	 rather	 than	
DNA	 sequence	 alterations,	 which	 lead	 to	 heritable	 effects	 on	 gene	 expression.	
Chromatin	modifications	include	histone	modifications	and	cytosine	methylation	and	
distinct	 epigenetic	 marks	 are	 associated	 with	 either	 an	 active	 or	 silent	 gene	
expression	state.	Chromatin	signatures	such	as	acetylation	of	histone	3	at	the	lysine	
residue	 at	 position	 27	 (H3K27ac)	 and	 monomethylation	 of	 histone	 3	 at	 lysine	 4	
(H3K4me1)	are	typically	associated	with	active	genes	and	enhancers	(Rada-Iglesias	et	
al.,	 2011);	 whereas	 trimethylation	 of	 histone	 3	 at	 lysine	 9	 (H3K9me3)	 and	
trimethylation	of	histone	3	at	lysine	27	(H3K27me3)	correlate	with	heterochromatin	
and	gene	 silencing	 (Bulut-Karslioglu	et	 al.,	 2014;	Matsui	 et	 al.,	 2010;	Walter	 et	 al.,	
2016).	 	 New	 ERV	 integrations	 can	 have	 two	 DNA-sequence	 driven	 effects	 on	 the	
host:	Firstly,	sequence	integration	itself	alters	the	genetic	content	of	our	genome		
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Figure	10	Putative	epigenetic	modifiers	involved	in	ERV	repression	in	differentiated	
cells.	
KRAB-ZFPs	 (KZNFs)	 partner	 with	 KAP1,	 SETDB1	 and	 DNMTs	 to	 silence	 ERVs	 in	 ESCs	 and	 early	
development	 but	 it	 is	 unclear	 which	 of	 these	 factors	 are	 required	 to	 maintain	 ERV	 repression	 in	
differentiated	 human	 cells.	 It	 is	 also	 unknown	 whether	 the	 recently	 described	 HUSH	 complex	 is	
necessary	for	ERV	repression.	
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and	 secondly,	 the	 transcription	 factor	 binding	 sites	 within	 the	 ERV	 regulatory	
elements	can	orchestrate	epigenetic	traits	heritable	in	the	daughter	cells.	
1.3.2	Epigenetic	regulation	of	ERVs	in	early	development	
KZNFs	and	KAP1	 
Transcriptional	 regulation	 of	 ERVs	 includes	 DNA	 methylation	 and	 histone	
methylation.	However,	 little	 is	known	about	how	these	silent	chromatin	marks	are	
targeted	 to	 ERVs	 early	 in	 development.	 One	 known	 mechanism	 utilizes	 Kruppel-
associated-box	 zinc	 finger	proteins	 (KZNFs)	 and	KAP1	 (Rowe	et	 al.,	 2010;	 Turelli	 et	
al.,	 2014)	 (Figure	10).	This	 is	 supported	by	data	 from	KAP1	and	KZNF	knockouts	 in	
early	 development,	 which	 have	 demonstrated	 their	 role	 in	 repressing	
retrotransposons	(Brattas	et	al.,	2017;	Ecco	et	al.,	2016;	Fasching	et	al.,	2015;	Rowe	
et	al.,	2010;	Wolf	et	al.,	2015).	One	of	these	studies	also	showed	that	the	KAP1	and	
KZNF	 pathway	 plays	 a	 minor	 role	 in	 retrotransposon	 repression	 in	 mouse	 liver	
following	the	liver-specific	knockout	of	KAP1	(Ecco	et	al.,	2016).	
The	 first	 line	of	 evidence	 implicating	KAP1	 in	 ERV	 repression	was	based	on	
murine	 leukemia	virus	 (MLV)	 repression	 in	murine	embryonic	 stem	cells	 (Wolf	and	
Goff,	2007;	Wolf	and	Goff,	2009).	Indeed,	Daniel	Wolf	showed	that	MLV	restriction	is	
initiated	by	recognition	of	 the	18	nucleotide-long	primer	binding	site	Pro	 (PBS-Pro)	
sequence	by	Zfp809	followed	by	KAP1	recruitment.	This	recognition	is	highly	specific	
such	 that	 a	 single	 mutation	 is	 sufficient	 to	 disrupt	 the	 interaction	 and	 thus	 MLV	
repression.	Although	KZNF/KAP1	 repression	 is	 highly	 conserved	between	mice	and	
humans,	ERV	populations	are	often	species-specific.	This	observation	 is	 in	 line	with	
the	 finding	 that	 KZNF	 repertoires	 are	 species-specific	 and	 many	 have	 undergone	
positive	 selection	 in	 parallel	 with	 the	 rise	 of	 new	 classes	 of	 ERVs	 in	 the	 genome	
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(Corsinotti	et	al.,	2013;	Emerson	and	Thomas,	2009;	Lukic	et	al.,	2014;	Najafabadi	et	
al.,	2015;	Thomas	and	Schneider,	2011).	
To	initiate	ERV	repression,	KZNFs	must	first	bind	to	their	DNA	targets	through	
their	arrays	of	C2H2-type	zinc	finger	domains.	The	C-terminal	regions	of	KRAB-ZNFs	
contain	tandemly	arranged	arrays	of	C2H2	zinc	finger	modules,	comprising	a	few	to	
more	than	30	fingers.		Each	of	these	fingers	is	separated	from	each	other	by	a	highly	
conserved	 linker	 sequence	and	can	 interact	with	 three	nucleotides	 (Looman	et	al.,	
2002).	 Their	 conserved	 N-terminal	 KRAB	 domains	 recruit	 KAP1	 protein	 to	 the	
recognized	 sequence	and	give	 specificity	 to	 the	 repression	pathway	 (Najafabadi	 et	
al.,	2015).		
The	 human	 genome	 encodes	 around	 350	 KZNFs,	 the	majority	 of	which	 are	
found	in	clusters,	a	result	of	their	evolution	through	duplication	and	deletion	of	zinc	
finger	modules	(Vogel	et	al.,	2006).	The	family	is	fast	evolving	and	has	recently	been	
traced	back	as	 far	 as	 the	 common	ancestor	of	 coelacanths,	 lungfish	and	 tetrapods	
(Imbeault	et	al.,	2017).	The	unique	repertoire	in	different	species,	however,	suggests	
that	they	have	evolved	to	perform	species-specific	transcriptional	regulation	and	/	or	
that	different	ones	perform	the	same	functions	across	species	(Huntley	et	al.,	2006).	
Of	note,	around	half	of	the	human	KZNFs	are	widely	conserved	and	their	functions	
are	mostly	 unknown,	 although	 presumably	 they	 bind	 to	 conserved	 targets.	 	 Large	
arrays	of	 zinc	 finger	proteins	 (ZNFs)	 can	be	 viewed	as	 a	 panel	 of	 effector	 proteins	
with	 specific	 DNA	 targets	 analogous	 to	 an	 antibody	 repertoire	 specific	 for	 foreign	
antigens.	Many	of	the	binding	targets	for	human	KZNFs	have	been	identified	through	
chromatin	 immunoprecipitation	 experiments	 (Imbeault	 et	 al.,	 2017;	 Najafabadi	 et	
al.,	 2015;	 Schmitges	 et	 al.,	 2016)	 but	 only	 a	 few,	 namely	 ZNF91	 and	 ZNF93,	 have	
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been	 functional	 characterized,	 in	 this	 case	 to	 repress	 SVA	 and	 L1	 subfamily	
sequences	 (Jacobs	 et	 al.,	 2014).	 Apart	 from	 SETDB1,	 the	 identities	 of	 the	 other	
enzymes	 required	 for	 KAP1	 repression	 of	 SVA	 and	 LINE1	 remain	 incompletely	
characterized,	although	a	 recent	 study	 in	mouse	ESCs	has	 revealed	other	potential	
candidates	such	as	Chaf1a	(Yang	et	al.,	2015).	
KAP1	 is	 a	ubiquitously	expressed	protein	 implicated	 in	numerous	processes	
including	 cell	 differentiation,	 pluripotency	 maintenance,	 tumor	 development,	 cell	
cycle	and	apoptosis	(Iyengar	and	Farnham,	2011).	 	 It	 is	composed	of	a	RING-B-box-
Coiled-coil	 (RBCC)	 domain	 at	 its	 N-terminal,	 a	 heterochromatin	 protein	 1	 (HP1)	
binding	domain,	a	plant	homeodomain	(PHD)	and	a	bromodomain	at	 its	C-terminal	
(Cammas	et	al.,	2000).	The	trimerisation	of	the	RBCC	domain	encapsulates	the	KRAB	
domain	 in	 a	 protease-resistant	 core	 to	 promote	 the	 folding	 of	 the	 KRAB	 domain,	
which	 enables	 an	 interaction	 between	 the	 two	 domains	 (Peng	 et	 al.,	 2000).	 	 The	
other	domains	are	 involved	 in	 the	 recruitment	of	downstream	silencing	complexes	
including	SETDB1,	heterochromatin	proteins	of	the	HP1	family	and	the	NuRD	histone	
deacetylase	 complex	 (Ayyanathan	 et	 al.,	 2003;	 Cammas	 et	 al.,	 2004;	 Ivanov	 et	 al.,	
2007;	 Peng	 et	 al.,	 2000;	 Satou	 et	 al.,	 2001;	 Sripathy	 et	 al.,	 2006;	 Underhill	 et	 al.,	
2000;	 Zeng	 et	 al.,	 2008).	 The	 central	 HP1	 binding	 domain	 contains	 a	 hydrophobic	
PxVxL	 pentapeptide	 and	 its	 interaction	 with	 the	 chromodomain	 domain	 of	 HP1	
proteins	has	been	shown	to	be	required	for	gene	silencing	(Nielsen	et	al.,	1999).	The	
rest	of	the	central	region	is	highly	extended	and	flexible,	possibly	providing	KAP1	the	
adaptability	to	interact	with	a	plethora	of	protein	complexes	(Lechner	et	al.,	2000).	
The	 bromodomain	 of	 KAP1	 can	 interact	 with	 the	 backbone	 of	 histone	 tails	 and,	
together	with	the	PHD	domain,	interact	with	the	NuRD	complex	and	SETDB1	(Schultz	
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et	 al.,	 2002;	 Schultz	 et	 al.,	 2001).	 Its	 interaction	 with	 SETDB1	 is	 dependent	 on	
sumoylation	at	lysines	554,	575,	676,	750,	779,	and	804	of	the	bromodomain	(Zeng	
et	al.,	2008)	and	this	is	mediated	by	the	intramolecular	E3	ligase	activity	of	the	PHD	
domain	 (Ivanov	 et	 al.,	 2007).	 The	 sumoylation	 of	 KAP1	 residues	 stimulates	 the	
histone	 methyltransferase	 activity	 of	 SETDB1	 and	 the	 resulting	 H3K9me3	 then	
creates	a	high	affinity	binding	site	 for	 the	KAP1-HP1	complex	 (Ivanov	et	al.,	2007).	
These	 interactions	 provide	 a	 mechanistic	 basis	 for	 the	 deposition	 of	 repressive	
chromatin	marks	and	the	spread	of	heterochromatin	(Frietze	et	al.,	2010).	
YY1	and	EBP1 
Zinc	 finger	 protein	 Yin	 Yang	1	 (YY1)	 and	 ErbB3-binding	protein	 (EBP1)	 have	
been	implicated	in	the	MLV	silencing	complex	(Schlesinger	et	al.,	2013;	Wang	et	al.,	
2014a)	 (Figure	 10).	 To	mediate	 repression,	 YY1	 needs	 to	 bind	 to	 the	 LTR	 of	 both	
exogenous	and	endogenous	 retroviruses	 in	ESCs	while	phosphorylation	of	 tyrosine	
residue	383	of	 the	protein	 can	 abrogate	 repression	by	 interrupting	 YY1	binding	 to	
DNA	 and	 RNA	 (Wang	 and	 Goff,	 2015).	 Intriguingly,	 loss	 of	 YY1	 can	 reactivate	
retroviral	genomes	and	leads	to	the	removal	of	H3K9me3	but	not	H3K27me3	histone	
marks	 from	 the	 loci	 (Schlesinger	 et	 al.,	 2013).	 YY1-mediated	 restriction	 and	 its	
interaction	with	KAP1	is	restricted	to	ESCs	and	this	pathway	plays	little	or	no	role	in	
differentiated	cells	 (Schlesinger	et	al.,	2013).	EBP1	was	previously	demonstrated	to	
be	part	of	 the	ZFP809-KAP1	 repression	complex	but	 its	exact	 role	 in	MLV	silencing	
and	ERV	regulation	requires	further	study	(Wang	et	al.,	2014a).		
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Heat	Shock	Protein	90	 
Heat	 Shock	 Protein	 (HSP90)	 was	 shown	 to	 utilise	 the	 KAP1-mediated	
epigenetic	pathway	 to	 insulate	 genes	 from	 the	 regulatory	 influence	of	nearby	ERV	
loci	 (Hummel	 et	 al.,	 2017;	 Rowe	 et	 al.,	 2013b)	 (Figure	 10).	 Its	 effect	 on	 KAP1-
regulated	ERVs	can	be	observed	outside	of	ESCs	 in	differentiated	macrophages	but	
its	mechanism	of	action	is	unknown	(Hummel	et	al.,	2017).			
Histone	modifications 
Histone	N-terminal	tails	can	be	targeted	for	chemical	modifications	including	
acetylation,	 phosphorylation,	 methylation	 and	 ubiquitination.	 These	 modifications	
directly	 impact	on	chromatin	structure	and	on	the	access	to	DNA	binding	proteins,	
which	in	turn	affects	gene	expression.	Histone	modifications	play	an	important	role	
in	 gene	 regulation	 as	 well	 as	 in	 retrotransposon	 control.	 Histone	 modifications	
mediated	 by	 proteins	 such	 as	 histone	 deacetylases	 (HDACs),	 histone	
methyltransferases	 (ESET/SETDB1,	 G9a	 and	 Suv420H1/2),	 lysine-specific	 histone	
demethylase	 1A	 (KDM1a/	 LSD1),	 polycomb	 complexes	 and	 the	 arginine	
methyltransferase	 PRMT5	 have	 all	 been	 implicated	 in	 retrotransposon	 repression	
(Garcia-Perez	 et	 al.,	 2010;	 Kim	 et	 al.,	 2014;	 Leeb	 et	 al.,	 2010;	 Leung	 et	 al.,	 2014;	
Leung	 et	 al.,	 2011;	Macfarlan	 et	 al.,	 2011;	Maksakova	 et	 al.,	 2013;	Matsui	 et	 al.,	
2010;	Reichmann	et	al.,	 2012;	Rowe	et	al.,	 2013a;	Rowe	et	al.,	 2013b;	Yang	et	 al.,	
2015).	 Of	 note,	 the	 role	 of	 histone	 methylation	 in	 retrotransposon	 repression	 is	
often	linked	to	DNA	methylation	so	it	is	crucial	to	understand	the	interplay	between	
these	two	types	of	modifications.	
H3K9me3	 is	 the	 most	 common	 repressive	 histone	 mark	 observed	 at	 LTR	
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elements	 and	 can	 be	 deposited	 by	 all	 histone	 methyltransferases	 (HMTases)	 that	
target	H3K9	(Martens	et	al.,	2005;	Mikkelsen	et	al.,	2007).	For	instance,	Suv39h1	and	
Suv39h2	are	involved	in	trimethylation	of	H3K9	at	satellite	repeats	and	knockout	of	
these	proteins	is	lethal	for	embryos	at	the	E12.5	stage	(Lehnertz	et	al.,	2003;	Peters	
et	 al.,	 2001)	 (Figure	 10).	 Another	 HMTase,	 G9a,	 is	 involved	 in	 the	 deposition	 of	
H3K9me1	and	H3K9me2	marks.	While	the	loss	of	G9a	does	not	impact	on	repressive	
H3K9me3	 marks	 at	 retrotransposons,	 DNA	 methylation	 is	 significantly	 reduced	
following	G9a	knockout,	indicating	a	separate	role	in	DNA	methylation	maintenance.	
This	 has	 been	 shown	 to	 be	 due	 to	 its	 recruitment	 of	 DNMTs	 (Dong	 et	 al.,	 2008;	
Tachibana	et	al.,	2008)	(Figure	10).	 In	addition,	the	loss	of	G9a	leads	to	only	a	mild	
upregulation	 of	 IAP	 elements	 suggesting	 that	 histone	 methylation	 is	 sufficient	 to	
silence	 certain	 retrotransposons	 in	 the	 absence	 of	 DNA	 methylation.	 SETDB1	 has	
directly	 been	 shown	 to	 play	 a	 role	 in	 repressing	 ERVs	 in	 both	 ESCs	 and	 somatic	
tissues	 (Collins	et	al.,	 2015;	 Jahner	et	al.,	 1982;	Matsui	et	al.,	 2010)	 (Figure	11).	 In	
support	of	this	being	a	main	function	of	SETDB1,	its	knockout	in	mouse	ESCs	results	
in	elevated	expression	of	MusD	and	 IAP	elements	 (Matsui	et	 al.,	 2010).	Repressed	
retrotransposons	are	often	enriched	for	multiple	histone	marrks	such	as	H4K20me3,	
H3K9me3	and	H3K27me3	(Kourmouli	et	al.,	2004;	Martens	et	al.,	2005;	Mikkelsen	et	
al.,	 2007)	 suggesting	a	 coordination	between	different	epigenetic	modifiers	 in	ERV	
repression.	For	 instance,	the	overlap	between	H3K9me3	and	H3K27me3	suggests	a	
potential	role	of	Polycomb	group	proteins	as	well	as	Setdb1	in	ERV	silencing	(Golding	
et	al.,	2010;	Leeb	et	al.,	2010).	
The	co-factor	HP1	is	made	of	two	structured	domains,	a	chromodomain	and	a	
chromoshadow	 domain,	 connected	 by	 an	 unstructured	 hinge.	 The	 chromodomain	
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interacts	 with	 KAP1	 and	 H3K9me3	 and	 is	 therefore	 necessary	 for	 ERV	 repression	
(Hiragami-Hamada	et	al.,	2016;	Lachner	et	al.,	2001;	Maksakova	et	al.,	2013;	Sripathy	
et	al.,	2006)	and	the	dimerisation	of	the	protein	is	involved	in	chromatin	compaction	
(Bannister	 et	 al.,	 2001;	 Lachner	 et	 al.,	 2001;	 Smothers	 and	 Henikoff,	 2000).	 Upon	
binding	to	methylated	nucleosomes,	HP1	undergoes	a	switch	from	an	auto-inhibitory	
state	 to	a	 spreading	 competent	 state	 (Canzio	et	 al.,	 2013)	 and	 this	 interaction	has	
also	been	observed	in	differentiated	cells	(Sharma	et	al.,	2012;	Wolf	et	al.,	2008a).		
H3.3	and	HUSH 
Recently,	the	chaperone	complex	containing	histone	variant	H3.3,	deposited	
by	α-thalassaemia/mental	retardation	syndrome	X-linked	(ATRX)	and	death-domain-
associated	protein	 (DAXX),	was	 shown	to	be	 required	 for	ERV	 repression	 in	mouse	
ESCs	(Elsässer	et	al.,	2015;	Sadic	et	al.,	2015)	(Figure	10).	This	study	shows	that	H3.3	
is	enriched	at	class	I	and	class	II	ERVs	(particularly	ETN/MusD	and	IAP	elements)	and	
deposition	at	these	elements	is	dependent	on	ATRX	and	DAXX	(Elsässer	et	al.,	2015).	
However,	whether	H3.3	plays	any	functional	role	 in	ERV	repression	 is	controversial	
(Wolf	et	al.,	2017).	
The	 Human	 silencing	 hub	 (HUSH)	 is	 another	 recently	 described	 complex	
implicated	 in	 the	 silencing	 of	 newly	 integrated	 DNA	 in	 the	 host	 genome	 and	may	
potentially	play	a	 role	 in	ERV	repression	 (Tchasovnikarova	et	al.,	2015)	 (Figure	10).	
This	complex	is	composed	of	Tasor,	MPP8,	and	periphilin	proteins	and	it	is	conserved	
from	fish	to	humans	(Tchasovnikarova	et	al.,	2015).	The	HUSH	complex	is	recruited	
to	genomic	loci	by	interacting	with	H3K9me3	resulting	in	more	Setdb1	recruitment,	
which	in	turn	increases	the	levels	of	H3K9me3	marks	in	a	positive	feedback	loop	(Li	
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et	 al.,	 2011;	 Tchasovnikarova	 et	 al.,	 2017;	 Tchasovnikarova	 et	 al.,	 2015).	 An	
independent	 study	 has	 reported	 an	 interaction	 between	 the	 chromodomain	 of	
MPP8,	dimethylated	DNMT3A	(at	lysine	residue	44)	(Dnmt3ak44me2)	by	G9a	or	GLP	
protein	 (Chang	 et	 al.,	 2011)	 leading	 to	 the	 formation	 of	 Dnmt3a-MPP8-G9a/GLP	
complex,	 providing	 a	 possible	 link	 between	 histone	 modifications	 and	 DNA	
methylation	(Chang	et	al.,	2011).	
Histone	deacetylation	 
Histone	 deacetylation	 occurs	 on	 histone	 3	 and	 histone	 4	 tails	 at	 lysine	
residues	 and	 plays	 a	 role	 in	 the	 repression	 of	 IAP	 elements.	 Consistent	 with	 this,	
inhibiting	 histone	 deacetylases	 (HDAC)	 has	 been	 connected	 to	 the	 reactivation	 of	
virus-like	 30S	 elements	 in	 mice	 (Chen	 and	 Townes,	 2000;	 Lorincz	 et	 al.,	 2000;	
Schübeler	et	al.,	2000).	In	addition,	chemical	modifications	can	also	act	cooperatively	
with	 other	 epigenetic	 modifications	 such	 as	 histone	 methylation.	 For	 instance,	
components	of	 the	CoRest	 complex,	which	 includes	 LSD1	 (or	KDM1A),	HDAC1	and	
HDAC2,	 can	 mediate	 the	 removal	 of	 H3K4me1	 and	 H3K4me2	 and	 loss	 of	 histone	
acetylation	 cooperatively	 to	 create	a	 repressive	 chromatin	environment	 (Shi	et	 al.,	
2004;	 You	 et	 al.,	 2001).	 DNA	 methylation	 has	 also	 been	 linked	 to	 histone	
deacetylation	through	an	interaction	between	methyl-CpG-binding	protein	(MeCP2)	
and	deacetylase	complexes	(Jones	et	al.,	1998;	Nan	et	al.,	1998).		
DNA	methylation 
DNA	 methylation	 of	 retrotransposons	 is	 re-established	 following	 global	
demethylation	and	zygotic	genome	activation	in	cleavage	embryos.	DNA	methylation	
is	 mediated	 by	 DNA	 methyltransferases	 (DNMTs),	 which	 comprise	 the	 four	
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members:	 DNMT3a,	 DNMT3b,	 DNMT1	 and	 DNMT3L	 (Figure	 10).	 DNMT3a	 and	
DNMT3b	mediate	de	novo	DNA	methylation,	while	DNMT1	protein	maintains	DNA	
methylation	 in	 dividing	 cells	 and	 DNMT3L,	 which	 lacks	 enzymatic	 activity,	 is	
important	 for	 targeting	 the	 de	 novo	 methylation	 complex	 involving	 DNMT3a	 and	
DNMT3b	 (Bestor	 et	 al.,	 1988;	 Bestor,	 1988;	 Chedin	 et	 al.,	 2002;	 Ooi	 et	 al.,	 2007;	
Suetake	 et	 al.,	 2004).	 In	 mice,	 the	 loss	 of	 DNMT3b	 has	 been	 shown	 to	 result	 in	
increased	 activity	 of	 IAP	 and	 endogenous	 MLV	 elements	 but	 the	 effect	 is	 more	
dramatic	upon	loss	of	DNMT1	(Okano	et	al.,	1998).	A	DNMT3a-DNMT3L	complex	has	
been	 reported	 to	 bind	 to	 unmethylated	 H3K4	 tails,	 thereby	 targeting	 DNA	
methylation	 away	 from	active	 regions	 that	 are	marked	by	mono-methylated	H3K4	
(Ooi	 et	 al.,	 2007).	 After	 de	 novo	 methylation,	 ERV	 silencing	 is	 dependent	 on	 the	
maintenance	of	methylation	at	these	loci	and	the	loss	of	DNMT1	or	DNA	methylation	
can	 lead	 to	 embryonic	 lethality	 and	 aberrant	 immune	 activation	 in	 cancer	 cells	
(Chiappinelli	et	al.,	2015;	Roulois	et	al.,	2015;	Walsh	et	al.,	1998).	The	mechanism	of	
DNA	methylation	maintenance	by	DNMT1	involves	binding	to	hemi-methylated	DNA	
and	H3K9me2/3	 in	 a	UHRF1	 (also	 known	as	NP95	or	 ICBP90)	 -	 dependent	manner	
(Liu	 et	 al.,	 2013).	 In	 pre-implantation	 embryos,	 however,	 DNMT1	 is	 involved	 in	
protecting	 certain	 IAP1	 insertions	 and	 imprinted	 regions	 from	 global	 DNA	
demethylation	 but	 it	 is	 unclear	 how	 DNMT1	 is	 preferentially	 maintained	 at	 these	
regions	(Lane	et	al.,	2003;	Reik,	2007).	
Lymphoid-specific	helicase	1	(LSH1)	has	also	been	reported	to	be	 important	
for	the	methylation	of	elements	such	as	IAPs,	L1s	and	SINE	B1s	in	mice	(Dennis	et	al.,	
2001).	LSH1	knockout	leads	to	the	loss	of	repressive	histone	marks	and	derepression	
of	retrotransposons	without	affecting	neighbouring	genes,	 indicating	the	specificity	
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of	LSH1-mediated	repression	(Huang	et	al.,	2004;	Yan	et	al.,	2003).	This	pathway	has	
previously	 been	 linked	 to	 DNMT3a	 and	 DNMT3b-mediated	 methylation	 by	 an	
unknown	mechanism	(Zhu	et	al.,	2006).	
1.3.3	ERV	regulation	in	somatic	cells		
It	is	known	that	embryonic	stem	cells	possess	intrinsic	factors	that	gradually	
repress	 retroviruses	and	part	of	 this	 silencing	activity	 is	 linked	 to	 the	KZNF	 /	KAP1	
pathway	 (Friedli	 et	 al.,	 2014;	Rowe	et	 al.,	 2010;	 Teich	 et	 al.,	 1977;	Wolf	 and	Goff,	
2007;	Wolf	and	Goff,	2009;	Wolf	et	al.,	2008b).	This	has	been	documented	 in	both	
mouse	 and	 human	 ES	 cells	 and	 is	 consistent	with	 in	 vivo	data	 (Grow	 et	 al.,	 2015;	
Macfarlan	 et	 al.,	 2012;	 Rowe	 et	 al.,	 2010).	 Beyond	 the	 blastocyst	 stage,	 ERV	
sequences	 are	 thought	 to	 regain	 DNA	 methylation,	 allowing	 their	 potential	
permanent	inactivation	in	somatic	tissues	(Yoder	et	al.,	1997)	in	which	KAP1	may	be	
redundant	(Martens	et	al.,	2005;	Meissner	et	al.,	2008;	Mikkelsen	et	al.,	2007;	Rowe	
et	al.,	2013a;	Rowe	et	al.,	2010).	DNA	methylation	becomes	the	dominant	silencing	
mechanism	later	 in	development,	for	example	in	E9.5	embryos	(Walsh	et	al.,	1998)	
and	in	murine	embryonic	fibroblasts	that	are	isolated	at	E13	(Rowe	et	al.,	2013a).	
Longstanding	 parallel	 data,	 however,	 has	 documented	 widespread	
transcription	 of	 ERVs	 in	multiple	 tissues	 including	 in	 blood	 and	 brain	 (Krieg	 et	 al.,	
1992;	Muotri	et	al.,	2005;	Reilly	et	al.,	2013)	strongly	suggesting	that	expression	of	
certain	ERVs	is	tissue–specific	similar	to	some	cellular	genes	(Ecco	et	al.,	2016;	Fort	
et	 al.,	 2014;	Goke	et	 al.,	 2015).	 Indeed,	KAP1	has	been	 reported	 to	 regulate	 some	
ERVs	 and	 related	 genes	 in	 neural	 progenitor	 cells	 and	 even	 in	 differentiated	 cells	
including	mouse	 liver	 (Brattas	et	al.,	2017;	Ecco	et	al.,	2016;	Fasching	et	al.,	2015).	
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Setdb1	 has	 been	 shown	 to	 repress	 ERVs	 in	mouse	 B-lymphocytes	 in	 collaboration	
with	 KAP1	 (Collins	 et	 al.,	 2015)	 suggesting	 KAP1	 plays	 a	 continuous	 role	 in	
differentiated	tissues.			
1.3.4	Small	RNA-mediated	repression		
In	plants,	small	RNA-mediated	gene	silencing	via	de	novo	methylation	is	well	
established	(Law	and	Jacobsen,	2010)	and	the	mechanism	appears	relevant	for	ERV	
repression	 because	 it	 involves	 sequence-specificity.	 Small	 RNA-mediated	 gene	
regulation	includes	Piwi-interacting	RNA	(piRNA),	short	interfering	RNA	(siRNA),	and	
microRNA	(miRNA).		
piRNAs	 are	 23-30	 nucleotides	 long	 and	 they	 are	 derived	 from	 repeat-rich	
clusters	and	this	process	 is	 independent	on	dicer.	This	pathway	is	well-described	in	
Drosophila	 in	which	antisense	piRNAs	bind	 to	Piwi	or	Aubergine	proteins	 to	cleave	
sense	mRNAs	from	retrotransposons	 (Aravin	et	al.,	2007).	Piwi-like	proteins	known	
as	Miwi,	Mili	and	Miwi2	are	found	in	the	germ	line	(Aravin	et	al.,	2007;	Girard	et	al.,	
2006).	 	 The	 resulting	 sense	 piRNAs	 can	 bind	 Ago3	 proteins,	 which	 then	 cleave	
antisense	mRNAs.	This	“ping-pong”	mechanism	amplifies	the	piRNAs	and	cleaves	the	
retrotransposon	mRNAs	resulting	in	silencing.	In	mice,	the	same	pathway	is	involved	
in	the	cleavage	of	retrotransposon	mRNAs	and	loss	of	these	proteins	has	been	linked	
to	the	activation	of	IAP	and	L1	elements.	
Unlike	piRNAs,	the	biogenesis	of	siRNA	is	Dicer-dependent	and	this	pathway	
is	well	characterized	in	Drosophila	(Ghildiyal	and	Zamore,	2009).	siRNA	production	is	
initiated	by	the	recognition	of	intracellular,	long,	double-stranded	RNAs	(dsRNAs)	by	
Dicer-2,	which	then	cleaves	them	into	siRNAs	(Weber	et	al.,	2006).	siRNAs	bind	Ago2	
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but	with	only	one	of	the	duplex	and	the	resulting	siRNA-Ago2	RNA-induced	silencing	
complex	(RISC)	recognises	complementary	transcripts	and	cleaves	them	(Bronkhorst	
and	 van	 Rij,	 2014;	 Ghildiyal	 and	 Zamore,	 2009).	 A	 proportion	 of	 siRNAs	 are	 of	
endogenous	 origin	 (endo-siRNAs)	 and	 can	 therefore	 be	 directed	 towards	
retrotransposons	 (Ghildiyal	 and	 Zamore,	 2009).	 There	 is	 also	 supporting	 evidence	
showing	that	siRNAs	play	a	role	 in	 the	repression	of	both	 IAPs	and	L1	 in	mouse	ES	
cells	(Svoboda	et	al.,	2004;	Yang	and	Kazazian,	2006).		
A	 third	 class	 of	 small	 RNAs	 is	 known	 as	 miRNAs	 that	 are	 synthesized	 in	 a	
Dicer-dependent	manner	(Ghildiyal	and	Zamore,	2009).	miRNAs	are	encoded	in	the	
genome	and	derived	 from	primary	miRNA	transcripts	 (pri-miRNAs),	which	are	 then	
cleaved	 into	 shorter	 precursors	 (pre-miRNAs)	 by	 Drosha	 protein	 (Ghildiyal	 and	
Zamore,	2009;	Siomi	et	al.,	2011).	Pre-miRNAs	are	then	processed	by	Dicer-1	and	the	
mechanism	of	degrading	complementary	transcripts	 is	mediated	by	Ago1	(Ghildiyal	
and	Zamore,	2009).		
Despite	 reports	 of	 small	 RNAs	 repressing	 retrotransposons	 or	 exogenous	
pathogens,	the	precise	importance	of	their	role	in	repression	in	human	cells	remains	
relatively	unexplored.	
1.3.5	Restriction	factors		
A	network	of	restriction	factors	including	APOBEC3s,	SAMHD1,	Fv1	and	Trex1	
have	evolved	to	protect	the	host	cell	from	exogenous	retroviral	(XRVs)	assaults	(Best	
et	 al.,	 1996;	 Lahouassa	 et	 al.,	 2012;	 Sheehy	 et	 al.,	 2002;	 Yan	 et	 al.,	 2010).	 The	
similarity	 of	 life	 cycle	 between	 ERVs	 and	 XRVs	means	 that	 these	 factors	 can	 also	
restrict	ERVs,	which	is	presumably	their	primary	purpose.	
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APOBEC3	 proteins	 work	 by	 interfering	 with	 the	 processivity	 of	 reverse	
transcriptase	 and	 induce	 hypermutation	 of	 viral	 cDNAs	 by	 cytidine	 deamination.	
APOBEC3	 has	 been	 shown	 to	 restrict	 the	 activities	 of	 L1,	 Alu,	 IAP1	 and	 MusD	
elements	 (Esnault	 et	 al.,	 2005).	 APOBEC3s	 can	 theoretically	 act	 at	 the	 post-
transcriptional	 stage	 of	 the	 ERV	 life-cycle	 and	 can	 introduce	 mutations	 to	
retrotransposons	rendering	them	inactive.		
Trex1	 is	 a	 3’-5’	 DNA	 exonuclease	 that	 plays	 a	 role	 in	 preventing	 the	
accumulation	of	 reverse-transcribed	cDNA	 in	 the	cytoplasm	 (Yan	et	al.,	2010).	This	
mechanism	has	been	demonstrated	 for	both	HIV-1	and	endogenous	retroelements	
(Stetson	et	al.,	2008;	Yan	et	al.,	2010),	the	latter	which	was	shown	using	TREX1	KO	
mice.	When	TREX1	was	overexpressed,	 it	 reduced	 the	 retrotransposition	of	L1	and	
IAP	 elements	 in	 vitro	while	 Trex1	 knockout	 (KO)	 led	 to	 an	 accumulation	 of	 single	
stranded	 DNA	 (ssDNA)	 from	 L1,	 SINEs	 and	 ERVs	 within	 heart	 cells	 of	 KO	 mice	
(Stetson	et	al.,	2008).	
The	role	of	SAMHD1	as	a	restriction	factor	was	first	reported	in	the	context	of	
HIV-1	infection	via	a	mechanism	involving	the	control	of	dNTP	pools	in	immune	cells	
(Ryoo	 et	 al.,	 2014).	 This	 is	 through	 SAMHD1’s	 ability	 to	 catalyse	 deoxynucleotides	
(dNTPs)	 into	 deoxyribonucleosides	 and	 triphosphates,	 rendering	 them	 unavailable	
for	DNA	replication	and	reverse	transcription	(Ryoo	et	al.,	2014).	SAMHD1	has	been	
shown	 to	 inhibit	 L1	 retrotransposition	 through	 stress	 granule	 formation	 but	 its	
importance	in	controlling	the	activity	of	ERVs	remains	unknown	(Zhao	et	al.,	2013).	
Restriction	 factors	 can	 also	 be	 derived	 from	 endogenous	 Env	 or	 Gag	 proteins	
produced	from	ERV	elements	themselves,	which	is	the	case	for	the	Fv1	protein.	Fv1	
resembles	 a	 MERV-L	 Gag	 and	 it	 can	 block	 MLV	 infection	 at	 a	 post-reverse	
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transcription	 stage	 (Best	 et	 al.,	 1996).	 This	 block	 is	 likely	 to	 be	mediated	 through	
capsid	 interaction	 and	 such	 protection	 offered	 by	 ERVs	 is	 similar	 to	 the	 recently	
proposed	role	of	HERV-K	Rec	protein	(Grow	et	al.,	2015;	Kaiser	et	al.,	2007).			
1.4	ERVs	and	the	immune	system	
The	 life	 cycle	 of	 ERVs	 involves	 proviral	 transcription,	 export	 of	 the	mRNA	 and	
translation	of	viral	proteins.	Transcripts	can	then	be	reverse	transcribed	into	cDNA	in	
the	 cytosol	 resulting	 in	 their	 potential	 integration	 into	 the	 host	 genome.	
Interestingly,	 nascent	 viral	 particles	 have	been	observed	budding	 from	 the	plasma	
membrane	 although	 these	 have	 been	 shown	 to	 be	 non-infectious	 retroviral-like	
particles	(RLPs)	(Bieda	et	al.,	2001;	Grow	et	al.,	2015).	Despite	ERVs	only	very	rarely	
giving	rise	to	 infectious	viruses,	ERVs	have	been	 linked	to	 immune	modulation	and	
autoimmune	diseases.		
Given	 the	exaptation	of	ERVs	over	millions	of	 years,	 it	has	been	proposed	 that	
the	host	should	have	developed	sufficient	immune	tolerance	to	ERV	proteins	and	see	
ERVs	as	‘self’	(Tugnet	et	al.,	2013).	However,	the	connection	between	autoimmune	
diseases	 and	 ERVs	 challenges	 this	 idea	 (Section	 1.2.3).	 In	 addition,	 ERV-induced	
innate	 immune	 activation	 in	 cancer	 cells	 as	well	 as	 in	 immune	 cells	 suggests	 that	
these	 elements	 still	 retain	 their	 ‘foreign’	 characteristics	 (Chiappinelli	 et	 al.,	 2015;	
Goel	et	al.,	2017;	Roulois	et	al.,	2015;	Zeng	et	al.,	2014).	One	mechanism	by	which	
ERVs	can	trigger	an	 immune	response	 is	by	producing	nucleic	acids	 (both	RNA	and	
DNA)	 that	 resemble	 pathogen-associated	 molecular	 patterns	 (PAMPs)	 thereby	
activating	 pattern	 recognition	 receptors	 (PRRs).	 PRR	 activation	 invokes	 a	 series	 of	
complex	 signalling	 pathways,	 which	 results	 in	 the	 production	 of	 pro-inflammatory	
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cytokines,	 chemokines	 and	 type	 I	 interferons	 (IFN-α	 and	 IFN-β).	 The	 causative	
contribution	 of	 ERVs	 to	 different	 disease	 phenotypes	 is	 unclear	 and	 how	 the	 host	
sees	 certain	 ERVs	 as	 self	 and	 others	 as	 foreign	 also	 requires	 further	 investigation.	
ERV	proteins	might	cause	damage	or	cellular	stress	to	host	cells	(Tang	et	al.,	2012),	
which	in	turn	gives	rise	to	danger-associated	molecular	patterns	(DAMPs)	that	would	
activate	similar	classes	of	PRRs	and	IFN	signalling	(Tang	et	al.,	2012).	
1.4.1	Toll-like	receptors	
Toll-like	 receptors	 (TLRs)	 are	 transmembrane	 proteins	 found	 either	 on	 the	
plasma	membrane	or	on	endosomal	membranes	and	there	are	10	human	TLRs,	each	
with	 different	 subcellular	 localisations	 and	 cognate	 ligands	 (Lester	 and	 Li,	 2014)	
(Figure	12).	TLRs	are	made	up	of	an	extracellular	ligand-binding	domain	with	leucine-
rich	repeats	and	a	conserved	cytosolic	domain	comprising	a	Toll-IL-1	resistance	(TIR)	
domain	(O'Neill	et	al.,	2013).	Upon	ligand	binding,	signalling	from	the	TLRs	involves	
dimerization	and	the	recruitment	of	TIR	domain-containing	adaptor	molecules,	such	
as	 myeloid	 differentiation	 factor	 88	 (MyD88)	 to	 the	 TIR	 domains	 (Lester	 and	 Li,	
2014).	 This	 then	 activates	 a	 cascade	 of	 intracellular	 kinases	 and	 ubiquitin	 ligases	
resulting	in	the	nuclear	translocation	of	transcription	factors	such	as	NF-κB	and	IRF	3	
and	 7	 (O'Neill	 et	 al.,	 2013)	 (Figure	 11),	 which	 in	 turn	 activates	 the	 expression	 of	
proinflammatory	cytokines	and	type	I	IFNs	(Figure	11).		
TLRs	 1,	 2,	 4,	 and	 5	 are	 all	 localised	 to	 the	 plasma	membrane.	 TLR2	 can	 recognise	
bacterial	 lipopeptides	 by	 heterodimerisation	 with	 TLR1	 to	 sense	 triacylated	
lipopeptides	 and	with	 TLR6	 to	 detect	 diacylated	 lipopeptides	 (O'Neill	 et	 al.,	 2013)	
(Figure	11).	TLR2	has	also	been	shown	to	recognise	a	wide	variety	of	non-lipopeptide	
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PAMPs	 (Kawai	 and	 Akira,	 2009).	 TLR4	 acts	 as	 a	 sensor	 for	 the	 bacterial	 product	
lipopolysaccharide	 (LPS)	 while	 TLR5	 has	 been	 shown	 to	 sense	 bacterial	 flagellin	
(O'Neill	et	al.,	2013)	(Figure	11).	On	the	other	hand,	TLRs	3,	7,	8,	and	9	are	localised	
to	 the	 endosomal	 lumen	 and	 bind	 nucleic	 acid	 ligands	 (Figure	 11).	 TLR3	 senses	
dsRNA,	TLR7	and	8	detect	ssRNA,	and	TLR9	recognises	unmethylated	CpG	DNA	and	
RNA:DNA	 hybrids	 (Gürtler	 and	 Bowie,	 2013;	 Rigby	 et	 al.,	 2014)	 (Figure	 11).	 The	
ligand	 for	 TLR10	 has	 not	 yet	 been	 identified	 but	 the	 sequence	 of	 the	 receptor	 is	
known	 to	 be	 most	 similar	 to	 that	 of	 TLR1	 and	 may	 have	 the	 capability	 to	
heterodimerise	 with	 TLR2	 (O'Neill	 et	 al.,	 2013).	 TLR2	 has	 been	 implicated	 in	 the	
induction	of	NF-κB	in	psoriasis	and	this	is	linked	to	single-nucleotide	polymorphisms	
in	 HERV-K	 dUTPase	 (Ariza	 and	 Williams,	 2011).	 This	 HERV-K	 mediated	 immune	
activation	 also	 results	 in	 a	 Th1	 and	 Th17	 cytokine	 response	 (Ariza	 and	 Williams,	
2011).	 Despite	 this	 link,	whether	 the	UTPase	 is	 detected	 by	 TLR2	 directly	 remains	
unknown	because	TLR2	 is	expressed	on	 the	cell	 surface	while	HERV-K	proteins	are	
expressed	intracellularly.		
TLR4	and	CD14	have	been	reported	to	interact	with	the	Env	protein	of	HERV-
W	in	the	context	of	multiple	sclerosis	(Rolland	et	al.,	2005;	Rolland	et	al.,	2006).		This	
interaction	results	 in	 the	production	of	pro-inflammatory	cytokines	 including	 IL-1β,	
IL-6	 and	 TNF-α	 (Rolland	 et	 al.,	 2006)	 in	 addition	 to	 activating	 dendritic	 cells	 and	
inducing	 a	 Th1	 response,	 potentially	 linking	 innate	 and	 adaptive	 aspects	 of	 the	
disease.		
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Figure	11	TLR	signalling	in	response	to	ligand	binding.	
TLRs	 on	 the	 cell	 surface	 (TLR1,	 2,	 4,	 5	 and	 6)	 typically	 detect	 foreign	 lipid	 or	 protein	 ligands	while	
endosomal	TLRs	(TLR3,	7,	8	and	9)	sense	nucleic	acids.	The	signalling	pathway	has	been	simplified	to	
show	all	the	members	of	the	TLR	family	as	well	as	their	respective	ligands.	The	signalling	pathways	for	
TLRs	involve	multiple	kinases	in	order	to	link	the	initial	sensing	to	a	resulting	pro-inflammatory	state.	
Following	ligand	binding,	TLR4	recruits	MyD88	using	its	TIR	domain.	This	then	leads	to	the	recruitment	
of	 IRAKs	and	activation	of	TRAF6,	an	E3	ubiquitin	 ligase	 for	TAK1.	Ubiquitinated	TAK1	 then	 forms	a	
complex	 with	 TAB1	 and	 TAB2.	 This	 activates	 TAK1,	 which	 then	 phosphorylates	 IκB	 kinase	 and	 the	
MAPK	kinases	and	sequentially	activates	NF-κB	followed	by	MAPKs.	MAPK	kinase	then	activates	JNK	
and	p38.	Activated	JNK	and	p38	activate	AP-1	to	drive	the	expression	of	pro-inflammatory	cytokines.	
Activated	NF-κB	also	participates	 in	the	production	of	cytokines	during	 inflammation.	The	 ligand	for	
TLR10	is	currently	unknown.	 
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TLR7	 and	 TLR9	 are	 both	 linked	 to	 the	 production	 of	 the	 ERV	 envelope	
glycoprotein	and	gp70,	an	autoantigen	postulated	to	function	in	the	pathogenesis	of	
SLE	(Yoshinobu	et	al.,	2009).	 In	a	lupus-prone	mouse	model,	TLR7	and	9	have	been	
demonstrated	 to	 induce	 the	 production	 of	 serum	 gp70	 and	 contribute	 to	
inflammation	 in	 the	mouse	model	 (Baudino	et	al.,	 2010).	Another	 line	of	evidence	
comes	 from	 the	 deficiency	 in	 IRF5	 a	 specific	 signalling	 pathway	 used	 by	 TLR7	 and	
TLR9	in	the	mouse	model.	This	deficiency	leads	to	an	increase	in	gp70	gag	and	env	
mRNA	suggesting	that	IRF5,	TLR7,	and	TLR9	are	involved	in	the	control	of	murine	ERV	
expression	 (Yu	 et	 al.,	 2012).	 Furthermore,	 TLR7	 has	 also	 been	 shown	 to	 facilitate	
antibody	 production	 and	 class	 switching	 in	 mice	 (Browne,	 2011)	 and	 a	 TLR7	
deficiency	 results	 in	 the	 failure	 of	 antibody	 production	 that	 is	 required	 to	 control	
ERV	viraemia	(Yu	et	al.,	2012).		
1.4.2	RNA	sensing		
In	 addition	 to	 the	 TLRs,	 cytosolic	 RNAs	 are	 sensed	 by	 a	 series	 of	 PRRs	
including	 retinoic	 acid-inducible	 gene	 I	 (RIG-I)	 and	 melanoma	 differentiation-
associated	 gene	 5	 (MDA5).	 These	 belong	 to	 the	 RIG-I-like	 receptor	 (RLR)	 family,	 a	
class	 of	 RNA	 helicases	 that	 recognise	 viral	 RNA	 in	 the	 cytoplasm	 and	 induce	 the	
production	of	 type	 I	 IFNs	 (Gürtler	and	Bowie,	2013).	RIG-I	 senses	short	dsRNA	and	
ssRNA	 with	 a	 5’-triphosphate	 moiety	 while	 MDA5	 detects	 long	 dsRNA	 molecules	
(Kato	et	al.,	2008)	 (Figure	12).	Following	detection,	RIG-I	and	MDA5	signal	 through	
their	 N-terminal	 homotypic	 CARD	 interaction	 with	 the	 mitochondrial	 outer-
membrane-localised	 adaptor	 molecule	 mitochondrial	 antiviral	 signalling	 (MAVS)	
(Gürtler	 and	 Bowie,	 2013)	 (Figure	 12).	 This	 leads	 to	 the	 phosphorylation	 of	
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transcription	 factors	 IRF	 3	 and	7.	 The	phosphorylated	 IRFs	 then	 translocate	 to	 the	
nucleus	 and	 bind	 to	 the	 IFN-stimulated	 regulatory	 element	 (ISRE)	 and	 induce	 IFN	
expression	along	with	other	antiviral	factors	(Hiscott,	2007)	(Figure	12).		
Evidence	 for	 cytosolic	 ERV	 RNA	 sensing	 has	 been	 lacking	 but	 two	
independent	studies	have	recently	shown	that	ERV	RNA	can	activate	innate	immune	
signalling	 in	 cancer	 cells	 (Chiappinelli	 et	 al.,	 2015;	Goel	 et	 al.,	 2017;	 Roulois	 et	 al.,	
2015).	 These	 studies	 utilised	 the	 DNA	methyltransferase	 inhibitor,	 5-Aza	 to	 reveal	
that	5-Aza-driven	immunotherapy	likely	depends	on	ERVs.	The	studies	showed	that	
the	 anti-tumour	 efficacy	 of	 the	 drugs	 is	 mediated	 through	 viral	 mimicry	 through	
dsRNA	 derived	 partly	 from	 ERVs.	 Immune	 activation	 depended	 on	 TLR3	 and	
MDA5/MAVS	recognition	pathways	as	well	as	IRF7,	leading	to	Type	III	IFN	production	
and	 apoptosis	 (Chiappinelli	 et	 al.,	 2015;	 Goel	 et	 al.,	 2017;	 Roulois	 et	 al.,	 2015).	
Sensing	of	ERV	RNA	by	MAVS	has	also	been	previously	documented	to	play	a	role	in	
T-cell	independent	B-cell	responses	in	mice	(Zeng	et	al.,	2014).	These	studies	point	to	
the	 immunostimulatory	 nature	 of	 ERV	 transcripts,	 which	 thus	 need	 to	 be	
metabolised	 in	 order	 to	 prevent	 unwanted	 innate	 immune	 activation.	 The	
mechanism	 by	 which	 the	 host	 metabolises	 cytosolic	 dsRNA	 is	 also	 relevant,	
therefore,	 in	 preventing	 ERV-mediated	 immune	 activation.	 For	 instance,	 the	 3’-5’	
RNA	 SKIV2L	 helicase	 found	 in	 exosomes	 has	 been	 shown	 to	 degrade	
immunostimulatory	 endogenous	 RNA	 molecules	 although	 its	 role	 in	 metabolising	
ERV	transcripts	remains	unknown	(Eckard	et	al.,	2014).		
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1.4.3	DNA	sensing		
Cells	have	also	evolved	a	collection	of	sensors	for	cytosolic	DNA	PAMPs.	The	
absent	in	melanoma	2	(AIM2)-like	receptor	has	been	demonstrated	to	sense	dsDNA	
(Hornung	 et	 al.,	 2009),	 while	 IFN-γ-inducible	 protein	 16	 (IFI16)	 can	 detect	 ssDNA	
(Unterholzner	et	al.,	2010)	(Figure	12).	ssDNA	detected	by	IFI16	has	been	reported	to	
have	 a	 stable	 stem	 loop	 structure	 (Jakobsen	 et	 al.,	 2013)	 (Figure	 12).	 Following	
cytosolic	DNA	detection,	IFI16	recruits	the	adaptor	stimulator	of	IFN	genes	(STING),	
resulting	 in	 IFN-β	 expression	 (Unterholzner	 et	 al.,	 2010)	 (Figure	 12).	 More	 recent	
studies,	however,	have	proposed	that	it	plays	a	major	role	as	an	adaptor	to	the	DNA	
sensing	 pathway	 that	 proceeds	 through	 cGAS	 activation	 (Almine	 et	 al.,	 2017).	
Alternatively,	DNA-dependent	activator	of	IFN	regulatory	factors	(DAI)	has	also	been	
demonstrated	 to	 detect	 long	 dsDNA	 (Takaoka	 et	 al.,	 2007).	 Importantly,	 cGAS	 has	
been	demonstrated	to	detect	DNA	from	retroviruses	(Gao	et	al.,	2013).	DNA	sensing	
by	 cGAS	 results	 in	 the	 production	 of	 2’3’	 cyclic-AMP-GMP	 (cGAMP),	 a	 secondary	
messenger	 molecule,	 which	 then	 activates	 STING	 and	 IRF3	 for	 IFN	 induction	
(Schoggins	et	al.,	2014;	Sun	et	al.,	2013)	(Figure	12).	cGAS	is	the	best	characterised	
DNA	 sensor	 to	date	 and	 is	 plays	 a	major	 role	 in	 cytosolic	DNA	 sensing	 (Sun	et	 al.,	
2013).	 The	 role	of	 ERV	DNA	 in	 stimulating	 the	 innate	 immune	 response	 first	 came	
from	 a	 study	 in	mice	 looking	 at	 the	 3’	 repair	 exonuclease	 1	 (TREX1)	 (Paludan	 and	
Bowie,	2013).	TREX1	is	upregulated	by	the	expression	of	type	I	IFN	and	NF-κB	and	it	
plays	 a	 role	 in	 regulating	 endogenous	 DNA	 PAMPs	 and	 DAMPs	 (Xu	 et	 al.,	 2014).	
TREX1	knockout	mice	induce	an	IRF3-dependent	immune	response	to	cytosolic	DNA,	
which	 is	 thought	 to	 include	 ERV	 cDNA,	 in	 a	 cGAS-	 and	 STING-	 dependent	manner	
(Ablasser	et	al.,	2014).	In	addition,	the	requirement	of	cGAS	to	sense	ERV	cDNA	was		
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Figure	12	Cytosolic	pathogen-recognition	receptor	(PRR)	signalling.	
Cytosolic	 RNA	 sensors	 interact	 with	 MAVS	 through	 CARD-CARD	 domain	 interactions.	 MAVS	 is	
anchored	to	the	outer	membrane	of	mitochondria	and	this	localisation	is	crucial	for	the	transduction	
of	pro-inflammatory	signals	during	the	activation	of	NF-κB	and	IRF3.	DNA	sensors	such	as	cGAS	and	
IFI16	signal	through	STING,	which	is	localised	to	the	endoplasmic	reticulum.	IFI16	can	also	be	found	in	
the	nucleus	 and	 its	 translocation	 to	 the	 cytosol	 in	 involved	 in	 the	 formation	of	 the	 inflammasome.	
Production	of	the	Inflammasome	activates	caspase	1-mediated	cleavage	of	pro-IL-1β.	The	formation	
of	the	inflammasome	can	also	be	induced	by	AIM2	following	ssDNA	detection. 
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also	demonstrated	 in	T-cell	 independent	B-cell	activation	(Zeng	et	al.,	2014).	These	
observations	 suggest	 that,	 at	 least	 in	mice,	 some	 ERVs	 have	 the	 capability	 to	 get	
reverse	transcribed	into	cDNA	and	stimulate	host	innate	immunity.	Despite	this,	the	
identity	of	the	ERVs	responsible	for	these	sensing	events	and	whether	they	encode	
functional	reverse	transcriptases	is	currently	unknown.		
1.4.4	Consequences	of	innate	immune	activation	
During	 infection,	 innate	 immune	activation	results	 in	the	production	of	pro-
inflammatory	mediators	 including	 IFNs,	 cytokines	 and	 chemokines	 and	 establishes	
an	antiviral	state	to	counteract	infection	until	it	is	cleared.	However,	in	the	event	of	
retrotransposon-induced	 immune	 activation,	 the	 presence	 of	 ERV	 transcripts	 may	
continue	 to	 stimulate	 the	 immune	 system	 leading	 to	 chronic	 inflammation	
potentially	contributing	to	autoimmunity.	Chronic	induction	of	potent	IFNs	can	have	
pathological	 effects	 on	 the	 cells.	 For	 instance,	 IFNs	 can	 mediate	 autocrine	 and	
paracrine	 signalling	 leading	 to	 an	 antiviral	 state,	 in	 which	 affected	 cells	 have	 low	
levels	of	cellular	metabolic	processes	and	ultimately	go	into	apoptosis	(Zuniga	et	al.,	
2007).	 Improper	 clearance	 of	 apoptotic	 cells	 can	 present	 another	 source	 of	
autoantigens	 and	 exacerbate	 inflammation	 (Szondy	 et	 al.,	 2014).	 Type	 I	 IFNs	
stimulate	natural	killer	cells	and	clonally	expand	cytotoxic	T	cells,	linking	innate	with	
adaptive	immunity	(Zuniga	et	al.,	2007).	In	a	lupus	model,	self-nucleic	acid	sensing	by	
TLRs	correlates	with	the	production	of	autoantibodies	providing	an	example	of	how	
ERV	detection	by	 PRRs	 can	potentiate	 the	production	of	 autoantibodies	 (Barrat	 et	
al.,	2005).		
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During	 inflammation,	 IFN	 secretion	 can	 create	 a	 positive-feedback	 loop	
whereby	the	transcription	factors	that	get	activated	during	a	change	of	disease	state	
can	bind	 to	and	activate	 the	 transcription	of	more	ERV	 loci.	 In	 silico	 studies	of	 the	
HERV-K	5’LTR	has	led	to	identification	of	multiple	binding	sites	for	pro-inflammatory	
transcription	 factors	 such	 as	 NF-κB	 (Manghera	 and	 Douville,	 2013).	 NF-κB	 is	
commonly	 activated	during	an	 inflammatory	 response	 its	binding	 to	 the	HERV	 LTR	
can	potentially	upregulate	HERV	transcription.	 Indeed,	this	has	been	demonstrated	
using	 LPS	and	TNF-α	 treatments,	 in	which	NF-κB	 induction	 results	 in	 the	 increased	
expression	 of	 HERV-K,	 HERV-H,	 and	 HERV-W	mRNAS	 (Johnston	 et	 al.,	 2001).	 Such	
interaction	 between	 ERVs	 and	 inflammatory	 transcription	 factors	 provides	 a	
mechanism	 through	 which	 endogenous	 elements	 can	 sustain	 inflammation	 and	
contribute	to	disease	progression.		
In	 contrast,	 several	ERV	viral	products	have	been	demonstrated	 to	have	an	
immunosuppressive	effect	on	host	 immunity	 including	 immunosurveillance	evasion	
of	 cancer	 cells	 (Kassiotis,	 2014).	 For	 example,	HERV-FRD	 Env	 protein	 can	 suppress	
the	maternal	 immune	response	 to	 fetal	alloantigens	while	HERV-H	Env	protein	has	
been	 found	 to	 play	 a	 role	 in	 preventing	 immune	 rejection	 of	 tumours	 in	 mice	
(Mangeney	et	al.,	2001;	Mangeney	et	al.,	2007).	In	addition,	HERV-K	Env	protein	has	
been	 found	 to	 contain	 an	 immunosuppressive	 domain	 and	 can	 induce	 the	
production	of	IL-10,	an	immunosuppressive	cytokine	(Morozov	et	al.,	2013).		
1.4.5	ERVs	and	adaptive	immunity	
As	discussed,	it	is	unclear	if	ERVs	are	sensed	as	“self’	or	‘foreign’	by	our	immune	
system	 and	 likely	 depends	 on	 the	 context.	 As	 part	 of	 our	 genome,	 ERV	 protein	
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expression	 during	 thymocyte	 selection	 would	 contribute	 to	 negative	 selection	 of	
cognate	 T-cell	 receptors	 (TCRs)	 in	 the	 thymus	 and	 the	 establishment	 of	
immunological	 tolerance	 towards	 ERV-derived	 antigens.	 While	 many	 ERVs	 are	
epigenetically	 repressed	 and	 therefore	 not	 expressed,	 some	 are	widely	 expressed.	
Indeed,	 these	 commonly-expressed	 endogenous	 retrotransposon-derived	 proteins	
contribute	to	‘self’	peptides	presented	to	developing	T	cells	(Ebert	et	al.,	2009;	Lo	et	
al.,	2009;	Young	et	al.,	2012).	Therefore,	we	would	not	expect	to	be	immune	tolerant	
to	ERVs	that	are	heavily	DNA	methylated	and	therefore	not	expressed	in	the	thymus.	
This	 notion	 is	 supported	 by	 a	 study	 in	 which	 the	 immunisation	 of	mice	 and	 non-
human	 primates	 with	 endogenous	 retroelement	 antigens	 resulted	 in	 strong	 T-cell	
and	 B	 cell	 responses	 suggesting	 that	 some	 endogenous	 antigens	 are	 sensed	 as	
‘foreign’	by	the	host	(Kershaw	et	al.,	2001;	Sacha	et	al.,	2012).	Once	the	TCR	and	BCR	
repertoires	are	established	in	an	individual,	any	endogenous	antigens	that	were	not	
expressed	during	negative	selection	 in	 the	thymus	will	 likely	 to	be	seen	as	 foreign.	
Therefore,	 ERVs	 must	 be	 examined	 individually	 with	 some	 potentially	 viewed	 as	
“self”	and	some	as	“foreign”.	
Importantly,	 when	 LTRs	 escape	 epigenetic	 repression,	 they	 can	 function	 as	
promoters	 and	 enhancers	 and	 potentially	 create	 neo-antigens	 through	 aberrant	
splicing	(see	section	1.2:	The	impact	of	ERVs	on	their	hosts).	For	example,	a	HERV-E	
locus	upstream	of	the	human	CD5	gene	has	been	shown	to	initiate	the	production	of	
an	 alternatively	 spliced	 CD5	 mRNA	 (Renaudineau	 et	 al.,	 2005)	 and	 in	 turn	 a	
truncated	 intracellular	 form	of	 the	CD5	protein.	Adaptive	 immunity	against	ERVs	 is	
not	 limited	 to	 T	 cell	 responses	 as	 antibody	 responses	 too	 have	 been	 found	 to	 be	
important	(Young	et	al.,	2012)	
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The	 best	 known	 example	 of	 a	 T	 cell	 population	 that	 is	 specific	 for	 an	 ERV	 is	 a	
particular	 TCR	 Vβ	 family	 that	 is	 reactive	 to	 endogenous	 MMTV-encoded	
superantigens	 (Ebert	 et	 al.,	 2009;	 Lo	et	 al.,	 2009).	 These	T	 cells	 are	not	negatively	
selected	 and	 interestingly,	 a	 fraction	 of	 the	 reactive	 thymocytes	 develop	 into	
regulatory	T	cells	(TReg),	which	can	suppress	stimulation	from	MMTV	while	retaining	
their	 ability	 to	 react	 to	 self-antigens	 (MMTV).	 Superantigen-reactive	 TReg	 cells	
circulate	 in	 the	 periphery	 and	 prevent	 excessive	 immune	 pathology	 (Myers	 et	 al.,	
2013;	Punkosdy	et	al.,	2011).		
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Rationale	
It	 is	 well	 known	 that	 embryonic	 stem	 cells	 possess	 intrinsic	 factors	 that	
repress	 retroviruses	and	part	of	 this	 silencing	activity	 is	 linked	 to	 the	KZNF	 /	KAP1	
pathway	 (Rowe	et	 al.,	 2010;	 Teich	et	 al.,	 1977;	 Turelli	 et	 al.,	 2014;	Wolf	 and	Goff,	
2007;	 Wolf	 and	 Goff,	 2009;	 Wolf	 et	 al.,	 2008b).	 This	 mechanism	 has	 been	
documented	 in	both	mouse	and	human	ES	cells	and	 is	consistent	with	 in	vivo	data	
showing	 that	 the	 activity	 of	 several	 ERVs	 peaks	 during	 early	 development	 before	
their	 KAP1-mediated	 repression	 around	 the	 blastocyst	 stage	 (Grow	 et	 al.,	 2015;	
Macfarlan	 et	 al.,	 2012;	 Rowe	 et	 al.,	 2010).	 KAP1	 repression	 results	 in	 histone	 and	
DNA	methylation,	 the	 latter	which	might	 replace	 the	 role	of	KAP1	 in	adult	 tissues,	
since	 KAP1	 is	 no	 longer	 required	 to	 repress	 IAP	 elements	 in	 mouse	 embryonic	
fibroblasts	(Rowe	et	al.,	2010).	
The	 focus	 of	 my	 thesis,	 therefore,	 is	 to	 investigate	 the	 role	 of	 KAP1	 in	
retroviral	 repression	 outside	 of	 development.	 The	 relevance	 of	 this	 work	 is	 that	
retroviral	 transcriptional	 repression	 mechanisms	 operating	 in	 adult	 tissues	 are	
essential	to	prevent	untoward	innate	and	adaptive	immune	recognition	of	ERVs	that	
may	lead	to	autoimmunity.	Moreover,	ERV	innate	sensing	has	recently	been	shown	
to	 lie	at	 the	heart	of	 cancer	and	 immunity	 (Chiappinelli	et	al.,	2015;	Roulois	et	al.,	
2015).	
Several	lines	of	evidence	suggest	that	KAP1	may	restrict	retroviruses	beyond	
early	 development.	 Firstly,	 intriguingly,	 it	 has	 been	 shown	 that	 in	 mouse	 neural	
progenitor	cells	(NPCs),	KAP1	still	plays	a	role	in	repressing	certain	ERV	families	and	
still	 also	 influences	 transcriptional	 networks	 through	 ERVs	 (Brattas	 et	 al.,	 2017;	
Fasching	 et	 al.,	 2015)	 like	 in	 ES	 cells	 (Rowe	 et	 al.,	 2013a;	 Turelli	 et	 al.,	 2014).	
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However,	since	NPCs	are	 isolated	from	developing	mouse	embryos,	 this	work	does	
not	 reveal	 a	 role	 for	 KAP1	 beyond	 development.	 Secondly,	 studies	 in	 ZFP809	
knockout	mice	showed	an	upregulation	of	VL30-pro	retroviral	transcripts	in	somatic	
tissues	(Wolf	et	al.,	2015).	However,	this	was	not	a	conditional	knockout	and	it	was	
molecularly	linked	back	to	the	failure	of	these	mice	to	establish	VL30	repression	and	
DNA	methylation	 in	 early	 development	 due	 to	 the	 lack	 of	 Zfp809	 protein.	 Thirdly,	
Setdb1	has	been	 shown	 to	 repress	 ERVs	 in	mouse	B	 lymphocytes	 and	 this	histone	
methyltransferase	 functions	 at	 least	 at	 some	 sites	 with	 KAP1(Collins	 et	 al.,	 2015).	
Finally	 and	 most	 importantly,	 KAP1	 represses	 several	 cellular	 genes	 through	 ERV	
binding	sites	in	mouse	liver	(Ecco	et	al.,	2016)	
Interestingly,	 not	 all	 ERVs	 are	 silenced	 during	 development.	 It	 has	 been	
shown	 that	 some	 ERV	 loci	 act	 as	 tissue-specific	 enhancers	 and	 are	 not	 DNA	
methylated	(Feuchter	and	Mager,	1990),	for	example	in	human	T	cells	and	fetal	brain	
(Ling	 et	 al.,	 2002;	Meissner	 et	 al.,	 2008).	 ERV	 expression	 that	 occurs	 in	 type	 II	 T-
independent	 B	 cell	 responses	 also	 suggests	 that	 at	 least	 a	 subset	 of	 ERVs	 are	 not	
DNA	methylated	as	otherwise	they	would	need	to	undergo	DNA	demethylation	prior	
to	 their	 activation	 (Zeng	 et	 al.,	 2014).	 These	 data	 imply	 that	 certain	 ERV	 loci	 are	
poised	 to	 become	 activated	 in	 response	 to	 stimuli	 or	 tissue-specific	 transcription	
factors.	Whether	KAP1	plays	a	role	in	maintaining	ERVs	in	a	poised	state	is	unknown.	
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Aims	
My	project	aims	to	explore	two	aspects	of	KAP1	repression	of	ERVs	in	differentiated	
human	cells,	the	first	focused	on	function	and	the	second	on	biological	relevance.	
Aim	1.	KAP1	repression	
I	sought	to	determine	whether	KAP1	represses	ERVs	in	differentiated	human	
cells	using	HERV-K14C	as	a	model	because	it	is	KAP1	regulated	at	least	in	human	ES	
cells	 (Turelli	 et	 al.,	 2014).	 HERV-K14C	 is	 a	 relatively	 recent	 integrant	 into	 the	
mammalian	 genome.	 It	 is	 unique	 to	 the	 Catarrhini	 lineage	 so	 it	 could	 potentially	
even	 regulate	 human-specific	 genes.	 However,	 given	 its	 young	 age	 and	 low	 copy	
number,	 its	 unlikely	 to	 regulate	 a	 network	 of	 genes.	 Of	 interest,	 HERVK14C	 is	
expressed	 at	 the	 8-cell	 stage	 of	 development	 and	 also	 in	 the	 process	 of	 iPSCs	
production	from	CD34+	cells	(Friedli	et	al.,	2014).	In	addition,	ENCODE	data	shows	it	
to	be	KAP1	bound.	
	
Specific	objectives:	
• Is	KAP1	necessary	to	repress	endogenous	HERVK14C	in	differentiated	human	
cells?	
• Can	KAP1	establish	de	novo	repression	of	newly	introduced	HERVK14C?	
• Is	DNA	methylation	involved	in	the	repression	of	HERVK14C?	
• What	other	repeats	and	genes	are	regulated	by	KAP1	in	differentiated	cells?	
• Does	 KAP1	 repression	 proceed	 through	 the	 same	 mechanism	 in	
differentiated	cells	as	in	embryonic	cells	e.g.	through	SETDB1	and	H3K9me3?	
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Aim	2.	Biological	relevance	
The	next	question	I	aimed	to	focus	on	is	whether	KAP1	epigenetic	repression	
prevents	innate	sensing	of	ERVs	in	differentiated	cells?	This	is	a	cutting-edge	topic	in	
light	of	two	recent	articles	that	have	revealed	that	the	drug	5-Aza-cytidine,	which	is	
used	to	treat	cancer	patients	likely	functions	by	activating	transcription	of	ERVs	that	
are	 usually	 epigenetically	 silenced.	 This	 leads	 to	 their	 innate	 sensing	 and	 an	 anti-
tumour	response	(Chiappinelli	et	al.,	2015;	Roulois	et	al.,	2015).	Epigenetic	silencing	
of	 ERVs	 has	 been	 linked	 to	 DNA	 methylation	 in	 these	 studies	 and	 my	 aim	 is	 to	
determine	 whether	 KAP1	 and	 associated	 epigenetic	 modifiers	 are	 necessary	 to	
sustain	this	DNA	methylation	block.	
	
Specific	objectives:	
• Establish	whether	 KAP1	 could	 be	 involved	 in	 the	 5-Aza-mediated	 effect	 by	
examining	if	5-Aza	treatment	leads	to	the	activation	of	KAP1-regulated	ERVs	
as	well	as	ISG	induction.	
• Deplete	 KAP1	 and	 associated	 epigenetic	 candidates	 to	 see	 if	 this	 can	
phenocopy	the	effects	of	5-Aza	treatment	on	ISG	induction.	
Pursue	 the	 mechanism,	 for	 example	 assessing	 whether	 activation	 depends	 on	
loss	of	histone	or	DNA	methylation	or	both,	what	 the	PAMPs	are	and	whether	 ISG	
induction	depends	on	RNA	or	DNA	sensing	or	both.	
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Chapter	2:	Materials	and	Methods	
2.1	General	solutions,	buffers	and	materials	
Table	1	List	of	commonly	used	materials	and	buffers.	
Material/Buffer	 Composition	 Manufacturer	(Cat.	no.)	
LB	broth		 20g/L	H2O	 Sigma	(L3022)	
LB	agar	 37g/L	H2O	 Millipore	(1.10283.0500)	
TAE	buffer		 1000x	 AppliChem	(A4686)	
Agarose	gel		 1%	in	TAE	(w/v),	4%	EtBr	(v/v)	 Sigma	(A9539)	
DNA	loading	buffer	 6x	 Thermo	Scientific	(#R0611)	
Gene	Ruler	1kb	 0.5ug/ul	 Thermo	Scientific	
(#SM0311)	
NuPage	LDS	sample	buffer	 4x	 Invitrogen	(NP0007)	
PageRuler	Prestained	
Protein	Ladder	
-	 Thermo	Scientific	(26616)	
Running	buffer		 0.1%	SDS,	1.44%	Glycine,	0.3%	
Tris-base	
-	
Transfer	buffer	 1.44%	Glycine,	0.3%	Tris-base,	
2%	methanol		
-	
Wash	buffer		 0.1%	Tween	(v/v),	PBS	 	
	
2.2	Western	Blotting	
2.2.1	SDS	polyacrylamide	gel	electrophoresis	(PAGE)	
Table	2	Composition	of	SDS-PAGE	used	in	the	studies.	
Solution		 Composition	
Stacking	gel	(6%)	 20%	Acrylamide,	8%	Bis-acrylamide,	0.5%	SDS,	125mM	Tris	
pH6.8,	0.1%	TEMED,	0.5%	APS	
Running	gel	(10%)	 33.3%	Acrylamide,	13.3%	Bis-acrylamide,	0.5%	SDS,	375mM	
Tris	pH8.8,	0.03%	TEMED,	0.5%	APS	
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2.2.2	SDS-PAGE	running		
Approximately	2x106	cells	were	counted,	washed	with	PBS	and	 lysed	 in	 the	
sample	buffer	with	5%	of	β-mercaptoethanol.	The	samples	were	then	sonicated	at	20	
Hertz	(Hz)	for	90	seconds	and	heated	at	95oC	for	5	minutes.	Lysates	were	then	loaded	
onto	handcast	SDS-PAGE	gels	in	TRIS-GLYCINE	running	buffer	using	the	mini-PROTEAN	
tanks	 (Biorad).	The	samples	were	stacked	at	60V	for	30	minutes	and	at	120V	until	a	
good	separation	of	proteins	of	interest	was	achieved.	
	
2.2.3	Transfer	
Polyvinylidene	 difluoride	 (PVDF)	 membranes	 (Armesham,	 10600023)	 were	
first	immersed	in	methanol	for	5	minutes	and	then	transferred	to	the	transfer	buffer.	
The	 proteins	 on	 the	 gel	 were	 then	 transferred	 onto	 the	 PVDF	 membrane	 via	 wet	
transfer	under	200V	for	90	minutes	on	ice.	For	overnight	transfer,	20V	was	used	and	
the	transfer	was	done	in	the	cold	room	at	4oC.		
	
2.2.4	Protein	visualisation		
Transferred	 membranes	 were	 blocked	 with	 5%	 non-fat	 dried	 milk	 (w/v)	
(Sainsbury’s)	in	wash	buffer	for	2	hours	at	room	temperature	(or	overnight	at	4oC).	All	
antibodies	 were	 diluted	 in	 wash	 buffer	 with	 3%	 non-fat	 dried	 milk	 (w/v)	 and	 the	
blocked	 membranes	 were	 incubated	 with	 the	 antibodies	 according	 to	 the	
manufacturer’s	protocols.	Membranes	were	washed	with	wash	buffer	for	10	minutes	
and	 the	 washing	 was	 repeated	 three	 times	 after	 each	 antibody	 staining.	 For	
visualization,	 the	 membranes	 were	 incubated	 briefly	 with	 enzymatic	
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chemiluminescent	 reagents	 (Amersham,	RPN2232,	2235,	2236)	and	exposed	 to	High	
Performance	 chemiluminescence	 film	 (Amersham,	 28906839)	 according	 to	 the	
manufacturer’s	instructions.	Films	were	then	developed	via	the	film	processor	(Konica	
Minolta,	SRX-101A).	
	
2.2.5	Antibodies	
Table	3	Antibodies	used	in	the	studies.	
Target	antigens	 Manufacturer,	Cat.	no.	 Comments	(Assay)	
Actin	 Chemicon,	MAB1501	 Mouse	monoclonal	(WB)	
KAP1	 Millipore,	MAB3662	 Mouse	monoclonal	(WB)	
PCNA	 Millipore,	clone	PC10	 Mouse	monoclonal	(WB)	
OCT3/4	 Santa	Cruz,	sc-5279	 Mouse	monoclonal	(WB)	
PE-Cγ	CD3	(ε-chain)	 BD	Bioscience,	555341	 Mouse	(FACS)	
FITC-CD4	 BD	Bioscience,	345768	 Mouse	(FACS)	
PE-OCT3/4	 eBioscience,	12-5841-80	 Rat	(FACS)	
FITC-IgG1	(κ	isotype	control)	 BD	Bioscience,	555909	 Mouse	(FACS)	
PE-Cγ5	IgG2a	(κ	isotype	control)	 BD	Bioscience,	555575	 Mouse	(FACS)	
PE-IgG2a	(κ	isotype	control)	 eBioscience,	12-4321-80	 Rat	(FACS)	
MPP8	 Proteintech,	16796-1-AP	 Rabbit	polyclonal	(WB)	
Mx1	 Atlas,	HPA030917	 Rabbit	polyclonal	(WB)	
BST2	 Invitrogen,	16-3179-82	 Mouse	monoclonal	(WB)	
HERV-K	Capsid	 Amsbio,	HERM-1831-5	 Mouse	monoclonal	(WB)	
ZNF33A	 Thermo	Fisher,	PA5-43694	 Rabbit	polyclonal	(WB)		
ZNF37A	 Santa	Cruz,	sc-98283	 Rabbit	polyclonal	(WB)	
ZNF320	 Abcam,	ab105824	 Rabbit	polyclonal	(WB)	
	
2.3	Cell	culture	
Table	4	Cell	types	used	throughout	the	studies.	
Cell	type		 Medium	condition		 Growth	condition		
NTERA-2	 DMEM,	10%	FCS,	50μg/ml	
Pen/Strep	
37oC,	5%	CO2	
HEK293T	 DMEM,	10%	FCS,	50μg/ml	
Pen/Strep	
37oC,	5%	CO2	
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HEK293	 DMEM,	10%	FCS,	50μg/ml	
Pen/Strep	
37oC,	5%	CO2	
HeLa	 DMEM,	10%	FCS,	50μg/ml	
Pen/Strep	
37oC,	5%	CO2	
CD4+T	cells	 RPMI,	10%	HS,	50μg/ml	
Pen/Strep,	10U/ml	IL-2	
37oC,	5%	CO2	(Activated	by	
α-CD3,	α-CD28	and	25U/ml	
IL-2)	
PBMCs	 RPMI,	20%	FCS,	50μg/ml	
Pen/Strep,	10U/ml	IL-2	
37oC,	5%	CO2	(Activated	by	
3ug/ml	PHA	and	10U/ml	of	
IL-2)	
	 	 	
References	for	the	cells	used	were	as	follow:	
NTERA-2	(Lee	and	Andrews,	1986);	HEK293T	(Phillips	et	al.,	1999);	HEK293	(Graham	et	
al.,	1977);	HeLa	(Scherer	et	al.,	1953)	
2.3.1	Antibiotics	for	cell	culture	
Table	5	Antibodies	used	for	cell	selection	in	the	studies.	
Antibiotic		 Concentration		 Manufacturer	
Puromycin		 2.5μg/ml		 Sigma-Aldrich	
	
2.3.2	Cell	culture	maintenance	
NT2	cells	were	split	every	3	days	at	a	ratio	of	1:3	via	cell	scraping	and	the	cells	
were	kept	in	T25	flasks.	All	other	adherent	cells	were	split	every	3	to	4	days	at	a	ratio	
of	1:4	using	trypsin.	THP-1	cells	were	kept	 in	T75	 flasks	and	split	every	2	days	at	a	
ratio	of	1:3.	THP-1	cells	were	maintained	at	the	density	of	2x105	cells	per	ml.	Both	
PBMCs	and	CD4+	T	cells	were	activated	under	the	conditions	 listed	in	Table	2.2	for	
72	hours.	Primary	cells	were	maintained	at	a	cell	density	of	1x106	cells	per	ml	and	
were	kept	for	not	more	than	14	days	post	activation.		
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2.3.3	Primary	cell	isolation		
PBMCs	were	 isolated	from	either	a	buffy	coat	or	 from	healthy	donors	using	
Lymphoprep	 (Axis-shield,	 1114544)	 according	 to	 the	 manufacturer’s	 instructions.	
From	PBMCs,	CD4+	T	cells	were	negatively	selected	and	isolated	using	a	CD4+	T	cell	
isolation	 kit	 (Miltenyl	 Biotec,130-042-401)	 according	 to	 the	 manufacturer’s	
instructions.	 The	 purity	 of	 the	 cells	 was	 verified	 using	 flow	 cytometry	 following	
antibody	staining	using	antibodies	listed	in	Table	3.		
	
2.4	CRISPR/Cas9	genome	editing	
A	 pool	 of	 guide	 RNA	 (sgRNA)	 pairs	 each	 targeting	 different	 exons	 of	 the	
human	KAP1	gene	were	designed	using	the	website:	http://crispr.mit.edu/	and	were	
ordered	 from	 Sigma-Aldrich.	 The	 oligos	 were	 resuspended	 in	 H2O	 to	 yield	 a	 final	
concentration	 of	 100μM.	 To	 anneal	 the	 sgRNAs,	 1μl	 of	 each	 sense	 and	 antisense	
oligo	 was	 mixed	 with	 1μl	 of	 T4	 ligation	 buffer	 (reference	 2.5.4),	 0.5μl	 of	 T4	
polynucleotide	 kinase	 (NEB,	 M0201S),	 and	 6.5μl	 of	 H2O.	 The	 mixture	 was	 then	
incubated	at	37oC	for	30	minutes,	heated	up	to	95oC	for	5	minutes	and	then	cooled	
gradually	on	the	bench	for	90	minutes	before	checking	the	concentration.	This	oligo	
duplex	was	 then	cloned	 into	 the	pSpCas9(BB)-2A-Puro	 (PX459)	plasmid	at	 the	BbsI	
site.	 The	digested	backbone	was	 run	on	an	 agarose	 gel	 and	 the	 right	product	was	
extracted	using	the	QIAquick	gel	extraction	kit	(Qiagen,	28704).		
For	the	 ligation,	50ng	of	the	cut	backbone	plasmid	was	mixed	with	1ul	of	the	oligo	
duplex	 (after	1:250	dilution),	 5μl	of	2X	Quickligase	buffer,	 1μl	of	Quickligase	 (NEB,	
M2200L),	 and	H2O	up	 to	a	 final	 volume	of	10μl.	 The	 ligation	mix	was	 left	 at	 room	
	 80	
temperature	for	10	minutes	before	adding	1.5μl	of	10x	PlasmidSafe	buffer,	1.5μl	of	
10mM	ATP,	 and	 1ul	 of	 PlasmidSafe	 exonuclease	 (Epicentre,	 E3101K).	 The	mixture	
was	 incubated	 at	 37oC	 for	 a	 further	 30	minutes	 after	 which	 the	 ligation	 products	
were	ready	for	HB101	transformation	(of	5ul).	The	inserts	were	then	verified	through	
Sanger	sequencing	using	the	U6_forward	primer.		
Once	verified,	the	plasmids	were	transfected	into	HeLa	and	293T	cells	for	24	
hours	before	puromycin	was	added	for	selection.	After	24	hours	of	selection	or	until	
all	the	control	cells	were	killed,	the	cells	were	then	expanded	and	used	for	single	cell	
cloning.	Surviving	cells	were	first	diluted	to	the	concentration	of	0.5	cells	per	100μl	
and	 plated	 into	 a	 96-well-plate	 at	 the	 volume	 of	 100μl	 per	well.	 Once	 clones	 had	
grown,	around	ten	were	expanded	and	the	presence	or	absence	of	KAP1	protein	was	
determined	by	Western	Blotting	using	the	KAP1	antibody	listed	in	Table	3.	
	
2.5	Cloning		
2.5.1	DNA	preparation		
All	plasmid	DNA	used	for	this	study	was	grown	in	HB101		E.	coli.	expanded	in	
house	 and	 plasmids	 were	 isolated	 using	 Qiaprep	 Mini	 (Qiagen,,	 27106)	 and	 Midi	
(Qiagen,	 12145)	 kits	 according	 to	 the	 manufacturer’s	 instructions	 and	 were	
resuspended	in	TE	buffer.	
2.5.2	Bacterial	Transformation	
Around	10ng	of	 plasmid	DNA	was	 incubated	with	 competent	HB101	on	 ice	
for	20	minutes	and	then	subjected	to	heat	shock	at	42oC	for	40	seconds.	Cells	were	
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then	 returned	 on	 ice	 for	 a	 further	 2	 minutes	 before	 spreading	 them	 onto	 pre-
warmed	LB	agar	with	the	appropriate	antibiotic.		
Table	6	Antibiotic	used	for	bacterial	selection	in	the	studies.	
Antibiotic		 Working	
concentration		
Manufacturer	
Ampicilin	 100μg	/	ml	 Calbiochem,	171254	
	
2.5.3	Oligo	annealing	for	shRNA	cloning		
	 The	 sequence	 of	 the	 target	 gene	 was	 downloaded	 from	 the	 Emsembl	
website:	 http://www.ensembl.org/index.html	 and	 the	 shRNA	oligos	were	 designed	
using	 the	 website:	 http://bioinfo.clontech.com/rnaidesigner/.	 5’-phosphorylated	
oligos	 (sense	 and	 antisense	 strands)	 were	 ordered	 from	 Sigma-Aldrich	 and	
resuspended	in	water	to	a	final	concentration	of	100μM.	10μl	of	each	oligo	pair	were	
mixed	with	2.5μl	of	2M	NaCl.	The	mixture	was	first	heated	up	to	98oC	for	5	minutes	
and	then	left	to	cool	down	to	room	temperature	on	the	bench.	After	that,	350μl	of	
H2O,	40μl	of	3M	NaAc,	and	1.1ml	of	EtOH	were	added	to	the	mixture.	The	mixture	
was	then	transferred	to	-80oC	overnight.	After	chilling,	the	mixture	was	spun	down	
by	centrifugation	(Eppendorf,	Centrifuge	5430	R)	at	4oC	at	a	maximum	speed	for	45	
minutes.	 The	 pellet	 was	 then	 resuspended	 in	 50μl	 of	 distilled	 H2O	 was	 ready	 for	
ligation	thereafter.		
	
2.5.4	Ligation	
	 Ligations	 were	 carried	 out	 using	 T4	 DNA	 ligase	 (Thermo	 Fisher,	 EL0011)	
unless	otherwise	stated	according	to	manufacturer’s	instruction.	Briefly,	inserts	and	
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digested	backbone	were	mixed	(10ul	final	volume)	and	incubated	at	16oC	overnight	
or	at	room	temperature	for	at	least	2	hours.	4ul	of	the	ligation	product	was	used	for	
transforming	the	HB101	(Section	2.5.2).	
	
2.5.5	Sequencing		
All	clones	were	verified	by	Sanger	sequencings	provided	by	Genewiz	(U.K.).		
	
2.6	Lentiviral	vectors	
2.6.1	Vector	Production		
All	 lentiviral	 vectors	 used	 were	 VSV-pseudotyped.	 The	 lentiviral	 genome	 is	
produced	 in	 combination	 with	 VSV	 envelope	 to	 alter	 the	 vector	 tropism.	 Around	
2x106	 293T	 cells	 were	 seeded	 onto	 a	 10cm	 plate.	 After	 24	 hours,	 cells	 were	 co-
transfected	 with	 1.5μg	 of	 the	 genome	 plasmid,	 1μg	 of	 p8.91	 and	 1μg	 of	 pMDG2	
encoding	 VSV-G.	 Fresh	 media	 was	 replaced	 24	 hours	 post-transfection	 and	
supernatant	 was	 harvested	 at	 48	 hours	 post-transfection.	 The	 vectors	 were	 used	
either	neat	or	concentrated	via	ultracentrifugation	(20,000g	for	2	hours	at	4oC).	The	
ultracentrifugation	was	done	as	per	 the	manufacturer’s	 instructions	using	a	Sorvall	
100SE	(Hitachi).	Vectors	were	resuspended	in	ice	cold	PBS	for	storage	at	-80oC.	
	
2.6.2	Virus	titration	
For	adherent	cells,	different	doses	of	GFP	lentivectors	were	titrated	onto	104	
cells/well	 (2*104	cells	 per	ml)	 in	 a	24-well	 plate.	 For	 suspension	 cells	 (CD4+	T	 cells	
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and	PBMCs),	cells	are	maintained	at	a	minimum	of	106	cells	per	ml	for	titration.		After	
24	 hours	 post-transduction,	 the	 cells	 were	 washed	 and	 replenished	 with	 fresh	
media.	 After	 48	 hours,	 the	 cells	 were	 harvested	 for	 a	 GFP	 readout	 using	 flow	
cytometry.	Within	 the	 linear	 range,	 virus	 doses	 that	 gave	 5-20%	of	 infection	were	
then	selected	to	calculate	the	infectious	viral	units	per	ml	(IU/ml)	using	the	formula:	
(Percentage	 of	 infection	 (%)	 *	 104	 cells)/	 Volume	 of	 the	 vector	 added	 (ml).	 The	
calculated	values	were	 then	used	as	a	guide	 to	obtain	 the	 same	 input	dose	across	
different	vectors	for	the	experiment.		
For	 knockdown	 and	 overexpression	 experiments,	 around	 500μl	 of	 non-
concentrated	 vector	 or	 up	 to	 2μl	 of	 concentrated	 vector	 was	 used	 to	 transduce	
1x10e5	cells	per	well	in	12	well	plates.	After	48	hours,	puromycin	was	added	for	24	
hours	 or	 until	 all	 control	 cells	 died.	 Cells	 were	 then	 used	 at	 stated	 time-points	
following	antibiotic	selection	for	Western	blot	and	qRT-PCR	to	verify	the	knockdown	
efficiency	and	for	retrotransposon	readouts.	
	
2.7	Polymerase	chain	reaction	(PCR)	
2.7.1	PCR	for	Bisulfite	sequencing		
PCRs	 yielding	 products	 <500bp	 using	 bisulfite-	 converted	 DNA	 were	
conducted	using	the	Hot	Start	Taq	kit	(Qiagen,	203203).	
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Reaction	mix:	
Table	7	Reaction	mix	for	Hot	start	PCR.	
	 Volume	(μl)	
Converted	DNA	 4	
10x	Buffer	 5	
DNTPs	(10mM)	 1	
Primer	mix	(Forward	and	reverse	10μM)	 1.25	
Hot	Start	Taq	polymerase	 0.25	
H2O	 38.5	
Total	 50	
	
A	 generic	 cycling	 protocol	 for	 the	 PCR	 is	 shown	 below	 and	 the	 exact	
annealing	temperature	is	noted	in	the	‘comments’	section	for	individual	primer	sets	
and	the	final	extension	time	is	dependent	on	the	size	of	the	amplicon.	
Table	8	Cycling	protocol	for	Hot	start	PCR.	
Step	 Hold	 PCR	cycle	(35	cycles)	 Final	
extension		
Denature	 Anneal			 Extension		
Temperature	 95.0oC	 95.0oC	 58.0oC	 72.0oC	 72.0oC	
Time	 15	minutes	 30	seconds	 1	minute	 1	minute	 7	minutes	
	
2.7.2	Phusion	PCR		
Phusion	(NEB,	M0530)	PCR	was	used	to	amplify	the	genomic	HERVK14C	LTR	
sequence	for	cloning	purposes	and	the	reaction	mix	is	as	follows:	
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Table	9	Reaction	mix	for	Phusion	PCR.	
	 Volume	(μl)	
Template	(Genomic	DNA)	 100ng		
5x		Phusion	buffer	 10	
DNTPs	(10mM)	 1	
Forward	primer		 2.5	
Reverse	primer	 2.5	
DMSO	 1.5	
Phusion	polymerase	 0.5	
H2O	 Variable	
Total	 50	
	
A	 generic	 cycling	 protocol	 for	 the	 PCR	 is	 shown	 below	 and	 the	 exact	
annealing	temperature	is	noted	in	the	‘comments’	section	for	individual	primer	sets	
and	the	final	extension	time	is	dependent	on	the	size	of	the	amplicon.	
Table	10	Cycling	protocol	for	Phusion	PCR.	
Step	 Hold	 PCR	cycle	(30	cycles)	 Final	
extension		
Denature	 Anneal			 Extension		
Temperature	 98.0oC	 98.0oC	 60.0oC	 72.0oC	 72.0oC	
Time	 15	minutes	 10	seconds	 30	seconds	 40	seconds	 7	minutes	
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2.8	HERVK14C	LTR	reporter		
2.8.1	Cloning		
A	HERVK14C	that	is	bound	by	KAP1	was	first	identified	using	ENCODE	binding	
data	 and	 its	 LTR	 sequence	 along	with	 or	without	 the	 following	 PBS	 sequence	was	
then	 amplified	 through	 PCR	 using	 Phusion	 High	 Fidelity	 DNA	 polymerase	 (New	
England	Biolabs,	M0530L).	Amplicons	were	then	digested	with	XhoI	and	BamHI	and	
ligated	with	digested	pPGK-GFP.	Clones	were	then	verified	using	Sanger	sequencing.		
	
2.8.2	Reporter	experimental	set-up		
Lentiviral	 vectors	 were	 produced	 as	 described	 in	 2.6.1	 using	 the	 genome	
plasmids	with	 the	 right	 inserts	 in	KAP1	knockout	293T	 cells.	 The	 infectious	 titer	of	
the	 vectors	was	 then	 determined	 by	 titrating	 the	 vectors	 on	 KAP1	 knockout	 293T	
cells	and	a	GFP	readout	was	determined	using	flow	cytometry.	
	
2.9	Flow	cytometry	
All	GFP	readouts	were	determined	by	flow	cytometry	using	either	a	BD	Accuri	
C6	 machine	 or	 a	 FACS	 Calibur	 machine	 both	 from	 BD	 Bioscience.	 Analysis	 was	
performed	using	FlowJo	and	live	cells	were	gated	on	using	the	forward	scatter	height	
(FSC-H)	and	side	scatter	height	(SSC-H)	parameters,	which	correspond	to	cell	size	and	
granularity,	 respectively.	10,000	 live	cells	were	used	 for	analysis	 in	each	sample.	A	
non-transduced	 (or	 control	 antibody	 treated)	 cell	 sample	 was	 used	 to	 define	 the	
percentage	 of	 GFP,	 or	 OCT-4	 positive	 cells,	 as	 measured	 using	 the	 FL1	 or	 FL2	
	 87	
channels	respectively.	
	
2.9.1	Intracellular	staining	
1x106	cells	per	condition	were	trypsinized,	counted,	and	washed	with	media.	
The	 cells	 were	 then	 resuspended	 in	 residual	 media	 and	 fixed	 by	 resuspending	 in	
100μl	 of	 formaldehyde-based	 fixation	 buffer	 (eBioscience).	 Samples	 were	 then	
incubated	at	room	temperature	in	the	dark	for	30-60	minutes.	After	incubation,	2ml	
of	 permeabilization	 buffer	 (eBioscience)	 was	 added	 directly,	 followed	 by	
centrifugation	 at	 300-400g	 for	 5	 minutes	 at	 room	 temperature.	 This	 wash	 was	
repeated	 before	 resuspending	 pellets	 in	 100μl	 of	 permeabilization	 buffer	 for	
staining.	The	recommended	amounts	of	fluorochrome-labeled	antibodies	were	then	
added	and	incubated	for	20-60	minutes	at	room	temperature	in	the	dark.	After	this,	
2	 washes	 with	 permeabilization	 buffer	 were	 performed	 and	 then	 pellets	 were	
resuspended	in	PBS	and	samples	acquired	on	a	flow	cytometer.		
	
2.9.2	Buffers	
Commercial	buffers	were	used	for	the	intracellular	staining	(eBioscience,	00-
5523-00).	
Table	11.	Buffers	used	for	intracellualr	staining	
Buffer	 Comment		
Permeabilisation	buffer	 00-8333-56	
Fixation/	permeabilisation	diluent	 00-5223-56	
Fixation/	permeabilisation	concentrate	 00-5123-43	
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2.10	Luciferase	assay	
2.10.1	Transfection		
On	day	1,	293T	cells	are	plated	at	a	concentration	1*105	cells/	ml	in	a	24	well	
plate	(with	500ul	per	well).	The	transfection	mix	was	prepared	as	follows:	
Table	12	Transfection	mix	for	luciferase	based	assay.	
	 Volume	per	well		
Reporter	plasmid		 X			
Thymidine-kinase	renilla	plasmid	 X/10	
Opti-MEM	 25μl	
Fugene		 1.5μl	
	
Different	 amounts	 of	 the	 reporter	 plasmids	 were	 titrated	 onto	 the	 cells	 in	
order	 to	 ensure	 that	 the	 luciferase	 readout	 was	 within	 the	 detection	 limit	 of	 the	
illuminometer.	 The	 renilla	 plasmid	 was	 added	 at	 a	 1	 to	 10	 ratio	 to	 the	 luciferase	
reporter	 plasmid.	 Fugene	 was	 added	 last	 before	 a	 20	minute	 incubation	 at	 room	
temperature	and	then	the	mix	was	added	drop-wise	to	cells.	Sendai	virus	was	added	
24	 hours	 before	 harvesting	 cells	 as	 a	 positive	 control	 ISG-reporter	 induction	 as	
shown	in	Figure	39.	
	
2.10.2	Luciferase	readout	
The	 cells	 were	 harvested	 48	 hours	 post-transfection	 for	 the	 luciferase	
readout	using	the	Dual	–Luciferase	®	Report	Assay	System	kit	(Promega,	E1960)	and	
the	 Glomax	 96	microplate	 luminometer	 (Promega).	 Briefly,	 the	 cells	were	washed	
with	 cold	 PBS	 and	 100μl	 of	 1x	 passive	 lysis	 buffer	 was	 then	 added	 to	 each	 well.	
Samples	were	then	subjected	to	a	round	of	 freeze-thaw	treatment.	After	thorough	
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resuspension,	20μl	of	the	thawed	samples	was	subsequently	transferred	to	a	white	
96	well	plate	and	30ul	of	the	luciferase	reagent	was	added	to	each	well.	The	signal	
was	 then	detected	 in	 the	 illuminometer	using	 the	standard	 ‘Steady	Glow’	protocol	
by	 Promega.	 After	 multiple	 readings,	 30ul	 of	 Renilla	 substrate	 was	 then	 added	
directly	into	each	well	before	the	renilla	readings	were	made.		
An	uninfected	negative	control	was	used	to	measure	the	background	signal	
and	 this	value	was	subtracted	 from	all	other	 readings.	The	output	 firefly	 luciferase	
relative	light	units	(RLU)	were	then	normalised	to	the	corresponsing	renilla	RLU.	The	
fold	induction	of	the	luciferase	signal	was	determined	by	calculating	the	fold	change	
between	the	normalised	RLU	in	knockdown	cells	and	empty	vector	transduced	cells.		
	
2.11	RNA	extraction		
	 Cells	were	 first	 trypsinized,	 spun	down	and	washed	with	PBS	once.	The	cell	
pellet	 was	 then	 lysed	 and	 RNA	 was	 harvested	 using	 an	 RNeasy	 mini	 kit	 (Qiagen,	
74104)	according	 to	 the	manufacturer’s	 instructions.	 The	RNA	was	 resuspended	 in	
RNase-free	water.	
	
2.12	 Quantitative	 reverse	 transcription	 polymerase	 chain	
reaction	(qRT-PCR)	
	2.12.1	cDNA	synthesis	
RNA	 was	 first	 incubated	 with	 Turbo	 DNase	 (Thermo	 Fisher	 Scientific,	
am1907)	at	37oC	for	25	minutes.	DNase	inactivating	beads	were	then	added	to	the	
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mixture,	mixed	and	 left	 at	 room	 temperature	 for	3	minutes.	 The	 treated	RNA	was	
then	spun	down	and	the	supernatant	was	collected.	The	concentration	of	RNA	was	
determined	using	the	Nanodrop	1000	(Thermo	Scientific).		
500ng	 of	 purified	 RNA	 was	mixed	 with	 1μl	 of	 dNTPs	 (10mM)	 and	 random	
primers	(150ng/μl)	(Invitrogen,	58875)	and	incubated	at	65oC	for	5	minutes	followed	
by	incubation	on	ice	for	a	further	5	minutes.	dTTs	(Thermo	Fisher	Scientific,	18064-
014),	 RNase	 OUT	 (Thermo	 Fisher	 Scientific,	 10777-019)	 and	 SuperScript	 II	 reverse	
transcriptase	 (Thermo	Fisher	Scientific,	18064-014)	were	then	added	together	with	
the	buffer	provided.	The	mixture	was	incubated	at	42oC	for	50	minutes	followed	by	
70oC	for	15	minutes.		
2.12.2	Reaction	mix	
Reaction	mix:	
Table	13	Reaction	mix	for	qRT-PCR.	
	 Volume	per	reaction	(μl)	
Fast	SYBR	Green	master	mix		 12.5	
Forward	and	reverse	primer	mix		 2.0	
cDNA	template	 2.0	
H2O	 8.5	
Total	 25.0	
	
Constituents	for	the	reaction	mix:	
Table	14	Reagents	used	in	qRT-PCR	reaction.	
Components	 Manufacturer,	Cat.	No.	 Comment		
Fast	SYBR	Green	master	mix	 Thermo	Fisher	Scientific,	
4385612	
-		
Primer	mix		 Sigma-Aldrich		 470μl	of	H2O,	15μl	of	forward	
primer	(100μM),	15μl	of	
reverse	primer	(100μM)	
	cDNA	template	 -		 Diluted	(e.g.	1:50)	in	H2O	
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2.12.3	Cycling	protocol		
The	protocol	for	the	qRT-PCR	is	as	follow:	
Table	15	Cycling	protocol	used	for	qRT-PCR.	
Step	 Hold	 PCR	cycle	(40	cycles)	
Denature	 Anneal	/	Extension	
Temperature	 95.0oC	 95.0oC	 60.0oC	
Time	 10	minutes	 15	seconds	 1	minute	
	
2.13	Taqman	qPCR	
The	DNA	template	was	first	extracted	as	described	 in	2.16	and	the	reaction	
mix	is	set	up	as	follows:	
Table	16	Reaction	mix	used	for	Taqman	qPCR.	
	 Volume	per	reaction	(μl)	
Taqman	Universal	master	mix		 12.5	
Forward	and	reverse	primer	mix		 2.0	
Probe	 1.5	
H2O	 7.0	
DNA	template	 2.0	
Total	 25.0	
	
A	DNA	 template	made	 from	a	 single	 copy	GFP	 integrant	 293T	 cell	 line	was	
used	as	a	reference	to	quantify	the	copy	number	of	integrants	in	samples	tested.		
Table	17	Reagents	used	in	Taqman	qPCR	reaction.		
Components	 Manufacturer,	Cat.	No.	 Comment		
Taqman	Universal	master	
mix	
Life	Technology,	4440040	 -		
Primer	mix		 Sigma-Aldrich		 Stock	concentration	of	3μM	
Probe	 Sigma-Aldrich	 Stock	concentration	of	250	
nM	
DNA	template	 -		 Diluted	to	stock	
concentration	of	50ng/μl	
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The	protocol	for	Taqman	qPCR	is	as	follow:	
Table	18	Cycling	protocol	used	for	Taqman	qPCR.	
Step	 Hold	 PCR	cycle	(40	cycles)	
Denature	 Anneal	/	Extension	
Temperature	 95.0oC	 95.0oC	 60.0oC	
Time	 10	minutes	 15	seconds	 1	minute	
	
2.14	RNA	sequencing		
Total	 RNA	 samples	 were	 diluted	 to	 50ng/μl	 (and	 1μg	 was	 supplied	 per	
sample)	for	RNA	sequencing,	which	was	performed	by	the	UCL	Genomics	Platform.	
	
	2.14.1	Library	preparation	
Samples	were	 processed	 using	 Illuminas	 Truseq	 Stranded	mRNA	 LT	 sample	
preparation	 kit	 (Illumina,	 RS-122-2101)	 according	 to	 manufacturer’s	 instructions.	
Deviations	from	the	protocol	were	as	follows:	
250ng	total	RNA	was	used	as	starting	material	and	fragmented	for	10	minutes	and	
14	cycles	of	PCR	were	used.	
Briefly,	mRNA	was	isolated	from	total	RNA	using	oligo	dT	beads	to	pull	down	
poly-adenylated	 transcripts.	 The	 purified	 mRNA	 was	 fragmented	 using	 chemical	
fragmentation	(heat	and	divalent	metal	cation)	and	primed	with	random	hexamers.	
Strand-specific	 first	 strand	 cDNA	 was	 generated	 using	 Reverse	 Transcriptase	 and	
Actinomycin	D.	This	allows	RNA	dependent	synthesis	while	preventing	spurious	DNA-
dependent	synthesis.	The	second	cDNA	strand	was	synthesized	using	dUTP	 instead	
of	 dTTP,	 to	mark	 the	 second	 strand.	 The	 cDNA	 is	 then	 “A-tailed”	 at	 the	 3’	 end	 to	
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prevent	self-ligation.	
Full-length	 TruSeq	 adaptors,	 containing	 a	 T	 overhang	 are	 ligated	 to	 the	 A-
Tailed	 cDNA.	 These	 adaptors	 contain	 sequences	 that	 allow	 the	 libraries	 to	 be	
uniquely	 identified	by	way	of	a	6bp	 Index	sequence.	Successfully	 ligated	fragments	
were	 enriched	 with	 14	 cycles	 of	 PCR.	 The	 polymerase	 is	 unable	 to	 read	 through	
uracil,	so	only	the	first	strand	is	amplified.	
		
2.14.2	Sequencing		
Libraries	 to	 be	 multiplexed	 in	 the	 same	 run	 are	 pooled	 in	 equimolar	
quantities,	 calculated	 from	Qubit	and	Bioanalyser	 fragment	analysis.	Samples	were	
sequenced	 on	 the	NextSeq	 500	 instrument	 (Illumina,	 San	Diego,	US)	 using	 a	 43bp	
paired-end	run	resulting	in	>15million	reads	per	sample.	
	
2.14.3	Data	analysis	(Genes)	
Run	 data	were	 demultiplexed	 and	 converted	 to	 fastq	 files	 using	 Illumina’	 s	
bcl2fastq	 Conversion	 Software	 v2.16.	 Fastq	 files	 were	 then	 aligned	 to	 the	 human	
genome	NCBI	 build	 37.2	 using	 Tophat	 2.014	 then	 deduplicated	 using	 Picard	 Tools	
1.79.	Reads	per	transcript	were	counted	using	HTSeq	and	differential	expression	was	
estimated	using	the	BioConductor	package	DESeq2.	
	
2.14.4	Data	analysis	(Repeats)	
TrimGalore	v0.4.0	with	Cutadapt	v1.6	was	used	to	remove	adaptors	and	trim	
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read	 ends	 using	 default	 parameters	 (quality	 phred	 score	 cutoff	 =20,	 minimum	
required	sequence	length	for	both	reads	before	a	sequence	pair	gets	removed	=	20	
bp	and	m	trimming	error	rate:	0.1)	on	the	mRNA-seq	data.	The	number	of	sequence	
pairs	 removed	varied	 from	2.11%	 to	11.21%.	Reads	were	 first	mapped	against	 the	
human	 genome	 hg38	 using	 Bowtie2	 v2.2.4	with	 default	 parameters,	which	means	
that:	
A)	It	searches	for	multiple	alignments	and	reports	the	best	one;	
B)	Reads	are	not	excluded	based	on	mismatches,	which	is	an	appropriate	approach	
for	mapping	genes	and	repetitive	regions	and;	
C)	Reads	were	not	filtered	based	on	mapping	quality	nor	duplicated	reads	removed.	
	
Reads	were	subsequently	mapped	against	the	RepBase	v20.06	human	library	
using	Bowtie2v2.2.4	as	above.	The	samtools	v.1.19	idxstat	utility	was	used	to	extract	
the	 number	 of	 mapped	 reads	 per	 repeat,	 that	 were	 inputed	 into	 the	 R	 package	
DESeq	 (https://bioconductor.org/packages/3.2/bioc/html/DESeq.html)	 to	 identify	
differentially	expressed	repeats	between	KAP1	KOs	and	controls.	DESeq	uses	a	test	
based	 on	 the	 negative	 binomial	 distribution	 and	 a	 shrinkage	 estimator	 for	 the	
distribution’s	variance	to	find	differentially	expressed	repeats	between	conditions.	P-
values	 were	 adjusted	 for	 multiple	 testing	 with	 the	 Benjamini-Hochberg	 false-
discovery-rate	(FDR)	procedure.	
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2.15	Chip-sequencing	analysis	
Chromatin-immunoprecipitation-sequencing	 data	 for	 human	 ESCs	 and	 293T	
cells	were	downloaded	from	NCBI	Gene	Expression	Omnibus	(GEO)	under	accession	
numbers	GSE57989	 (HuESC)	 and	GSE27929	 (293T).	 TrimGalore	 v0.4.0	was	 used	 to	
remove	 adaptors	 and	 trim	 read	 ends,	 and	 reads	were	mapped	 against	 the	human	
genome	(hg19	assembly)	using	Bowtie2	v2.2.4.	Peaks	were	called	 in	each	replicate	
using	Macs2	v	 2.1.1,	 and	 the	 bioconductor	 package	 DiffBind	
(https://bioconductor.org/packages/DiffBind)	was	used	to	construct	Venn	diagrams	
and	 identify	 overlapping	 ESC	 and	 293T	 peaks.	 Human	 repeat	 and	 gene	 locations	
were	downloaded	from	the	UCSC	browser	(RepeatMasker	and	RefGene	tables)	and	
the	 repeats	 and	 genes	 closest	 to	 the	 overlapping	 ESC/293T	 peaks	 were	 identified	
using	bedtools-2-17-0.	 Chip-sequencing	 correlations	were	 analysed	using	 the	Chip-
Cor	website:	http://ccg.vital-it.ch/chipseq/chip_cor.php.	
	
2.16	DNA	extraction		
	 Cells	were	 first	 trypsinized,	 spun	down	and	washed	with	PBS	once.	The	cell	
pellet	 was	 then	 lysed	 and	 DNA	 was	 harvested	 using	 a	 DNeasy	 Blood	 &	 tissue	 kit	
(Qiagen,	69504)	according	to	the	manufacturer’s	instructions.		
	
2.17	DNA	methylation	analysis	
1μg	of	DNA	was	used	for	bisulphite	conversion	using	the	EpiTect	Bisulfite	Kit	
(Qiagen,	59104)	 following	the	manufacturer’s	protocol.	4	μl	of	converted	DNA	was	
then	 amplified	 through	 PCR	 using	 HotStarTaq	 DNA	 polymerase	 (Qiagen,	 203203)	
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(see	 Section	 2.7.1).	 Primers	 for	 this	 procedure	 were	 designed	 using	 the	 site:	
http://urogene.org/methprimer/	 and	 the	 PCR	 products	 were	 then	 cloned	 into	 the	
pCR2.1TOPO	vector	using	a	TOPO	cloning	kit	(Invitrogen,	45-0641).	A	T7P	primer	was	
used	 to	 sequence	 the	 products.	 The	 DNA	 methylation	 status	 of	 the	 clones	 was	
measured	and	analysed	using	the	QUMA	online	tool:	http://quma.cdb.riken.jp	by	the	
Riken	Institute.	
	
2.18	Statistical	analysis	
All	data	in	the	studies	are	presented	as	standard	deviation	(where	there	are	
three	or	more	samples)	assessed	by	using	two-tailed,	unpaired	Student	t	tests	(see	
individual	 figure	 legends	for	 further	details).	A	P-value	of	≤	0.05	was	considered	as	
statistically	significant	(****:	p≤	0.0001,	***:	p≤	0.001,	**:	p≤	0.01,	*:	p≤	0.05).	
	
2.19	Oligonucleotides	
Table	19	Primers	for	qRT-PCR	in	the	studies.	
Primer	 Sequence	(5’-3’)	 Comment	(No.	of		loci	
detected	
B2M	
	
F:		
TGC	TCG	CGC	TAC	TCT	CTC	TTT	
R:	
TCT	GCT	GGA	TGA	CGT	GAG	
TAA	AC	
qRT-PCR	(1)	
GAPDH	
	
F:	
GGG	AAA	CTG	TGG	CGT	GAT	
R:	
GGA	GGA	GTG	GGT	GTC	GCT	
GTT	
qRT-PCR	(1)	
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KAP1	
	
F:	
AAG	GAC	CAT	ACT	GTG	CGC	
TCT	AC	
R:	
ACG	TTG	CAA	TAG	ACA	GTA	
CGT	TCA	C	
qRT-PCR	(1)	
LIPA4_1	
	
F:	
TCA	CCA	ATA	TCC	GCT	GTT	CTG	
R:	
GTC	TGT	TGG	AGT	TTA	CTG	
GAG	G	
qRT-PCR	(63)	
LIPA4_2	
	
F:	
TGA	TAC	CCA	GGC	AAA	CAG	G	
R:	
TCT	AAC	AGT	CAG	GAC	CCT	
CAG	
qRT-PCR	(1025)	
HERVK14C_1	
	
F:	
AAY	AGC	ACT	GGA	GCC	CTT	
R:	
CGA	CTG	TGA	TGG	TTS	AYT	TTG	
qRT-PCR	(5)	
HERVK14C_2	
	
F:	
GTA	ATT	GTG	AGT	ACC	CAA	
AAT	CTC	
R:	
ACC	TTG	TCC	CAA	TCT	TTT	AC	
qRT-PCR	(5)	
SVA	D	VNTR	
	
F:	
GCT	GCC	CAT	CGT	CTG	AG	
R:	
TCC	TCA	CCT	CCC	AGA	CAG	
qRT-PCR	(7)	
ISG56	
	
F:	
CCT	GAA	AGG	CCA	GAA	TGA	
GG	
R:	
TCC	ACC	TTG	TCC	AGG	TAA	GT	
qRT-PCR	(1)	
CCL5	
	
F:	
CCC	AGC	AGT	CGT	CTT	TGT	CA	
R:	
TCC	CGA	ACC	CAT	TTC	TTC	TCT	
qRT-PCR	(1*)	
CXCL10	
	
F:	
GTG	GCA	TTC	AAG	GAG	TAC	
CTC	
R:	
GCC	TTC	GAT	TCT	GGA	TTC	
AGA	
qRT-PCR	(1*)	
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Mxα	
	
F:	
ATC	CTG	GGA	TTT	TGG		GGC	TT	
R:	
CCG	CTT	GTC	GCT	GGT	GTC	G	
qRT-PCR	(1*)	
Ikβα	
	
F:	
CTC	CGA	GAC	TTT	CGA	GGA	
AAT	
R:	
GCC	ATT	GTA	GTT	GGT	AGC	
CTT	
qRT-PCR	(1)	
HKR1	 F:	
CCA	AAA	CTC	ATT	GCT	CAG	
CTG	
R:	
GAG	AAA	ATC	AGA	GGG	CAG	
GAG	
qRT-PCR	(1*)	
ZNF45	 F:	
CTG	TAC	CGA	GAT	GTG	ATG	
CTG	
R:	
TCT	GGG	TTG	CCA	TCT	TCA	TC	
qRT-PCR	(1)	
ZNF274	 F:	
CTG	AAG	ATG	GAA	GCC	TGA	
GTG	
R:	
TGT	CCT	TAT	AAC	GGA	ACT	
GCC	
qRT-PCR	(1)	
ZNF300	 F:	
GGG	TAT	CCA	GTT	TCC	AAA	
CCA	G	
R:	
GTC	TCC	CAT	CTG	CCT	GAT	ATT	
C	
qRT-PCR	(1)	
ZNF607	 F:	
GGA	CAT	TCC	GTA	TCT	AAG	
CCA	G	
R:	
CTC	TCC	TCT	TGT	TTC	TTC	CCT	
C	
qRT-PCR	(1)	
ZNF140	 F:	
CTG	GTC	TCA	CTG	GGT	CTT	TC	
R:	
TTC	ACT	TCC	CTT	TTC	CCC	AG	
qRT-PCR	(1*)	
	 99	
The	copy	number	of	 loci	detected	by	 the	primers	are	determined	using	 the	 in-silico	
PCR	 programme	 (https://genome.ucsc.edu/cgi-bin/hgPcr).	 *	 -	 Denotes	 cross-exonic	
primers.	F:	forward;	R:	reverse.	
Table	20	shRNAs	for	knockdown	in	the	studies.	
shRNA	 Sequence	(5’-3’)	 Comment	
shKAP1_1	 F:	 Targeting	
ZNF350	 F:	
AGA	AAA	TGA	TCC	AGG	CCC	AG	
R:	
AGG	TTG	CTG	TAG	TTC	TCC	
AAC	
qRT-PCR	(1*)	
ZNF432	 F:	
CAA	AGA	CAG	AGT	ATC	CCA	
GGT	G	
R:	
CCG	GTA	CAA	ATC	CTT	CTG	
AAA	AG	
qRT-PCR	(1*)	
MPP8	 F:	
TGC	CTG	TAT	CTG	CCC	AAA	C	
R:	
CCT	TGT	CAG	AAT	CAT	GCC	TTT	
TC	
qRT-PCR	
Tasor	 F:	
TGA	AGA	CAT	TGC	AGG	TTT	
CAT	TC	
R:	
CAT	CCA	GGC	TAT	CAA	CAC	
CAG	
qRT-PCR	
Periphilin	 F:	
GGT	TCC	AGT	GTC	AGT	AGC	AG	
R:	
TCA	TTC	TGC	CGT	TTG	TAG	
GAG	
qRT-PCR	
SETDB1	 F:	
CAA	GCT	GGG	ACT	ACA	ATA	
CCG	
R:	
TCT	GGT	CTT	TTG	GAG	TTC	TGC	
qRT-PCR	
HERVK14C		(Old	
primer)	
F:	
CCA	TTG	TGC	TCC	ATT	GGA	AG	
R:	
CCC	TCT	GTG	CCG	ATT	GAA	AG	
qRT-PCR	(1)	
	 100	
	 GAT	CCG	TAA	GCA	CAG	GTT	TGG	TCT	
CAG	TTC	AAG	AGA	CTG	AGA	CCA	AAC	
CTG	TGC	TTA	TTT	TTT	ACG	CGT	G	
R:	
AAT	TCA	CGC	GTA	AAA	AAT	AAG	CAC	
AGG	TTT	GGT	CTC	AGT	CTC	TTG	AAC	
TGA	GAC	CAA	ACC	TGT	GCT	TAC	G	
coding	regions	
shKAP1_2	
	
F:	
GAT	CCG	TAA	GAA	CTG	GTA	CTG	GTG	
GTC	TTC	AAG	AGA	GAC	CAC	CAG	TAC	
CAG	TTC	TTA	TTT	TTT	ACG	CGT	G	
R:	
AAT	TCA	CGC	GTA	AAA	AAT	AAG	AAC	
TGG	TAC	TGG	TGG	TCT	CTC	TTG	AAG	
ACC	ACC	AGT	ACC	AGT	TCT	TAC	G	
Targeting	
coding	regions	
shKAP1		 F:	
GAT	CCG	CCT	GGC	TCT	GTT	CTC	TGT	
CCT	TTC	AAG	AGA	AGG	ACA	GAG	AAC	
AGA	GCC	AGG	TTT	TTT	ACG	CGT	G	
R:	
AAT	TCA	CGC	GTA	AAA	AAC	CTG	GCT	
CTG	TTC	TCT	GTC	CTT	CTC	TTG	AAA	
GGA	CAG	AGA	ACA	GAG	CCA	GGC	G	
Targeting	UTR	
shTasor	 F:	
GAT	CCG	AGG	AAG	CTT	GAG	GAT	CTA	
TTC	AAG	AGA	TAG	ATC	CTC	AAG	CTT	
CCT	CTT	TTT	TG	
R:	
AAT	TCA	AAA	AAG	AGG	AAG	CTT	GAG	
GAT	CTA	TCT	CTT	GAA	TAG	ATC	CTC	
AAG	CTT	CCT	CG	
Targeting	
coding	regions	
shMPP8	 F:	
GAT	CCA	AGA	AGA	CCC	CGA	GAA	AGG	
TTC	AAG	AGA	CCT	TTC	TCG	GGG	TCT	
TCT	TTT	TTT	TG	
R:	
AAT	TCA	AAA	AAA	AGA	AGA	CCC	CGA	
GAA	AGG	TCT	CTT	GAA	CCT	TTC	TCG	
GGG	TCT	TCT	TGG	ATC	G	
Targeting	
coding	regions	
shPeriphilin		 F:	
GAT	CCA	GCT	AAC	CAC	TCG	CTC	TAA	
TTC	AAG	AGA	TTA	GAG	CGA	GTG	GTT	
AGC	TTT	TTT	T	
R:	
GAA	TTC	AAA	AAA	AGC	TAA	CCA	CTC	
GCT	CTA	ATC	TCT	TGA	ATT	AGA	GCG	
AGT	GGT	TAG	CTG	GAT	CG	
Targeting	
coding	regions	
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shSETDB1	 F:	
GAT	CCA	CCA	GAT	GAT	CCC	TTC	CAA	
TTC	AAG	AGA	TTG	GAA	GGG	ATC	ATC	
TGG	TTT	TTT	TAC	GCG	TG	
R:	
AAT	TCA	CGC	GTA	AAA		AAC	CAG	ATG	
ATC	CC	TTC	CAA	TCT	CTT	GAA	TTG	
GAA	GGG	ATC	ATC	TGG	TG	
Targeting	
coding	regions	
F:	forward;	R:	reverse.	
	
Table	21	sgRNAs	for	generating	CRISPR	knockout	cells.		
sgRNA	 Sequence	(5’-3’)	 Comment	
KAP1_	Ex1	
	
F:	
CAC	CGG	AGC	GCT	TTT	CGC	CGC	CAG	
R:	
AAA	CCT	GGC	GGC	GAA	AAG	CGC	TCC	
Targeting	Exon	
1	
KAP1_Ex9	
	
F:	
CAC	CGC	GTC	CTG	GCA	CTA	ACT	CAA	
C	
R:	
AAA	CGT	TGA	GTT	AGT	GCC	AGG	ACG	
C	
Targeting	Exon	
9	
F:	forward;	R:	reverse.	
Table	22	PCR	primers	used	for	bisulfite	sequencing.	
Bisulfite	PCR	 Sequence	(5’-3’)	 Comment	
HERVK14C_LTR	
	
F:	
AGG	TTT	AGG	AAG	GTG	GAT	TAT	TTG	
R:	
ACA	ACC	CAA	AAC	TCT	CAA	ACT	CTA	C	
Annealing	
temperature:	
55.0oC		
OCT-4	
	
F:	
ATT	TGT	TTT	TTG	GGT	AGT	TAA	AGG	T	
R:	
CCA	ACT	ATC	TTC	ATC	TTA	ATA	ACA	
TCC	
Annealing	
temperature:	
58.0oC	
SVA	 F:	
TTG	TAA	TTT	TTT	TGT	TTG	ATT	TTT	
TTG	T 
R:	
TAC	ACT	CCA	ACC	TAA	ACA	CCA	TTA	A 
Annealing	
temperature:	
58.0oC	
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LIPA4	 F:	
GGG	TGA	TTT	TTG	TAT	TTT	TAA	TTG	
AG	
R:	
AAA	AAA	AAT	TCC	CTA	ACC	CCT	TAC	
Annealing	
temperature:	
58.0oC	
F:	forward;	R:	reverse.	
Table	23	Sequencing	primers	used	throughout	the	studies.	
Sequencing	primer	 Sequence	(5’-3’)	 Comment	
T7	 TAA	TAC	GAC	TCA	CTA	TAG	GG	 TOPO	cloning	
CPPT_F	 CAG	GCC	CGA	AGG	AAT	AGA	AG	 Reporter	
cloning		
U6_F	 GAG	GGC	CTA	TTT	CCC	ATG	ATT	CC	 CRIPSR	cloning	
AF159	 ATG	CCA	ATT	GCT	CCT	TCT	CTA	GGC	
GCC	GGA	AT	
shRNA	cloning	
F:	forward;	R:	reverse.	
Table	24	Primers	and	probes	used	for	Taqman	qPCR.	
Taqman	qPCR	 Sequence	(5’-3’)	 Comment	
GFP		
	
F:	
CTG	CTG	CCC	GAC	AAC	CAC	
R:	
ACC	ATG	TGA	TCG	CGC	TTC	TC	
Probe:	
[6FAM]	CCA	GTC	CGC	CCC	TGA	GCA	
AAG	ACC	[BHQ1]	
	
Human	Albumin	
	
F:	
GCT	GTT	CAT	CTT	GTG	GGC	TGT	
R:	
ACT	CAT	GGG	AGC	TGC	TGG	TTC	
Probe:	
[6FAM]	CCT	GTC	ATG	CCC	ACA	CAA	
ATC	TCT	CC	[BHQ1]	
	
F:	forward;	R:	reverse.	
Table	25	Primers	used	for	amplifying	genomic	sequence	in	reporter	plasmid	
generation.	
Reporter	PCR	 Sequence	(5’-3’)	 Comment	
Con_LTR	 F:	 Contain	
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	 TCG	AGG	CAC	GCG	TTC	TGG	CGC	CCA	
ACG	TGG	GGC	TCC	CCA	TAA	TCC	
R:	
TCG	AGG	ATT	ATG	GGG	AGC	CCC	ACG	
TTG	GGC	GCC	AGA	ACG	CGT	GCC	
consensus	
PBS-K	and	are	
annealed	
before	cloning	
upstream	of	
the	LTR	
promoter	in	
the	reporter	
plasmid.	
Chr15_LTR	
	
F:	
GCC	TCG	AGG	GAT	TAT	GGG	GAG	CCC	
CAT	GTT	GGG	CGC	CAG	AGC	ACG	CGT	
TGT	GAG	AAA	GAG	AGT	TTC	TGA	GGT	
GC	
R:	
GCG	GAT	CCT	GTT	GGG	GAA	ACC	AGC	
CC	
Forward	
primer	
contains	
specific	PBS-K	
sequence	in	
antisense	
orientation.	
LTR	
	
F:	
GCC	TCG	AGA	GAC	CTG	TGA	GAA	AGA	
GAG	TTT	CTG	AGG	TGC	
R:	
GCG	GAT	CCT	GTT	GGG	GAA	ACC	AGC	
CC	
Annealing	
temperature:	
57.0oC	
F:	forward;	R:	reverse.	
2.20	Plasmid	list	
Table	26	List	of	plasmids	used	in	the	studies.	
Plasmid	 Comment	
p8.91Ex		 Packaging	plasmid	for	lentivector	production	
pMD.G	 Envelope	plasmid	for	lentivector	production		
pKAP1	 Wild	type	KAP1	overexpression	plasmid	
pPGK-GFP	 Lentiviral	vector-based	GFP	reporter		
pSIREN.HIV	 Lentiviral	vector	for	shRNA	expression	
pzfp809	 Zfp809	expressing	plasmid	
pzfp819	 Zfp819	expressing	plasmid	
pPro-GFP	 GFP	expression	plasmid	with	PBS-Pro	upstream	of	the	
promoter		
SVA-SV40-Luc	 Luciferase	plasmid	driven	by	SV40	minimal	promoter	with	
SVA	VNTR	sequence	upstream	of	the	promoter		
LIPA4-SV40-Luc	 Luciferase	plasmid	driven	by	SV40	minimal	promoter	with	
LIPA4	sequence	upstream	of	the	promoter		
pZNF91	 ZNF91	expressing	plasmid	
pZNF93	 ZNF93	expressing	plasmid	
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pTK-Renilla		 Renilla	plasmid	driven	by	thymidine	kinase	promoter	
pISGs-Firefly-Luc	 Luciferase	plasmid	driven	by	various	ISG	promoters	
	
2.21	Drug	list	
Table	27	List	of	drugs	used	in	the	studies.	
Drug	 Working	concentration	 Manufacturer	
5-Aza-2’-deoxycytidine	 7	μM	 Sigma-Aldrich	
Trichostatin	A	 200nM	 Sigma-Aldrich	
	
2.22	Data	access	
mRNA-sequencing	data	are	being	submitted	to	the	NCBI	Gene	Expression	Omnibus	
(GEO)	 (http://www.ncbi.nlm.nih.gov/geo/)	 database.	 Accession	 numbers	 for	 the	
public	data	are	as	follows:	293T:	GSE27929	(Chip-seq),	HuESC:	GSE57989	(Chip-seq),	
293T:	GSE44267	(mRNA-seq),	HeLa:	this	study	(mRNA-seq),	Macrophages:	GSE36952	
(mRNA-seq),	CD4+	T	cells:	GSE69549	(mRNA-seq).	
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Chapter	3:	KAP1	regulates	ERVs	in	differentiated	
human	cells	
3.1	HERVK14C	as	 a	model	 to	 study	 the	 role	of	KAP1	 in	differentiated	
cells	
KAP1-mediated	 repression	 of	 ERVs	 in	 ESCs	 has	 been	 well	 documented	 by	
multiple	 studies	 (Maksakova	 et	 al.,	 2013;	 Rowe	 et	 al.,	 2010;	 Rowe	 et	 al.,	 2013b;	
Turelli	 et	 al.,	 2014).	 However,	 it	 is	 unclear	 if	 KAP1	 is	 necessary	 to	 suppress	 ERVs	
outside	of	 development.	 Importantly,	 one	 study	 showed	 that	 several	murine	 ERVs	
become	 derepressed	 in	 mouse	 liver	 following	 the	 liver-specific	 knockout	 of	 KAP1	
(Ecco	et	al.,	2016)	but	 to	date	 there	are	no	publications	about	 the	 role	of	KAP1	 in	
differentiated	 human	 cells.	 To	 dissect	 the	 relationship	 between	 KAP1	 and	 ERVs	 in	
differentiated	human	cells,	we	first	selected	HERVK14C,	because	it	is	an	endogenous	
retrovirus	known	to	be	repressed	by	KAP1	in	human	ESCs	(Friedli	et	al.,	2014;	Turelli	
et	 al.,	 2014).	We	 found	 HERVK14C	 to	 be	 restricted	 to	 Great	 Apes	 and	 Old	World	
Monkeys	 through	 sequence	analysis	 (Figure	13A)	and	 it	 is	 a	 low	copy	number	ERV	
making	 it	 relatively	 easy	 to	 study	 (Figure	 13B).	 The	 number	 of	 proviral	 copies	
depicted	 (Figure	 13B)	 include	 only	 those	 that	 have	 internal	 regions	 (at	 least	 one	
open	reading	frame),	which	we	chose	to	focus	on	because	KAP1	is	known	to	target	
several	internal	sites	such	as	the	primer	binding	site	(PBS)	and	group	specific	antigen	
(GAG)	(Sadic	et	al.,	2015;	Schlesinger	et	al.,	2013;	Wang	et	al.,	2014a;	Wolf	and	Goff,	
2007;	Wolf	et	al.,	2008b).	These	copies	were	also	flanked	by	LTRs	at	both	5’	and	3’	
ends	 (Figure	 13B).	While	 solo	 LTRs	 are	 not	 included	 in	 our	 initial	 qRT-PCR	 studies	
here,	all	types	of	repeats	are	included	in	our	mRNA-sequencing	analyses	(Figure	18).		
First,	 we	 depleted	 KAP1	 using	 short	 hairpin	 RNA	 (shRNA),	 encoded	 by	 a	
VSVG-pseudotyped	lentivector	and	using	this	system,	we	achieved	efficient	
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Figure	13	HERVK14C	as	a	model	to	explore	the	role	of	KAP1.	
(A) Schematic	diagram	depicting	the	age	of	HERVK14C.		
(B) Chromosome	map	showing	 the	 loci	of	HERVK14C	with	at	 least	one	 internal	open	 reading	 frame	
flanked	by	both	5’	and	3’	LTRs.	
(C) Western	blot	showing	the	knockdown	efficiency	of	KAP1	using	two	distinct	hairpin	vectors.		
(D) Plot	showing	the	expression	of	LINE1,	HERVK14C	and	SVAs	upon	KAP1	knockdown.	Here,	the	old	
primers	 were	 used	 to	 detect	 HERVK14C.	 The	 inlay	 shows	 the	 level	 of	 KAP1	 mRNA	 upon	
knockdown.	 One	 representative	 experiment	 of	 2	 experiments	 is	 shown	 here.	 All	 mRNA	
expressions	were	normalised	to	B2M.		
						Two-tailed	unpaired	Student	t-tests	were	performed.		
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Figure	14	Design	of	new	HERVK14C	primer	sets.	
(A) Diagram	with	highlighted	sequences	in	blue	showing	the	region	upon	which	the	new	primers	were	
designed.	Point	mutations	within	the	blue	region	are	annotated	with	asterisks.	
(B) Loci	 targeted	 by	 the	 old	 and	 new	 qRT-PCR	 primers.	 The	 new	 primer	 sets	 are	 labelled	 as	
‘HERVK14C_1’	and	‘HERVK14C_2’.	
(C) Histogram	showing	the	comparison	of	qRT-PCR	Ct	values	using	the	old	and	new	HERVK14C	primer	
sets.	The	same	template	was	used	in	all	the	reaction	mixes.		
(D) Diagrams	showing	the	melting	curves	of	the	new	primer	sets.	Tm:	melting	temperature.	
						Two-tailed	unpaired	Student	t-tests	were	performed.			
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knockdown	 of	 KAP1	 in	 HeLa	 cells	 (Figure	 13C).	 We	 checked	 the	 expression	 of	
HERVK14C	 as	well	 as	 of	 global	 LINE1	 and	 SVA	 elements	 using	 qRT-PCR.	 LINE1	 and	
SVA	elements	were	only	modestly	upregulated,	while	HERVK14C	was	more	potently	
derepressed	(up	to	6	 fold)	 (Figure	13D).	However,	 results	 for	LINE1	and	SVAs	were	
significant,	whereas	HERVK14C	upregulation	was	not	significant	due	to	its	extremely	
low	 and	 variable	 expression	 level	 at	 baseline	 (Figure	 13D).	 Indeed,	 the	 HERVK14C	
primers	 detect	 only	 a	 single	 copy	 of	 HERVK14C	 on	 Chromosome	 4	 (Turelli	 et	 al.,	
2014).	 To	 circumvent	 this	 issue,	 we	 designed	 two	 new	 primer	 sets	 to	 recognize	
multiple	copies	based	on	a	HERVK14C	alignment	(Figure	14A	&	B).	We	then	verified	
the	new	primer	sets	in	terms	of	their	Ct	values	and	specificity	(Figure	14C	&	D).	The	
new	 primer	 sets	 produce	 significantly	 lower	 Ct	 values	 following	 qRT-PCR	 on	 both	
control	and	knockdown	samples,	as	expected	(Figure	14C).	This	improvement	did	not	
compromise	their	specificity	as	shown	by	their	melting	curves	(Figure	14D).	
	
3.2	KAP1	mediates	HERVK14C	repression	 in	undifferentiated	NTERA-2	
cells		
As	 part	 of	 the	 validation	 of	 our	model,	 we	 utilised	 the	 pluripotent	 human	
embryonic	 carcinoma	NTERA-2	 cell	 line	 to	 confirm	 KAP1	 repression	 of	 HERVK14C.	
Oct4	 is	 a	 marker	 for	 undifferentiated	 embryonic	 cells	 so	 we	 started	 by	 staining	
NTERA-2	cells	for	 intracellular	Oct4	protein	(also	known	as	POU5F1)	to	confirm	the	
undifferentiated	 status	of	 these	cells.	We	 found	 that	 the	vast	majority	of	NTERA-2	
cells	expressed	Oct4,	while	this	marker	was	undetectable	in	293T	cells,	as	expected	
(Figure	15A).	We	then	depleted	KAP1	in	NTERA-2	cells	and	verified	the	loss	of	KAP1	
protein	by	Western	blot	(day	6	post	transduction)	(Figure	15B).	Oct4	expression,	in		
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Figure	15	KAP1	regulates	HERVK14C	in	NTERA-2	cells.	
(A) Intracellular	staining	of	OCT4	protein	in	NTERA-2	(left)	and	293T	control	cells	(right).		
(B) Western	blot	showing	the	level	of	KAP1	and	OCT4	protein	6	days	post-KAP1	knockdown.		
(C) Plots	 showing	 the	 expression	 of	 various	 repeats	 at	multiple	 time	 points	 post-KAP1	 knockdown.	
The	inlay	shows	the	level	of	KAP1	mRNA.	A	representative	experiment	of	2	experiments	is	shown	
here.	B2M	was	used	as	the	normalising	gene	for	mRNA	expression.	Data	for	all	time	points	were	
pooled	for	statistical	analyses.	A	two-tailed	unpaired	Student	T-test	was	done	and	the	p-value	for	
HERVK14C_2	was	0.0023.				
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Figure	16	KAP1	represses	HERVK14C	in	differentiated	cells.	
(A) The	 bar	 chart	 shows	 the	 functional	 verification	 of	 KAP1	 KO	 cells	 (left),	 n=2.	 The	Western	 blot	
shows	the	expression	of	KAP1	in	WT,	KO	and	KAP1	reconstituted	cells	(right).	
(B) Graph	 showing	 the	 relative	 expression	 level	 of	 various	 repeats	 in	WT	 and	 KO	HeLa	 clones.	 The	
inlay	shows	the	level	of	KAP1	mRNA	while	the	Western	blot	(below)	shows	the	protein	level	in	the	
tested	 clones.	 B2M	 was	 used	 as	 the	 normalising	 gene.	 Data	 across	 all	 clones	 was	 pooled	 for	
statistical	analyses.	Clones	8,	12	and	15	were	subsequently	used	for	mRNA	sequencing.		
(C) KAP1	KO	293T	cells	were	functionally	verified	using	a	luciferase	based	readout	assay.		
(D) 	Graph	showing	the	expression	level	of	various	repeats	in	WT	and	KO	293T	clones.	The	inlay	shows	
the	 level	 of	 KAP1	mRNA	while	 the	Western	 blot	 (below)	 shows	 the	 protein	 level	 of	 the	 tested	
clones.	B2M	was	used	as	the	normalising	gene.	Data	were	pooled	across	all	clones	for	statistical	
analyses.	
(E) Bisulfite	sequencing	of	multiple	 loci	of	endogenous	SVA	D	VNTRs	and	the	OCT4	gene	body.	Each	
circle	 represents	 a	 CpG	 dinucleotide.	 Open	 circles	 represent	 a	 lack	 of	 methylation	 while	 filled	
circles	represent	methylation	of	the	CpG.		
						Two-tailed	unpaired	Student	T-tests	were	done.		
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comparison	 was	 not	 affected	 in	 the	 same	 timeframe	 (Figure	 15B).	 HERVK14C	
upregulation	 could	 be	 observed	 by	 as	 early	 as	 day	 2	 post	 knockdown	 and	 this	
phenotype	was	sustained	at	least	up	to	day	6	post	knockdown	(Figure	15C).	We	also	
looked	at	expression	of	LIPA4	and	SVA	D	VNTR,	both	of	which	have	previously	been	
shown	to	be	bound	by	KAP1	(Jacobs	et	al.,	2014).	However,	KAP1-depletion	had	little	
or	 no	 effect	 on	 the	 expression	 of	 these	 elements	 compared	 to	 its	 effect	 on	
HERVK14C	(Figure	15C).	Of	note,	the	Ct	values	of	these	retrotransposons	were	much	
lower	than	of	HERVK14C	in	control	NTERA-2	cells	pointing	to	their	higher	expression	
level	 (and	copy	number)	at	baseline.	 Indeed,	LINE1	elements	have	been	previously	
documented	to	be	readily	expressed	in	NTERA-2	cells	(Chen	et	al.,	2012).	
	
3.3	KAP1	represses	HERVK14C	in	differentiated	cells		
We	then	asked	the	question	of	whether	KAP1	was	necessary	to	repress	these	
retrotransposons	 in	 differentiated	 cells.	 We	 therefore	 repeated	 these	 knockdown	
experiments	 in	 293T	 cells	 and	 HeLa	 cells	 and	 took	 advantage	 of	 the	 CRIPSR/Cas9	
genome-editing	 system	 to	 additionally	 generate	 KAP1	 knockout	 differentiated	 cell	
lines.	 We	 first	 validated	 the	 HeLa	 KAP1	 knockout	 clones	 functionally	 using	 a	
previously	 described	 zfp809	 and	 Pro-PBS	 system	 (Wolf	 and	 Goff,	 2009)	 using	
reporters	generated	before	(Rowe	et	al.,	2013a)	(Figure	16A).	In	wild	type	cells,	GFP	
expression	was	significantly	reduced	in	the	presence	of	zfp809,	whereas	in	KAP1	KO	
clones	 (which	were	 validated	 to	 be	 KAP1	 KO	 by	Western	 blot)	 (Figure	 16A,	 right),	
such	 repression	 was	 completely	 abrogated,	 as	 expected.	 Zfp819	 was	 used	 as	 a	
negative	 control.	 Upon	 complementation	 with	 KAP1	 cDNA,	 GFP	 repression	 was	
rescued	 to	 a	 level	 similar	 to	 that	 induced	 in	wild	 type	 cells	 (Figure	 16A).	We	 then	
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selected	 several	 KAP1	 knockout	 clones	 and	 looked	 at	 the	 impact	 of	 knockout	 on	
retrotransposon	 expression	 (Figure	 16B).	 All	 clones	 showed	 a	 consistent	
upregulation	of	HERVK14C	compared	to	controls	as	detected	using	both	primer	sets,	
while	 SVA	 D	 VNTR	 elements	 were	 also	 upregulated	 in	 some	 of	 the	 clones	 tested	
(Figure	 16B).	We	 validated	 KAP1	 knockout	 in	 these	 clones	 at	 both	 the	mRNA	 and	
protein	 level	 (Figure	16B).	 Similarly,	we	verified	KAP1	 loss	 functionally	 in	293T	 cell	
knockout	clones	by	using	previously	described	KAP1	reporters	(Jacobs	et	al.,	2014).	
The	SV40-Luciferase	(SVA-Luc)	reporter	plasmids,	which	contained	either	an	LIPA4	or	
SVA	D	VNTR	(SVA)	KAP1	target	sequence	were	co-transfected	with	either	ZNF91	or	
ZNF93	as	previously	described	 (Jacobs	et	 al.,	 2014).	 ZNF91	mediated	 repression	of	
SVA-SV40-Luc	and	ZNF93	mediated	repression	of	LIPA4-SV40-Luc	and	both	reporters	
were	dependent	on	KAP1	(Figure	16C).	We	then	assessed	repeat	expression	in	these	
clones	 and	 found	 that	 HERVK14C	was	 upregulated	 in	 KAP1	 KO	 293T	 cells	 but	 this	
phenotype	was	restricted	to	the	second	primer	set	(HERVK14C_2)	suggesting	some	
heterogeneity	 in	 HERVK14C	 regulation	 between	 cell	 types	 (Figure	 16D).	 Through	
bisulfite	 sequencing,	 we	 found	 high	 levels	 of	 DNA	 methylation	 at	 SVA	 element	
promoters	(Figure	16E).	This	 is	consistent	with	previous	findings	that	SVA	elements	
are	enriched	for	cytosine	methylation	(Turelli	et	al.,	2014)	and	may	explain	the	lack	
of	SVA	upregulation	upon	KAP1	knockout.	The	Oct4	gene	body	served	as	a	positive	
control	for	endogenous	DNA	methylation	(Figure	16E).	
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Figure	17	Analysis	of	KAP1	repressed	cellular	genes.	
(A) Screenshots	of	UCSC	genome	browser	 tracks	showing	the	mRNA	 level	of	KAP1.	The	upper	 three	
tracks	illustrate	the	level	of	expression	in	KO	samples	while	the	lower	three	tracks	show	the	levels	
in	WT	cells.	
(B) Dot	 plot	 showing	 the	 enriched	 functional	 clusters	 among	 the	 upregulated	 genes	 (>2	 fold	 with	
adjusted	p-values	<	0.05)	in	KAP1	KO	cells	compared	to	the	WT	according	to	DAVID	gene	ontology	
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analysis.	Inlaid	Venn	diagrams	show	the	proportion	of	ZNFs	and	KZNFs	among	all	the	upregulated	
genes.		
(C) Table	showing	the	identities	of	all	the	upregulated	KRAB-ZNFs	and	the	status	of	KAP1	binding	to	
these	loci	according	to	ENCODE	data.	
(D) 	–	(H)	Screenshots	of	UCSC	genome	browser	tracks	showing	the	mRNA	expression	level	of	various	
genes	using	our	mRNA	sequencing	data.	The	upper	three	tracks	 illustrate	the	expression	 level	 in	
KO	samples	while	the	lower	three	tracks	show	the	expression	level	in	WT	cells.				
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Figure	18	Analysis	of	HERVs	repressed	by	KAP1.	
(A) Box	plots	(mean	±	SD)	showing	the	difference	in	expression	of	upregulated	repeats	between	WT	
and	 KO	 cells.	 The	 KAP1	 binding	 status	 of	 these	 families	 is	 represented	 below	 the	 respective	
graphs.		
(B) Examples	of	loci	in	(A)	bound	by	KAP1	and	other	transcription	factors	according	to	ENCODE	data.		
(C) The	estimated	age	of	HERVs	in	(A)	mapped	onto	the	evolutionary	tree.	The	estimated	ages	of	the	
stated	lineages	are	shown	and	marked	with	an	asterisk.	myr:	million	years.	
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3.4	KAP1	binds	to	and	represses	cellular	genes		
In	order	to	further	dissect	KAP1	targets	in	differentiated	cells	in	a	systematic	
and	 unbiased	manner,	we	 employed	mRNA	 sequencing	 using	 three	wild	 type	 and	
three	 KAP1	 knockout	 HeLa	 samples	 (KO	 clones	 8,	 12	 and	 15,	 see	 Figure	 16B).	
Consistent	with	our	qRT-PCR	results,	we	saw	a	reduction	in	reads	mapping	the	KAP1	
transcript	in	all	the	knockout	clones	compared	to	the	wild	type	ones	(Figure	17A).	In	
addition	 to	 KAP1,	 we	 also	 found	 several	 hundred	 cellular	 genes	 that	 were	 either	
positively	 or	 negatively	 affected	 following	 the	 knockout.	When	we	 focused	on	 the	
upregulated	 genes	 (>2	 fold	with	 adjusted	 p	 values	 of	 ≤	 0.05),	 interestingly,	 DAVID	
analysis	 revealed	 zinc	 finger	 proteins	 (ZNFs)	 to	 be	 the	 class	 of	 genes	 most	
significantly	affected	(Figure	17B).	Strikingly,	the	majority	of	these	ZNFs	(9	out	of	13)	
have	a	KRAB	domain	(Figure	17B).	These	loci	are	all	also	direct	KAP1-binding	targets	
according	to	ENCODE	data	(Figure	17C),	which	is	consistent	with	the	reported	role	of	
KAP1	targeting	to	ZNFs,	including	through	ZNF274	and	ZNF75D	(Frietze	et	al.,	2010;	
Imbeault	 et	 al.,	 2017;	 Iyengar	 et	 al.,	 2011).	 Together,	 these	 observations	 reveal	 a	
functional	 role	 for	 KAP1	 in	 fine-tuning	 cellular	 gene	 expression	 at	multiple	 targets	
across	 chromosomes	 in	 differentiated	 human	 cells	 (Figure	 17D-H).	 Indeed,	 this	 is	
consistent	with	the	described	role	of	KAP1	 in	regulating	gene	expression	 in	several	
mouse	tissues	and	cell	types	including	T	cells,	B	cells	and	mouse	liver	(Bojkowska	et	
al.,	2012;	Santoni	de	Sio	et	al.,	2012a;	Santoni	de	Sio	et	al.,	2012b).	
	
3.5	KAP1	represses	multiple	HERV	families	in	differentiated	cells		
We	 then	 mapped	 the	 mRNA	 sequencing	 reads	 to	 Repbase	 extending	 our	
analysis	 to	 repetitive	 elements	 and	 selected	 those	 that	 were	 >2	 affected	 with	 p-
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values	of	≤	0.05.	 In	addition	to	HERVK14C,	we	 identified	two	other	classes	of	ERVs	
(HERV-T	and	HERV-S)	that	were	upregulated	following	KAP1	knockout	(Figure	18A).	
As	expected,	these	ERV	families	were	also	bound	by	KAP1	according	to	ENCODE	data	
(Figure	18A	&	B).	Interestingly,	while	HERV-T	and	HERV-K	are	both	relatively	recent,	
HERV-S	appears	to	be	an	ancient	lineage	and	present	in	diverse	primates	and	other	
mammals	(Figure	18C),	suggesting	it	may	be	regulated	through	a	conserved	ZNF.	In	
addition	to	KAP1	binding,	we	also	found	clusters	of	transcription	factors	binding	to	
these	ERVs	suggesting	that	they	may	function	as	regulatory	hubs	and	that	repression	
may	be	dynamic	(Figure	18B).	
	
3.6	 KAP1	 knockout	 leads	 to	 downregulation	 of	 certain	 cellular	 genes	
and	repeats	
mRNA-sequencing	 also	 revealed	 several	 cellular	 genes	 to	 become	
downregulated	 (>2	 fold	with	adjusted	p-values	of	≤	0.05)	 following	KAP1	knockout	
(Figure	19).	Of	particular	 interest,	 innate	 immune	response	genes	were	among	the	
downregulated	 genes.	 Several	 publications	 link	 repetitive	 elements	 to	 innate	
immune	responses	(Chiappinelli	et	al.,	2015;	Roulois	et	al.,	2015)	and	we	will	follow	
up	 this	 link	 in	 Chapter	 5.	 Since	 KAP1	 has	 also	 been	 described	 as	 a	 transcriptional	
activator	 (Chang	 et	 al.,	 1998;	 Rambaud	 et	 al.,	 2009;	 Singh	 et	 al.,	 2015),	 one	
possibility	is	that	KAP1	promotes	transcription	of	these	genes	in	a	wild	type	context.	
However,	 this	 hypothesis	 is	 not	 supported	 by	 the	 fact	 that	 KAP1	 binding	 is	 not	
enriched	 in	 these	 gene	 clusters	 (Figure	 21B).	 This	 suggests	 that	 these	 genes	 are	
indirect	targets	affected	as	a	secondary	consequence	of	KAP1	knockout.	Likewise,	we	
also	found	several	classes	of	repetitive	elements	(HUERS-P1,	LIPBA1_5,	LIM2C_5)	to		
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Figure	19	Analysis	of	cellular	genes	downregulated	upon	KAP1	KO.	
Dot	 plot	 showing	 the	 enriched	 functional	 clusters	 of	 the	 downregulated	 genes	 in	 KAP1	 KO	 cells	
compared	to	the	WT	according	to	DAVID	gene	ontology	analysis.										
	
Figure	20	Analysis	of	repeats	downregulated	upon	KAP1	KO.	
Box	plots	(mean	±	SD)	showing	the	difference	 in	expression	of	downregulated	repeats	between	WT	
and	KO	cells.				 	
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be	downregulated	in	our	mRNA-sequencing	reads	(>2	fold	with	adjusted	p-values	of	
≤	0.05,	Figure	20).	
	
3.7	 KAP1	 binds	 to	 common	 ERVs	 and	 ZNFs	 in	 undifferentiated	 and	
differentiated	cells	
Since	 we	 observed	 KAP1	 repression	 of	 ERVs	 in	 NTERA-2	 cells	 and	
differentiated	cell	lines,	we	hypothesised	that	KAP1	binds	to	common	targets	in	both	
undifferentiated	and	differentiated	cells.	To	 test	 this	hypothesis,	we	utilised	public	
KAP1	ChIP-seq	and	ENCODE	data	from	293T	cells	and	human	ESCs.	We	identified	614	
common	KAP1	binding	ChIP-seq	peaks	between	the	two	cell	types	(Figure	21A).	We	
then	 selected	 the	 nearest	 genes	 to	 these	 sites	 and	 interestingly,	 gene	 ontology	
analysis	showed	that	the	most	enriched	gene	cluster	was	ZNFs	(including	40	KZNFs	
out	 of	 the	 61	 ZNFs)	mirroring	 our	 functional	mRNA-sequencing	 data	 (Figure	 17B).	
When	we	looked	at	where	these	loci	fall	in	the	genome,	we	found	them	to	be	highly	
enriched	 within	 LINE1	 elements	 and	 ERV	 families	 compared	 to	 the	 abundance	 of	
these	 repeats	 in	 the	 genome	 (Figure	 21C).	We	 then	 looked	 at	 the	 distribution	 of	
LINE1	and	ERVs	and	found	a	slight	enrichment	for	ERV1	(ERV	class	I)	elements	within	
the	 common	binding	 sites	 compared	 to	 the	expected	distribution	of	 this	 ERV	class	
(Figure	21D)	as	well	as	to	its	prevalence	within	either	the	ESC	or	293T	datasets.	ERVs	
can	generally	be	categorised	into	Class	I,	II	or	III	based	on	their	sequence	similarities	
to	their	exogenous	counterparts.	Class	I	ERVs	are	Gammaretrovirus-like,	Class	II	ERVs	
are	 Betaretrovirus-like	while	 Class	 III	 are	 Spumavirus-like.	 Interestingly,	 the	 Class	 I	
clade	 includes	 HERV-T	 elements	 and	 this	 is	 consistent	 with	 KAP1	 regulation	 and	
binding	of	this	family	(Figure	18A	and	B).	Overall,	these	data	show	that	a	proportion		
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Figure	21	Analysis	of	conserved	KAP1	binding	loci	as	revealed	through	ChIP-seq.	
(A) Venn	 diagram	 showing	 the	 overlapping	 KAP1	 binding	 sites	 between	 replicates	 of	 ESC	 and	 293T	
cells	and	between	the	two	cell	types.		
(B) Dot	plot	 showing	 the	 functional	 clusters	enriched	 from	the	614	KAP1	binding	peaks	 in	 (A)	using	
DAVID	analysis.	The	Inlaid	Venn	diagram	shows	the	proportion	of	ZNFs	and	KZNFs.	
(C) Pie	 charts	 illustrating	 the	 identity	 of	 common	 KAP1	 binding	 sites	 (left)	 compared	 to	 the	
distribution	of	these	features	in	the	human	genome	(right).	
(D) Bar	chart	 showing	 the	distribution	of	 LINE1s	and	ERV	 families	 in	 the	genome	 (Total),	 and	 in	 the	
ESC	KAP1	binding	data	(KAP1	ESC)	and	the	293T	KAP1	binding	data	(KAP1	293T)	and	the	common	
binding	sites	(KAP1	common).				
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of	 the	KAP1	binding	 landscape	 is	preserved	 from	undifferentiated	 to	differentiated	
cells.		
	
3.8	KAP1	common	binding	sites	are	enriched	for	repressive	chromatin	
marks		
We	then	further	hypothesised	that	KAP1	repression	at	these	common	sites	is	
a	 conserved	 feature	 across	 multiple	 cell	 types.	 To	 address	 this,	 we	 probed	 the	
ENCODE	 data	 of	 epigenetic	marks	 in	 various	 differentiated	 cells	 including	 primary	
cells	to	assess	whether	silent	chromatin	marks	overlap	with	KAP1	common	binding	
sites.		
We	indeed	found	that	these	loci	correlate	with	KAP1	and	SETDB1	binding	as	
well	as	with	H3K9me3	in	multiple	cell	types	(Figure	22A).	In	contrast,	we	detected	no	
enrichment	 of	 the	 active	 chromatin	 marks,	 H3K4me1	 and	 H3K27ac,	 at	 these	
common	binding	sites,	as	expected	(Figure	22A).	Since	KAP1	is	recruited	to	its	targets	
by	KZNFs	(Iyengar	et	al.,	2011),	we	hypothesised	that	a	proportion	of	KZNFs	must	be	
widely	 expressed	 and	 at	 a	 level	 sufficient	 to	 recruit	 KAP1	 to	 its	 targets	 in	
differentiated	cells.	 Indeed,	our	HeLa	mRNA-sequencing	data	revealed	many	KZNFs	
to	be	expressed	at	a	 low	 level	 (several	examples	are	shown	 in	Figure	17D	&	E).	To	
investigate	the	profile	of	targets	bound	by	KZNFs	that	are	expressed	in	differentiated	
cells,	we	first	 identified	the	top	one	hundred	most	highly	expressed	KZNFs	 in	293T	
cells	 using	public	mRNA-sequencing	data	 (Zuin	 et	 al.,	 2014).	We	 then	 verified	 that	
these	KZNFs	are	expressed	at	the	protein	expression	level	using	the	human	protein	
atlas	 (Uhlen	et	al.,	2010)	and	recorded	their	 targets	where	known	(Imbeault	et	al.,	
2017;	Schmitges	et	al.,	2016).	Interestingly,	many	of	these	KZNFs	bind	to	ERVs		 	
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Figure	22	KAP1	common	binding	sites	are	enriched	for	repressive	histone	marks	
and	overlap	with	KZNF-bound	ERV	loci.	
(A) ChIP-Cor	 analysis	 of	 the	 common	 KAP1	 binding	 sites	 defined	 above	 (Figure	 21A).	 Genomic	
coordinates	 were	 used	 as	 the	 input	 and	 intersected	 with	 ChIP-seq	 peaks	 using	 ChIP-Cor	
(Ambrosini	et	al.,	 2016).	 Each	 line	plot	 shows	 two	biological	duplicates	of	ChIP-seq	experiments	
from	ENCODE.		
(B) Diagram	 showing	 the	 known	 targets	 within	 the	 genome	 of	 the	 top	 100	most	 highly	 expressed	
KZNFs	 in	 293T	 (as	 defined	 by	 RNA-seq	 RPKM	 values).	 The	 level	 of	 protein	 expression	 of	 these	
candidates	was	verified	using	the	site:	http://www.proteinatlas.org/cell.	
(C) Diagram	showing	the	common	KAP1	binding	sites	within	the	genome.	
(D) Distribution	of	the	age	and	types	of	ERVs	bound	by	the	KZNFs	in	(B).		
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(Figure	22B),	reflecting	KAP1	common	binding	loci	(Figure	22C).	Intriguingly,	the	ERV-
binding	KZNFs	are	conserved	among	different	primates	and	mammals	reflecting	the	
wide	age	spectrum	of	their	ERV	targets	(Figure	22D).	These	data	indicate	that	KAP1	
and	 KZNFs	 regulate	 a	 subset	 of	 common	 ERVs	 and	 cellular	 genes	 between	
undifferentiated	and	differentiated	cells	and	potentially	also	between	species.		
	
3.9	KAP1	mediates	de	novo	 repression	of	 incoming	ERVs	 through	 the	
primer	binding	site	sequence		
Next,	 since	 KAP1	 is	 known	 to	 target	 a	 lysine	 primer	 binding	 site	 (PBS)	
sequence	(Turelli	et	al.,	2014;	Wolf	and	Goff,	2007;	Wolf	et	al.,	2008b),	we	asked	if	
KZNFs	and	KAP1	were	expressed	at	sufficient	levels	in	differentiated	cells	to	induce	
de	novo	repression	of	incoming	HERVK	sequences.	We	first	identified	a	KAP1-bound	
and	repressed	HERVK14C	integrant	on	Chromosome	15	and	used	its	LTR	to	construct	
a	GFP-based	reporter	system	to	measure	de	novo	KAP1	repression	in	differentiated	
cells.	We	then	cloned	its	PBS	sequence	(PBSChr15),	which	was	similar	to	a	lysine	PBS,	
upstream	 of	 the	 LTR	 in	 an	 antisense	 orientation	 (termed	 PBSChr15-LTR-GFP)	 and	
compared	this	vector	 to	one	containing	 the	consensus	 lysine1,2	PBS	 (PBS)	 (termed	
PBS-LTR-GFP)	 and	 a	 control	 vector	 containing	 no	 PBS	 sequence	 (LTR-GFP)	 (Figure	
23A).	 Using	 this	 system,	we	 could	 demonstrate	 that	 the	 HERVK14C	 PBS	 sequence	
and	 the	consensus	PBS	 sequence	were	 sufficient	 to	 induce	modest	GFP	 repression	
and	 this	was	 dependent	 on	 KAP1	 in	 both	 undifferentiated	 and	 differentiated	 cells	
(Figure	 23B	 and	 C).	We	 confirmed	 that	 the	 difference	 in	 GFP	 levels	 between	wild	
type	 and	 knockout	 cells	 was	 not	 due	 to	 a	 difference	 in	 vector	 integration	 (Figure	
23D).		
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Figure	23	KAP1	is	crucial	for	PBS-mediated	de	novo	silencing	of	incoming	ERVs.	
(A) Schematic	diagram	of	the	reporter	constructs	used.		
(B) NTERA-2	cells	were	transduced	with	either	a	KAP1	knockdown	vector	(KD)	or	a	control	vector	(WT)	
and	were	challenged	with	multiple	doses	of	the	reporter	vectors	and	GFP	was	assessed	72	hours	
post	 challenge.	 One	 representative	 experiment	 of	 2	 experiments	 is	 shown	 here.	 Data	 from	 2	
experiments	was	pooled	for	statistical	tests.		
(C) WT	or	KAP1	KO	293T	cell	clones	were	challenged	with	multiple	doses	of	the	reporter	vectors	and	
GFP	was	 assessed	 72	 hours	 post	 challenge.	One	 representative	 experiment	 of	 3	 experiments	 is	
shown	here.	Data	from	3	experiments	was	combined	for	statistical	tests.		
(D) Taqman	qPCR	 looking	at	the	relative	 levels	of	 integrated	vector	between	WT	and	KAP1	KO	293T	
cells	challenged	with	various	doses	of	reporters.	Samples	were	harvested	at	the	same	time	as	the	
GFP	readout.	A	PGK-GFP	transduced	cell	line	was	used	as	a	single	copy	reference.		
Two-tailed	unpaired	Student	T-tests	were	done.				
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Figure	24	Model.	
KAP1	represses	ERVs	and	cellular	genes	 (particularly	ZNFs)	 in	differentiated	cells	and	this	correlates	
with	KAP1	binding.	These	loci	are	also	enriched	for	SETDB1	binding	and	the	repressive	histone	mark	
H3K9me3,	which	 is	conserved	across	multiple	cell	 types.	 It	may	be	that	 repression	 is	not	stable	but	
dynamic	as	 indicated,	 leading	 to	potential	 tissue-specific	activation	of	gene	expression	programmes	
through	 ERV	 platforms.	 In	 addition,	 KAP1	 can	 restrict	 incoming	 DNA	 in	 a	 sequence-specific	 way	
suggesting	 that	 a	 subset	 of	 KZNFs	 are	 constitutively	 expressed	 in	 differentiated	 cells	 including	 the	
cognate	KZNF	for	the	lysine	PBS.	Overall,	this	points	to	the	conservation	and	importance	of	the	KAP1-
KZNF	repression	pathway	in	differentiated	cells.		
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Discussion	I	
In	sum,	our	data	illustrate	that	in	differentiated	cells,	KAP1	binding	and	repression	of	
a	subset	of	ERVs	 is	 intact.	The	precise	ERVs	that	become	depressed	upon	KAP1	KO	
likely	 depend	 on	 the	 availability	 of	 activating	 transcription	 factors	 as	 suggested	
before	 (Wolf	 et	 al.,	 2015;	 Yang	 et	 al.,	 2015).	 KAP1	 binding	 correlates	 with	 the	
presence	 of	 repressive	 chromatin	 marks	 that	 are	 conserved	 across	 multiple	 cell	
types.	 KAP1	 repression	 can	 also	 be	 observed	 at	 KZNF	 genes	 suggesting	 that	
expression	of	ERVs	and	KZNFs	is	co-regulated.	The	continued	expression	of	KZNFs	in	
differentiated	cells	may	allow	cells	to	be	poised	to	react	to	 insults	from	exogenous	
retroviruses.	 Their	 expression	 may	 also	 reflect	 their	 role	 in	 fine-tuning	 gene	
expression	through	dynamic	regulation	of	ERVs	and	ZNFs	(Figure	24).	
These	results	also	show	that	DNA	methylation	perpetuated	by	DNMT1	is	not	
sufficient	 to	maintain	 ERVs	 in	 a	 silent	 state	 in	 adult	 tissues	 as	 has	 been	 proposed	
(Yoder	 et	 al.,	 1997).	 In	 contrast,	we	 reveal	 an	 ongoing	 requirement	 for	 the	 KZNF-
KAP1	 pathway	 as	 suggested	 before	 from	 studies	 in	 mice	 (Ecco	 et	 al.,	 2016).	 The	
continued	requirement	of	the	KAP1	pathway	in	differentiated	cells	may	be	explained	
by	 the	 fact	 that	 many	 ERVs	 have	 been	 exapted	 by	 the	 host	 to	 mediate	 cell-type	
specific	 functions,	 for	 example	 in	 immune	 cells	 (Chuong	et	 al.,	 2016;	Collins	 et	 al.,	
2015;	Hummel	et	al.,	2017;	Zeng	et	al.,	2014)	and	potentially	in	the	developing	brain	
(Brattas	 et	 al.,	 2017;	 Fasching	 et	 al.,	 2015).	 KAP1-mediated	 regulation	 may	 allow	
ERVs	 to	 be	 expressed	 in	 a	 tissue-specific	 way	 or	 in	 response	 to	 environmental	
stimuli.	Indeed,	ERVs	are	transcribed	in	an	organised	manner	during	the	early	stages	
of	 development	 and,	 despite	 being	 categorised	 under	 the	 same	 family,	 individual	
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transcripts	might	have	different	impacts	on	the	host	(Durruthy-Durruthy	et	al.,	2016;	
Goke	et	al.,	2015;	Wang	et	al.,	2014b).	The	chromosomal	positioning	of	a	locus	might	
be	important	in	determining	its	fate	in	different	developmental	stages.		
In	 comparison	 to	 HERVK14C,	 SVAs	 and	 LINE1s	 are	 only	 marginally	
upregulated	 upon	 KAP1	 knockout	 indicating	 that	 dense	 DNA	methylation	 may	 be	
difficult	to	reverse	at	these	elements	or	that	their	activating	transcription	factors	are	
lacking	 (Turelli	 et	 al.,	 2014).	 The	 enrichment	 of	 ZNF91,	 the	 cognate	 ZFP	 that	
recognises	SVA	elements	 (Jacobs	et	al.,	2014),	exclusively	 in	embryonic	cells	points	
to	the	possibility	that	KAP1	and	ZNF91	are	not	required	to	repress	these	elements	in	
differentiated	cells.		
Previous	studies	have	shown	KAP1	enrichment	at	the	3’	ends	of	KZNF	genes	
on	Chromosome	19	(Iyengar	et	al.,	2011;	O'Geen	et	al.,	2007).	KAP1	can	also	mediate	
the	spread	of	HP1β	and	repressive	H3K9me3	histone	marks	at	these	KZNF	clusters	if	
it	 is	 artificially	 tethered	 to	 them	 (Groner	 et	 al.,	 2010).	 It	 has	 been	 proposed	 that	
KAP1	 binding	 to	 KZNF	 gene	 bodies	 may	 primarily	 be	 to	 prevent	 recombination	
(Iyengar	et	al.,	2011).	However,	our	mRNA-seq	data	is	consistent	with	a	role	for	KAP1	
in	 negative	 regulation	 of	 KZNFs,	 including	 on	 Chromosome	 19.	 Interestingly,	 the	
presence	of	H3K9me3	on	these	loci	does	not	correlate	with	the	expression	of	KZNF	
genes	 upon	 KAP1	 knockout	 (Kauzlaric	 et	 al.,	 2017).	 Alternatively,	 this	 observation	
can	 be	 explained	 by	 the	 loss	 of	 silent	 chromatin	 spreading	 from	 nearby	 ERV	
enhancers	 (or	 other	 repeats)	 that	 are	 KAP1	 regulated	 as	 observed	 in	 recent	
publication	in	mice	(Kauzlaric	et	al.,	2017).	Whether	this	is	the	case	and	the	identities	
of	the	repeats	that	regulate	KZNF	expression	in	human	cells	are	yet	to	be	elucidated.	
We	found	that	a	common	feature	of	KAP1-regulated	ERVs	(HERVK14c,	HERV-
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S	 and	HERV-T)	was	 that	 they	 bound	multiple	 transcription	 factors,	 suggesting	 that	
they	function	as	regulatory	hubs	for	genes	in	their	vicinity.	A	recent	example	of	ERVs	
regulating	 adjacent	 genes	 is	 MER41	 ERVs	 that	 have	 been	 co-opted	 to	 drive	 the	
expression	of	ISGs	(Chuong	et	al.,	2016).		
Interrogation	of	the	expression	profile	of	KZNFs	revealed	many	to	be	widely	
expressed	 in	differentiated	cell	 types,	which	we	also	 found	competent	 for	de	novo	
repression	of	incoming	DNA.	Therefore,	KAP1	may	serve	to	restrict	incoming	human	
retroviruses	(at	least	with	Lys1,2,	serine	or	threonine	PBS	sequences)	in	adult	tissues,	
whereas	 in	 embryos	 it	 needs	 to	 silence	 retrotransposons	more	 broadly,	 reflecting	
the	 deeper	 breadth	 of	 KZNFs	 expressed	 in	 early	 development.	 Overall,	 in	 this	
chapter,	we	have	shown	that:	
i) The	 KZNF/KAP1	 pathway	 continues	 to	 regulate	 a	 subset	 of	 ERVs	 and	
cellular	genes	in	human	differentiated	cells	
ii) This	subset	of	ERVs	are	enriched	for	ERV1	and	ERV-K	elements	
iii) KAP1	can	induce	de	novo	repression	of	ERVs	in	a	PBS-dependent	manner	
potentially	through	KZNFs	
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Chapter	4:	RKAP1	regulates	ERVs	in	primary	human	
cells	
4.1	 KAP1	 knockdown	 in	 PBMCs	 leads	 to	 upregulation	 of	
retrotransposons	
To	extend	our	studies	on	the	role	of	KAP1	in	differentiated	cells	beyond	cell	
lines,	we	employed	primary	human	peripheral	blood	mononuclear	cells	(PBMCs).	We	
isolated	PBMCs	either	directly	from	fresh	blood	donated	by	healthy	donors	or	from	
buffy	 coats	 as	 described	 in	 the	 methods.	 We	 found	 that	 around	 60%	 of	 the	
population	were	positive	 for	CD3,	of	which	70%	were	also	positive	 for	CD4	 (Figure	
25A).	We	then	transduced	the	cells	with	shRNA-encoding	lentivectors	to	knockdown	
KAP1.	The	knockdown	efficiency	was	 confirmed	using	qRT-PCR	 (Figure	25B	and	C).	
We	observed	 a	 significant	 upregulation	 of	HERVK14C	 and	 to	 a	 lesser	 extent	 LIPA4	
and	SVA	D	VNTR	in	both	PBMC	donors	(Figure	25B	and	C).		
	
4.2	KAP1	regulates	multiple	KZNFs	in	PBMCs	
Since	we	previously	found	KZNFs	to	be	the	main	cellular	gene	targets	of	KAP1	
repression	in	cell	 lines,	we	asked	if	this	pathway	was	conserved	in	primary	cells.	To	
this	end,	we	checked	the	expression	level	of	various	KZNFs	in	KAP1	knockdown	cells	
and	 found	 that	 five	 out	 of	 six	 candidates	 exhibited	 robust	 and	 significant	
upregulation	(Figure	25D).	 	All	of	these	genes	are	also	KAP1	binding	targets	(Figure	
17C).		
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Figure	25	KAP1	repression	of	ERVs	is	conserved	in	PBMCs.	
(A) FACS	plots	showing	staining	of	T	cell	markers	in	PBMCs.		
(B) qRT-PCR	 expression	 of	 retrotransposons	 following	 KAP1	 knockdown	 in	 PBMCs.	 Results	 were	
normalised	to	B2M.	The	 level	of	KAP1	expression	 is	shown	 in	a	separate	graph	(right)	with	B2M	
and	GAPDH	used	as	normalisers.		
(C) The	same	experiment	as	in	(B)	using	PBMCs	from	a	different	donor.	
(D) The	expression	levels	of	various	KZNFs	in	two	independent	experiments	(B	&	C).	B2M	was	used	as	
the	normaliser	gene.		
Two-tailed	unpaired	Student	T-tests	were	done.					
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4.3	 KAP1	 knockdown	 is	 not	 sufficient	 for	 robust	 upregulation	 of	
HERVK14C	in	CD4+	T	cells	
Since	PBMCs	represent	a	mixed	population	of	cells,	we	further	purified	them	
to	isolate	CD4+	T	cells,	which	formed	the	bulk	of	our	PBMCs	(Figure	25A),	to	ask	if	we	
could	 detect	 KAP1-regulation	 of	 ERVs	 within	 this	 population.	 Using	 our	 isolation	
procedure	(see	methods),	we	could	achieve	up	to	95%	purity	(Figure	26A).	We	then	
transduced	the	cells	with	shRNA-encoding	 lentivectors	and	verified	the	knockdown	
efficiency	with	Western	blot	and	qRT-PCR	over	several	time	points	(Figure	26B	and	
C).	 Surprisingly,	 despite	 an	 efficient	 depletion	 of	 KAP1,	 we	 did	 not	 see	 a	 robust	
upregulation	of	HERVK14C	(Figure	26C).	We	hypothesised	that	DNA	methylation	may	
be	 enriched	 at	HERVK14C	 and	pose	 a	 barrier	 to	 its	 reactivation.	 In	 support	 of	 this	
possibility,	we	observed	an	enrichment	of	cytosine	methylation	at	the	HERVK14C	LTR	
(Figure	26D).	Finally,	consistent	with	the	lack	of	HERVK14C	reactivation	in	these	cells,	
we	also	saw	little	effect	on	the	expression	of	KAP1	targeted	KZNFs	(Figure	26E).	It’s	
possible	 that	 KAP1	 targets	 would	 have	 become	 activated	 over	 time	 or	 that	 the	
cognate	 KZNFs	 and	 /	 or	 an	 activation	 signal	 was	 simply	missing	 in	 these	 cells.	 To	
partly	 address	 this,	 we	 employed	 our	 de	 novo	 reporter	 assay	 in	 these	 cells	 (see	
below).	
	
4.4	 KAP1	 can	 restrict	 incoming	 ERVs	 through	 the	 PBS	 sequence	 in	
PBMCs	
We	 took	 advantage	 of	 our	 HERVK14C	 reporters	 developed	 previously	 and	
transduced	first	PBMCs	with	increasing	doses	of	the	reporters.	Interestingly,	we		
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Figure	26	KAP1	depletion	leads	to	little	or	no	HERVK14C	upregulation	in	CD4+	T	
cells.			
(A) FACS	plots	showing	the	purity	of	CD4+	T	cells	used	in	the	experiments.			
(B) Western	blot	showing	the	KAP1	knockdown	efficiency	in	CD4+	T	cells	at	various	time-points.	
(C) qRT-PCR	expression	of	HERVK14C	following	KAP1	knockdown.	The	inlay	shows	the	mRNA	level	of	
KAP1	post-knockdown.	Results	were	normalised	to	B2M.	
(D) DNA	methylation	analysis	of	a	single	locus	of	endogenous	HERVK14C	LTR	in	CD4+	T	cells.	
(E) qRT-PCR	expression	of	various	KZNF	genes	previously	 identified	(Figure	17C)	 in	KAP1	knockdown	
cells.	Results	were	normalised	to	B2M.		
Two-tailed	unpaired	Student	T-tests	were	done.			
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consistently	 saw	 a	 modest	 GFP	 repression	 of	 the	 PBSChr15-LTR-GFP	 vector	
compared	to	the	control	vector,	LTR-GFP	(Figure	27A,	left).	This	observation	was	not	
due	to	a	difference	in	vector	dose	as	evidenced	by	equivalent	integration	of	the	two	
reporters	(Figure	27A,	right).	In	contrast,	we	saw	no	repression	when	we	performed	
the	same	experiment	 in	CD4+	T	cells	 (Figure	27B).	 Intriguingly,	 the	presence	of	the	
endogenous	 HERVK14C	 regulation	 phenotype	 appeared	 to	mirror	 the	 presence	 of	
the	reporter	repression	phenotype	with	both	being	present	in	PBMCs	but	absent	in	
purified	CD4+	T	cells	(Figure	25	and	26).	This	suggests	that	differences	may	relate	to	
a	difference	in	the	expression	profiles	of	KZNFs.	Indeed,	using	the	publicly	available	
data	 (accession	 number	 for	 the	 data	 -	 macrophages:	 GSE36952;	 CD4+	 T	 cells:	
GSE69549),	we	 found	 that	 despite	 a	 large	 overlap	 in	 the	 KZNFs	 expressed,	 118	 of	
them	are	expressed	in	macrophages	but	not	in	CD4+	T	cells	(Figure	27C).	
	
4.5	Multiple	KZNFs	are	widely	expressed	 in	various	differentiated	cell	
types		
The	 fact	 that	 de	 novo	 reporter	 KAP1	 repression	 and	 endogenous	
retrotransposon	and	ZNF	repression	is	intact	in	PBMCs	suggests	that	a	proportion	of	
KZNFs	must	be	expressed	in	all	the	cell	types	we	have	tested.	We,	therefore	utilised	
publicly	available	mRNA-sequencing	data	 from	293T	cells,	HeLa	cells,	macrophages	
and	CD4+	T	cells.	As	hypothesised,	we	found	many	KZNFs	(77)	to	be	expressed	at	the	
mRNA	level	across	all	data	sets	and	159	KZNFs	detected	in	at	least	2	of	the	cell	types	
tested	(Figure	28A).	Among	the	77	KZNFs,	around	two	thirds	of	them	are	bound	by	
KAP1	(Figure	28A).	For	the	top	100	KZNFs	expressed	in	293T	cells,	we	verified	them	
to	be	expressed	at	the	protein	level	using	the	human	protein	atlas	and	we		
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Figure	27	PBS-mediated	de	novo	repression	of	ERVs	is	conserved	in	primary	cells.			
(A) PBMCs	were	transduced	with	 increasing	doses	of	GFP	reporter	vectors	(vectors	were	titrated	on	
KAP1	KO	293T	cells	prior	to	use	in	primary	cell	experiments)	and	GFP	was	assessed	72	hours	post	
transduction	(left).	The	bar	chart	(right)	shows	vector	integration	measured	by	Taqman	qPCR	with	
GFP	primers.	A	293T	cell	line	with	a	single	vector	copy	integrant	(PGK-GFP)	was	used	as	a	control	
(right).	A	representative	of	3	experiments	is	shown	here.	Data	from	3	experiments	was	pooled	for	
statistics.	
(B) The	same	experiment	as	in	(A)	but	with	CD4+	T	cells.	A	representative	of	2	experiments	is	shown	
here.	Data	from	2	experiments	was	pooled	for	statistics.	
(C) Venn	diagram	showing	the	KZNF	expression	profile	between	macrophages	and	CD4+	T	cells.		
Two-tailed	unpaired	Student	T-tests.					
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Figure	28	ZNFs	are	expressed	widely	at	the	mRNA	level.	
(A) Venn	 diagram	 showing	 the	 unique	 and	 overlapping	 ZNFs	 expressed	 in	multiple	 cell	 types	 (top).	
Venn	 diagram	 showing	 the	 proportion	 of	 conserved	 ZNFs	 that	 are	 KAP1	 bound	 (50	 out	 of	 77)	
(bottom).		
(B) Western	blots	confirming	 the	expression	of	 three	KZNFs	 in	both	undifferentiated	 (NTERA-2)	and	
differentiated	cells	(293Ts	and	HeLa	cells).	
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additionally	 verified	 several	 of	 them	 to	 be	 expressed	 in	 our	 cell	 types	 of	 interest	
using	Western	blot	(Figure	28B).	
Discussion	II	
In	 conclusion,	 our	 data	 show	 that	 KAP1	 is	 required	 to	 maintain	 ERVs	
repressed	and	to	regulate	ZNFs	in	primary	human	cells	(Figure	29,	top).	Hundreds	of	
KZNFs	 are	 widely	 expressed	 in	 various	 differentiated	 cell	 types,	 illustrating	 the	
widespread	 importance	 of	 the	 KAP1-KZNF	 pathway	 in	 regulating	 ERVs.	 However,	
differences	exist	between	cell	 types	 in	sequence-specific	 regulation,	since	we	were	
unable	 to	 detect	 KAP1	 repression	 in	 CD4+	 T	 cells	 (Figure	 29,	 bottom).	 This	 likely	
relates	to	subtle	differences	in	the	repertoire	of	ZNFs	expressed	and	potentially	also	
to	differences	 in	activating	 transcription	 factors.	 It	may	also	be	 the	case	 that	KAP1	
repression	 is	 dynamic	 as	 indicated	 (Figure	 29,	 top)	 and	 in	 activated	 CD4+	 T	 cells,	
transcription	 of	 assessed	 KAP1	 targets	 is	 “ON”	 despite	 detectable	 cytosine	
methylation	consistent	with	previous	observation	(Ecco	et	al.,	2016).	
The	 human	 immune	 system	 is	 an	 interactive	 network,	 the	 cellular	
components	 of	 which	 are	 transcriptionally	 dynamic,	 allowing	 them	 to	 adapt	 to	
infections	 (Parkin	 and	 Cohen,	 2001).	 Such	 plasticity	 suggests	 that	 epigenetic	
regulation	 of	 these	 components	 likely	 involves	 histone	 modifications	 rather	 than	
DNA	methylation.	It	has	previously	been	shown	that	ERVs	play	a	role	in	immune	cells	
(Chuong	et	al.,	2016;	Collins	et	al.,	2015;	Hummel	et	al.,	2017;	Zeng	et	al.,	2014)	as	
well	as	KAP1	(Collins	et	al.,	2015;	Hummel	et	al.,	2017).	From	our	own	PBMC	data,	
KAP1	knockdown	resulted	in	the	upregulation	of	HERVK14C	and	KZNFs.	Interestingly,	
in	contrast	to	cell	 lines,	LIPA4	and	SVA	elements	were	also	upregulated.	This	might	
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Figure	29	Model.	
Like	 in	 differentiated	 cell	 lines,	 KAP1	 is	 required	 to	 repress	 ERVs	 and	 to	 regulate	 ZNFs	 in	 primary	
human	cells,	 a	process	 that	may	be	dynamic.	KAP1	de	novo	 repression	of	 foreign	DNA	 through	 the	
PBS	sequence	is	also	intact	in	PBMCs	suggesting	that	the	components	of	this	pathway	are	expressed	
at	a	sufficient	 level	to	restrict	 incoming	exogenous	retroviruses.	CD4+	T	cells,	 in	contrast,	 lack	lysine	
PBS	repression.	This	may	be	due	to	low	/	absent	expression	of	the	cognate	KZNF(s),	despite	the	fact	
that	we	detect	118	KZNFs	to	be	expressed	in	these	cells.	We	also	did	not	observe	reactivation	of	ERVs	
and	 ZNFs	 in	 KAP1-depleted	 CD4+	 T	 cells.	 This	 may	 be	 due	 to	 knockdown	 efficiency	 or	 redundant	
repression	pathways	or	suggest	that	ERV	and	ZNF	transcription	is	highly	active	at	baseline.		
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reflect	differences	in	DNA	methylation	between	cancer	lines	and	PBMCs	as	it	is	well-
documented	that	the	landscape	of	DNA	methylation	is	disrupted	in	cancer	cells	(Kulis	
and	Esteller,	2010).	The	fact	 that	the	DNA	methylation	 inhibitor	5-Aza	affects	SVAs	
more	 in	 cell	 lines	 than	 in	 PBMCs	 (see	 Chapter	 3)	 indicates	 that	 SVAs	 retain	 DNA	
methylation	in	cell	lines	but	may	not	be	so	in	PBMCs.		
The	 fact	 that	we	 detect	 KAP1-regulation	 in	 PBMCs	 but	 not	 in	 CD4+	 T	 cells	
suggests	 that	 the	 co-culture	 of	 immune	 cells	 is	 important	 for	 the	 upregulation	
phenotype	and	may	influence	the	profile	of	transcriptional	factors	expressed	(Goke	
et	al.,	2015;	Grow	et	al.,	2015;	Lu	et	al.,	2014b)	
Of	 note,	 KAP1-repression	 is	 only	modest	 in	 differentiated	 cells,	 which	may	
relate	to	the	low	expression	levels	of	KZNFs.	Intriguingly,	the	mouse	KZFP,	Zfp809	is	
rapidly	 degraded	 at	 the	 protein	 level	 in	 differentiated	 cells,	 restricting	 its	 potency	
mainly	to	embryonic	cells	 (Lee	and	Bieniasz,	2007;	Wang	and	Goff,	2017).	An	open	
question	that	remains	 is	whether	KZNFs	could	become	induced	in	response	to	viral	
infections,	 interferon	 treatment	 or	 other	 stimuli	 to	 make	 them	 more	 potent	 in	
differentiated	 cells	 thus	 supporting	 their	 potential	 function	 as	 restriction	 factors.	
Overall,	in	this	chapter,	we	have	shown	that:	
i) KZNFs/KAP1	are	involved	in	the	repression	of	ERVs	in	PBMCs	and	in	
the	initiation	of	de	novo	silencing	of	incoming	ERVs	
ii) Many	KZNFs	are	universally	 transcribed	and	 translated	 in	multiple	
cell	types,	suggesting	they	may	function	broadly	to	regulate	ERVs	
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Chapter	5:	Epigenetic	control	of	ERVs	prevents	viral	
mimicry	
5.1	 DNA	 methylation	 and	 histone	 acetylation	 regulate	
retrotransposons	
Recent	 publications	 (Chiappinelli	 et	 al.,	 2015;	 Roulois	 et	 al.,	 2015)	 have	
proposed	a	potential	working	mechanism	for	the	cancer	drug,	5-Aza,	involving	DNA	
demethylation	 of	 ERVs	 and	 innate	 immune	 activation,	 which	 then	 contributes	 to	
cancer	 cell	 death	 along	 with	 adaptive	 anti-tumour	 immunity	 (Figure	 30A).	 These	
publications	 support	 a	 dominant	 role	 for	 DNA	 methylation	 in	 the	 suppression	 of	
retrotransposons	 in	adult	tissues,	 in	 line	with	previous	articles	 (Rowe	et	al.,	2013a;	
Rowe	et	 al.,	 2010;	Walsh	 et	 al.,	 1998).	DNA	methylation	 is	 triggered	by	 the	KZNF-
KAP1	 pathway	 (Rowe	 et	 al.,	 2013a),	 as	 well	 as	 through	 KAP1-independent	
mechanisms	(Leung	et	al.,	2011).	While	it	is	known	that	aberrant	activation	of	ERVs	
can	 induce	 viral	 mimicry	 and	 innate	 immune	 activation	 (Chiappinelli	 et	 al.,	 2015;	
Roulois	et	al.,	2015),	almost	nothing	is	known	about	the	epigenetic	factors	required	
to	 maintain	 repression	 and	 DNA	 methylation	 of	 immune-triggering	 ERVs.	 In	 this	
chapter,	we	asked	if	KAP1	and	related	epigenetic	factors	were	necessary	to	prevent	
viral	mimicry	 in	differentiated	human	cells	 (Figure	30A).	We	 first	assessed	 if	KAP1-
regulated	ERVs	were	DNA	methylated	since	immune-triggering	ERVs	are	known	to	be	
regulated	 through	DNA	methylation	 (Chiappinelli	et	al.,	2015;	Roulois	et	al.,	2015).	
To	 test	 this,	 we	 treated	 HeLa	 cells	 with	 either	 the	 DNMT	 inhibitor,	 5-Aza,	 or	 the	
HDAC	 inhibitor,	 TSA	 for	 comparison	 (Figure	 30B-D).	 Following	 5-Aza	 treatment,	
KAP1-regulated	HERVK14C	and	SVA	D	VNTR	were	upregulated	as	measured	by	qRT-
PCR	(Figure	30C).	SVA	D	VNTR	was	more	potently	affected,	as	expected,	since	these		
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Figure	30	KAP1-regulated	retrotransposons	are	subject	to	DNA	methylation.	
(A) Model	 proposed	 to	 explain	 how	 5-Aza	 treatment	 leads	 to	 induction	 of	 ISGs.	 A	 filled	 lollipop	
represents	a	methylated	CpG	while	an	open	lollipop	represents	an	unmethylated	CpG.	
(B) Model	 illustrating	 the	question	we	are	asking	here	of	whether	KAP1-regulated	 retrotransposons	
are	DNA	methylated	and	sensitive	to	5-Aza.		
(C) Expression	 of	 KAP1-regulated	 retrotransposons	was	measured	 by	 qRT-PCR	 following	 5-Aza	 drug	
treatment	 of	 HeLa	 cells.	 B2M	 was	 used	 as	 the	 normalising	 gene.	 -	 :	 dependency	 on	 DNA	
methylation	 not	 detected;	 +	 :	 dependency	 on	 DNA	 methylation.	 The	 inlay	 shows	 the	 DNA	
methylation	status	of	LIPA4	elements	 in	293T	cells.	 	 ‘x’	denotes	the	missing	CpG	at	the	specified	
location	of	the	LIPA4	promoters.		
(D) The	 same	 experiment	 as	 in	 (C)	 but	 here	 with	 TSA	 as	 the	 drug.	 The	 dependency	 on	 HDACs	 for	
repression	is	scored	below.	-/+:	inconclusive.				
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elements	are	enriched	for	DNA	methylation	(Figure	16E)	(Turelli	et	al.,	2014).	L1PA4	
was	 unaffected,	 in	 contrast,	 perhaps	 reflecting	 its	 low	 DNA	 methylation	 status	
(Figure	 30C,	 see	 inlay).	 TSA	 treatment,	 which	 inhibits	 class	 I	 and	 II	 HDACs,	 also	
induced	upregulation	of	these	retrotransposons,	particularly	HERVK14C	(Figure	30D),	
showing	 that	 KAP1-regulated	 ERVs	 are	 subject	 to	 histone	 deacetylation	 as	well	 as	
DNA	methylation,	as	predicted	from	previous	work	(Ivanov	et	al.,	2007;	Rowe	et	al.,	
2010).	
	
5.2	KAP1	contributes	to	the	prevention	of	an	aberrant	innate	immune	
response	
We	then	asked	 if	KAP1-depletion	would	 lead	 to	aberrant	 immune	activation	as	
well	as	induction	of	retrotransposon	expression.	Indeed,	we	found	that	loss	of	KAP1	
in	HeLa	cells	 led	 to	 the	overexpression	of	HERVK14C	and	SVA	D	VNTR	elements	as	
noted	 previously	 (see	 Chapter	 3)	 and	 was	 sufficient	 to	 trigger	 the	 activation	 of	
several	chemokines,	mainly	CCL5	(Figure	31A).	Results	were	not	reproducible	in	293T	
cells	 and	 PBMCs	 (Figure	 31B	 and	 C),	 however,	 despite	 consistent	 retrotransposon	
induction	 (see	 Figure	 25B	 and	 C	 for	 PBMC	 retrotransposon	 expression	 data),	
suggesting	 that	 KAP1	 depletion	 alone	 is	 not	 sufficient	 for	 global	 induction	 of	
interferon-stimulated	genes	(ISGs).	It	is	likely	that	the	phenotype	is	dependent	on	a	
range	of	factors	including	the	timing,	the	knockdown	efficiency	and	/	or	the	type	and	
magnitude	of	retrotransposons	reactivated.	
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Figure	31	KAP1	depletion	affects	expression	of	ISGs.	
(A) Expression	 was	measured	 by	 qRT-PCR	 of	 KAP1-regulated	 retrotransposons	 (left),	 ISGs	 (middle),	
and	KAP1	(right)	following	KAP1	knockdown	in	HeLa	cells.	Results	were	normalised	to	B2M	and	/	
or	GAPDH.	Two	sets	of	independent	experiments	are	shown	here	(top	and	bottom).		
(B) The	same	as	 in	 (A)	but	here	with	293T	cells.	One	representative	experiment	of	3	experiments	 is	
shown	here.	
(C) PBMCs	 from	 Figure	 3.1B	 and	 C	 were	 assessed	 for	 ISG	 induction	 using	 qRT-PCR.	 Results	 were	
normalised	to	GAPDH.		
Two-tailed	unpaired	Student	T-tests	were	done.		
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5.3	5-Aza	treatment	triggers	an	ISG	response		
We	next	asked	if	5-Aza	treatment	would	lead	to	aberrant	immune	activation	
as	has	been	proposed	 to	be	 the	 case	 in	 cancer	 cell	 lines	 (Chiappinelli	 et	 al.,	 2015;	
Roulois	et	al.,	2015).	We	therefore	treated	HeLa	and	293T	with	5-Aza	 for	96	hours	
and	 checked	 the	 relative	 expression	 levels	 of	 repeats	 and	 ISGs.	 As	 previously	
observed	 (Figure	 30C),	 SVA	 D	 VNTR	 and	 HERVK14C	were	 upregulated	 in	 both	 cell	
types	 (Figure	 32A	 and	 B)	 and	 this	 was	 accompanied	 by	 a	 clear	 induction	 of	 ISGs	
(Figure	32A	and	B).	It	is	unknown	whether	5-Aza	treatment,	which	is	used	in	cancer	
patients	 stimulates	 an	 innate	 immune	 response	 only	 in	 cancer	 cells	 or	
indiscriminately	in	all	dividing	cells.	We	therefore	treated	PBMCs	with	the	drug	and	
surprisingly,	 we	 could	 also	 observe	 ISG	 induction	 that	was	 significant	 albeit	 lower	
(Figure	 32C).	 Importantly,	 this	 was	 accompanied	 by	 an	 overexpression	 of	 KAP1-
regulated	retrotransposons,	suggesting	a	 link	between	KAP1,	DNA	methylation	and	
the	 prevention	 of	 viral	 mimicry	 in	 differentiated	 cells.	 Of	 note,	 however,	 the	
induction	of	viral	mimicry	may	result	from	loss	of	H3K9me3	(that	can	also	be	KAP1-
dependent	(Rowe	et	al.,	2010)),	rather	than	loss	of	DNA	methylation	since	5-Aza	has	
been	reported	to	also	 lead	to	H3K9me3	depletion	(Komashko	and	Farnham,	2010).	
We	 tested	 the	 drug	 TSA	 for	 comparison	 and	 we	 found	 that	 this	 drug	 had	 only	 a	
modest	effect	on	the	expression	of	ISGs	(Figure	32D).	One	difference	was	that	SVA	D	
VNTR	elements	were	not	activated,	suggesting	that	these	retrotransposons	may	be	
one	of	the	elements	that	produce	immuno-stimulatory	nucleic	acids.	
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Figure	32	5-Aza	treatment	leads	to	an	upregulation	of	KAP1-regulated	
retrotransposons	and	robust	ISG	induction	in	cancer	cell	lines	and	primary	cells.		
(A) Expression	 as	 measured	 by	 qRT-PCR	 of	 KAP1-regulated	 retrotransposons	 (left)	 and	 ISGs	 (right)	
following	5-Aza	 treatment	of	HeLa	 cells.	Results	were	normalised	 to	B2M	and	 /	or	GAPDH.	One	
representative	experiment	of	at	least	2	independent	experiments	is	shown	here.		
(B) The	same	experiment	as	in	(A)	but	here	in	293T	cells.	
(C) The	same	experiment	as	in	(A)	but	here	in	PBMCs.	
(D) The	same	experiment	as	in	(A)	but	here	with	TSA	treatment.	
							Two-tailed	unpaired	Student	T-tests	were	done.			
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5.4	 There	 is	 redundancy	 between	 KAP1	 repression	 and	 DNA	
methylation	
We	asked	 if	KAP1	depletion	and	5-Aza	treatment	would	have	an	additive	effect	on	
the	induction	of	retrotransposons	and	ISGs.	To	address	this,	we	knocked	down	KAP1	
and	combined	this	with	5-Aza	drug	treatment	in	both	cell	lines	followed	by	qRT-PCR.	
Knockdown	 efficiencies	 were	 first	 verified	 using	 qRT-PCR	 (Figure	 33A	 and	 B,	 see	
inlays).	As	before,	 the	phenotype	was	striking	with	5-Aza,	whereas	KAP1	depletion	
had	only	 a	modest	 effect	 on	 retrotransposons	 and	 ISGs	 and	 combined	 treatments	
had	 no	 additive	 nor	 synergistic	 effect	 (Figure	 33A	 and	 B).	 This	 suggests	 that	 DNA	
methylation	 is	 the	 major	 gatekeeper	 that	 prevents	 viral	 mimicry	 through	
retrotransposons	and	KAP1	likely	acts	in	the	same	pathway	but	is	largely	redundant	
with	 DNA	methylation.	 For	 comparison,	 we	 performed	 the	 same	 experiments	 but	
with	the	drug	TSA.	KAP1	knockdown	or	TSA	treatment	led	to	modest	upregulation	of	
HERVK14C	 and	 the	 combination	 showed	 only	 a	 marginal	 additive	 effect	 on	
HERVK14C	 expression	 (Figure	 33C	 and	D)	with	 no	 additive	 effect	 on	 ISG	 induction	
(Figure	 33D).	 This	 further	 supports	 the	 idea	 that	 viral	 mimicry	 results	 from	
retrotransposons	that	are	epigenetically	silent	through	DNA	methylation	rather	than	
histone	deacetylation	alone.	
	
5.5	KAP1	is	involved	in	the	maintenance	of	DNA	methylation	at	ERVs	
Here,	 we	 have	 shown	 evidence	 that	 DNA	 methylation	 is	 key	 to	 the	
prevention	of	 viral	mimicry	 (Figure	32	and	33).	KAP1	 is	 linked	 to	DNA	methylation	
because	 de	 novo	 KAP1	 repression	 leads	 to	 de	 novo	 DNA	 methylation	 of	 ERVs	 in	
embryonic	cells	(Rowe	et	al.,	2013a).	We	asked	here	if	KAP1	is	necessary	to	maintain	
DNA	methylation	at	ERVs.	A	 limitation	of	our	KAP1	knockdown	experiments	 is	 that	
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Figure	33	Combining	KAP1	knockdown	with	5-Aza	treatment	did	not	have	an	
additive	effect.		
(A) Expression	 as	 measured	 by	 qRT-PCR	 of	 KAP1-regulated	 retrotransposons	 (left)	 and	 ISGs	 (right)	
following	KAP1	knockdown	and	/or	5-Aza	treatment	of	HeLa	cells.	The	inlay	shows	the	knockdown	
efficiency	 of	 KAP1.	 Results	 were	 normalised	 to	 GAPDH.	 One	 representative	 experiment	 of	 2	 is	
shown	here.		
(B) The	same	experiment	as	in	(A)	but	here	in	293T	cells.	Results	were	normalised	to	B2M	or	GAPDH.	
A	representative	of	2	experiments	is	shown	here.		
(C) and	(D)	The	same	experiment	as	in	(A)	but	here	TSA	treatment	is	used	instead	of	5-Aza	and	ISGs	
were	 only	 measured	 in	 (D).	 Results	 were	 normalised	 to	 B2M	 or	 GAPDH.	 One	 representative	
experiment	of	3	experiments	(C)	or	2	experiments	(D)	is	shown.		
Two-tailed	unpaired	Student	T-tests	were	done.			
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KAP1	may	still	be	expressed	at	sufficient	levels	to	maintain	DNA	methylation	at	ERVs.	
We	 therefore	 employed	 our	 KAP1	 knockout	 HeLa	 cell	 clones	 to	 assess	 DNA	
methylation	at	endogenous	HERVK14C.	Indeed,	we	found	that	DNA	methylation	was	
reduced	at	HERVK14C	in	knockout	compared	to	wild	type	cells	(Figure	34).	
	
5.6	The	role	of	epigenetic	regulators	that	KAP1	collaborates	with	in	the	
prevention	of	viral	mimicry	
In	addition	to	KAP1,	we	also	explored	the	role	of	other	epigenetic	modifiers	
in	protecting	cells	 from	aberrant	 innate	 immune	activation.	We	 focused	on	 factors	
that	KAP1	collaborates	with,	namely	the	histone	methyltransferase	SETDB1	and	the	
recently	discovered	HUSH	complex	(Tchasovnikarova	et	al.,	2015).	SETDB1	mediates	
H3K9me3	and	partners	with	KAP1	to	maintain	H3K9me3	at	retrotransposons	(Matsui	
et	 al.,	 2010;	 Rowe	 et	 al.,	 2013b).	 The	 HUSH	 complex	 is	 composed	 of	 three	
components:	 TASOR,	 encoded	 by	 FAM208A,	 MPP8,	 encoded	 by	MPHOSPH8	 and	
periphilin	 encoded	 by	 PPHLN1,	 and	 interacts	 with	 SETDB1	 and	 MORC2	
(Tchasovnikarova	 et	 al.,	 2017).	 The	 HUSH	 complex	 is	 implicated	 in	 H3K9me3	
spreading	 (Tchasovnikarova	 et	 al.,	 2017;	 Tchasovnikarova	 et	 al.,	 2015)	 and	 our	
unpublished	work	shows	that	it	collaborates	with	KAP1	to	repress	retrotransposons	
including	 HERVK14C	 in	 embryonic	 cells	 (Figure	 35A	 and	 B).	 Interestingly,	 in	
embryonic	 NTERA-2	 cells,	 HERVK14C	 repression	 appears	 to	 be	 dependent	 on	
SETDB1,	 TASOR	 and	 periphilin	 but	 not	 on	MPP8	 (Figure	 35B).	 However,	 we	 have	
been	able	to	document	a	requirement	for	MPP8	in	repression	of	LINE1	elements	in	
both	 human	 and	 mouse	 embryonic	 cells	 (unpublished)	 so	 all	 three	 HUSH	
components	are	implicated	in	retrotransposon	repression.	We	therefore	depleted	all		
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Figure	34	KAP1	is	required	to	maintain	DNA	methylation	at	HERVK14C.	
KAP1	knockout	 leads	 to	a	 reduction	 in	DNA	methylation	at	 the	HERVK14C	LTR	on	Chromosome	15.	
The	box	plots	show	the	quantification	of	DNA	methylation	over	all	sequences	and	they	represent	the	
minimum	 value,	 first	 quartile	 value,	 median,	 third	 quartile	 value	 and	 maximum	 value	 form	 the	
bottom	whisker	to	the	top	whisker	respectively.		Two-tailed	unpaired	Student	T-tests	were	done.			
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Figure	35	Multiple	epigenetic	modifiers	are	involved	in	repressing	ERVs.		
(A) Working	model	of	KAP1	repression	made	from	unpublished	work,	which	shows	that	KAP1	partners	
up	with	 the	 HUSH	 complex	 as	 well	 as	 with	 SETDB1	 to	maintain	 heterochromatin	 repression	 of	
retrotransposons,	including	HERVK14C.		
(B) Expression	 of	 HERVK14C	 as	 measured	 by	 qRT-PCR	 following	 SETDB1	 and	 HUSH	 component	
knockdown	in	NTERA-2	cells.	Results	were	normalised	to	TFRC	or	B2M.		
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the	above	components	 in	293T	cells	and	measured	expression	of	 retrotransposons	
and	ISGs.	In	the	case	of	KAP1,	we	used	two	hairpins,	one	targeting	the	UTR	(labelled	
UTR)	and	one	targeting	the	CDS	(labelled	shKAP1)	(Figure	36A	and	B).	
Results	(Figure	36A-E)	showed	that	KAP1	and	to	a	lesser	extent	SETDB1	and	
periphilin	 depletions	 led	 to	 a	 significant	 overexpression	 of	 retrotransposons.	
Likewise,	 KAP1	also	 led	 to	 a	 small	 but	 significant	 induction	of	 ISGs	 and	 to	 a	 lesser	
extent	periphilin	and	TASOR.	Of	 interest,	CCL5	was	upregulated	in	both	TASOR	and	
periphilin	 knockdowns	 (Figure	 36D	 and	 E).	 MPP8	 depletion,	 in	 contrast,	 led	 to	 a	
dramatic	 induction	 of	 ISGs	 and	 this	 was	 interestingly	 accompanied	 by	 a	 parallel	
significant	 downregulation	 of	 retrotransposon	 expression	 (Figure	 36F).	 This	
phenotype	 of	 ISG	 induction	 and	 retrotransposon	 downregulation	 following	 MPP8	
depletion	 was	 confirmed	 in	 at	 least	 two	 other	 independent	 experiments.	 These	
results	 suggest	 that	 MPP8	 plays	 a	 unique	 and	 integral	 role	 in	 preventing	 viral	
mimicry	or	that	the	striking	phenotype	observed	with	MPP8	depletion	relates	to	the	
knockdown	efficiency,	which	is	around	tenfold	greater	than	the	others.	The	fact	that	
retrotransposons	 are	 downregulated	 may	 reflect	 a	 global	 anti-viral	 state	 in	 these	
cells	 following	 massive	 ISG	 induction.	 Alternatively,	 retrotransposons	 may	 not	 be	
directly	 responsible	 for	 ISG	 induction	here,	 as	we	do	not	 know	 the	 identity	 of	 the	
PAMP.		
	
5.7	MPP8	protects	cells	from	aberrant	ISG	activation	
We	 next	 assessed	 if	 the	 magnitude	 of	 the	 MPP8	 phenotype	 related	 to	 the	
knockdown	 efficiency.	 We	 therefore	 transduced	 cells	 with	 different	 doses	 of	
knockdown	 vector.	 We	 confirmed	 the	 knockdown	 efficiency	 via	 qRT-PCR	 and	
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Figure	36	MPP8	prevents	viral	mimicry	and	innate	immune	activation.	
(A	 –	 F)	 Expression	 as	 measured	 by	 qRT-PCR	 of	 KAP1-regulated	 retrotransposons	 (left),	 the	 stated	
mRNAs	 depleted	 (middle)	 as	 well	 as	 ISGs	 (right)	 following	 knockdown	 of	 stated	 epigenetic	
modifiers.	Results	were	normalised	to	GAPDH	or	B2M.	One	representative	experiment	of	at	least	
2	independent	experiments	is	shown	here.	Two-tailed	unpaired	Student	T-tests	were	done.				
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Figure	37	MPP8	depletion	leads	to	a	striking	induction	of	ISGs	while	KAP1-
regulated	retrotransposons	are	downregulated.	
(A) Western	blot	and	qRT-PCR	showing	MPP8	knockdown	efficiency.	Results	were	normalised	to	B2M.	
(B) Expression	 of	 ISGs	 as	 measured	 by	 qRT-PCR	 following	 MPP8	 depletion.	 5-Aza	 was	 used	 as	 a	
positive	 control.	 Results	 were	 normalised	 to	 GAPDH.	 One	 representative	 experiment	 of	 2	
experiments	is	shown	here.		
(C) Expression	of	KAP1-regulated	retrotransposons	as	measured	by	qRT-PCR.	Results	were	normalised	
to	B2M.		
Two-tailed	unpaired	Student	T-tests	were	done.		
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Western	 blot	 (Figure	 37A).	 MPP8	 depletion	 was	 extremely	 robust	 at	 both	 vector	
dilutions	 and	 we	 measured	 it	 to	 be	 50	 fold	 and	 100	 fold	 at	 the	 500ul	 and	 1ml	
amounts	of	knockdown	vector,	respectively	 (Figure	37A).	As	before	(Figure	36),	we	
observed	 a	 striking	 upregulation	 of	 ISGs	 upon	 MPP8	 knockdown	 along	 with	 a	
downregulation	of	retrotransposons	(Figure	37B	and	C).	Importantly,	the	phenotype	
of	 ISG	 induction	 did	 relate	 to	 the	 knockdown	 efficiency	 because	 the	 higher	MPP8	
depletion	correlated	with	more	pronounced	ISG	upregulation	(Figure	37B).	We	next	
used	a	luciferase	based	reporter	that	is	driven	by	an	IFN-B	promoter	to	reinforce	our	
findings.	We,	therefore	transfected	the	knockdown	cells	that	were	depleted	for	the	
stated	 epigenetic	 modifiers	 with	 increasing	 doses	 of	 the	 luciferase	 reporter	 and	
measured	luciferase	2	days	later.	We	found	that	the	reporter	was	only	activated	in	
the	MPP8	knockdown	cells	(Figure	38A)	and	in	cells	loaded	with	Sendai	virus,	which	
was	used	as	a	positive	control	(Figure	38B).	The	fact	that	there	was	no	effect	on	the	
reporter	in	KAP1-depleted	cells	despite	there	being	modest	activation	of	some	ISGs	
in	 these	 cells	 as	 detected	 by	 qRT-PCR	 (Figure	 36)	 may	 relate	 to	 the	 different	
sensitivities	 of	 the	 assays	 and	 /	 or	 differences	 in	 genes	 measured.	 These	 data	
support	 an	 integral	 role	 for	MPP8	 in	 preventing	 an	 innate	 immune	 response	 and	
show	 that	 the	 magnitude	 of	 the	 response	 is	 tightly	 linked	 to	 the	 knockdown	
efficiency.	
	
5.8	 MPP8	 depletion	 activates	 classical	 type	 I	 IFN	 signalling	 involving	
IRF3	and	JAK-STAT	
To	reinforce	the	link	between	MPP8	and	the	protection	from	immune	reactivity,	
we	sought	to	demonstrate	that	MPP8	knockdown	activates	classical	type	I	IFN		
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Figure	38	MPP8	depletion	leads	to	activation	of	an	IFNβ	reporter.	(A) 293T	 cells	 transduced	 with	 different	 knockdown	 vectors	 were	 transfected	 with	 increasing	
amounts	 of	 a	 luciferase-expressing	 plasmid	 driven	 by	 an	 IFNβ	 promoter.	 The	 luciferase	 signal	
(RLU)	was	normalised	to	the	renilla	signal.		(B) Wild	 type	 293T	 cells	 were	 transfected	 with	 10ng	 of	 the	 reporter	 plasmid	 used	 in	 (A)	 in	 the	
presence	 of	 increasing	 doses	 of	 Sendai	 virus.	 The	 luciferase	 signal	 (RLU)	was	 normalised	 to	 the	
renilla	signal.		
Two-tailed	unpaired	Student	T-tests	were	done.		
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Figure	39	MPP8	depletion	leads	to	activation	of	IRF3	and	JAK-STAT	dependent	
reporters.		
The	 same	experiment	 as	 in	 Figure	4.8	but	here	 various	 luciferase	 reporters	were	used	as	 stated.	A	
map	of	each	reporter	is	shown	at	the	top	of	the	graphs.	The	PCNA	control	does	not	encode	luciferase	
and	serves	as	a	control	for	background	fluorescence.	Two-tailed	unpaired	Student	T-tests	were	done.				
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signalling.	We	therefore	transfected	MPP8-depleted	cells	with	a	panel	of	 luciferase	
plasmids	 driven	 by	 various	 promoters.	 We	 observed	 significant	 and	 consistent	
activation	of	IFN-B,	ISG56	and	ISRE	promoters	while	the	IgK	and	synthetic	promoters	
were	 less	 affected	 because	 with	 the	 latter	 two	 promoters,	 a	 difference	 between	
MPP8	knockdown	and	control	cells	was	only	observed	at	one	dose	of	plasmid	(Figure	
39).	According	to	the	transcription	factor	binding	sites	of	these	reporters	(Figure	39),	
these	 results	 indicate	 that	 IRF3	 and	 JAK-STAT	 signalling	 are	 active	 in	 MPP8-
knockdown	cells,	both	of	which	are	upstream	of	ISG	induction.	
	
Discussion	III	
Overall,	our	data	suggest	an	active	role	of	epigenetic	modifiers	in	protecting	
cells	from	an	unwanted	immune	response	through	sensing	of	endogenously-derived	
PAMPs	and	activation	of	type	I	IFN	signalling	(Figure	40).	We	provide	evidence	here	
to	 show	 that	 MPP8	 is	 an	 integral	 gatekeeper	 preventing	 immune	 reactivity,	
presumably	 due	 to	 its	 function	 in	 heterochromatin	 spreading	 at	 retrotransposons.	
KAP1	 plays	 a	 more	 minor	 role	 in	 this	 immune	 protection	 perhaps	 reflecting	 the	
redundancy	 of	 epigenetic	 pathways	 (Figure	 40)	 or	 simply	 the	 lower	 knockdown	
efficiency	of	KAP1	compared	 to	MPP8.	Our	experiments	with	 the	5-Aza	drug	show	
that	DNA	methylation	is	crucial	to	prevent	an	innate	immune	response	and	we	have	
shown	 that	 KAP1	 is	 involved	 in	 the	 maintenance	 of	 this	 mark	 at	 least	 at	 some	
retrotransposons.	This	is	an	emerging	field	with	many	questions	unanswered.	Future	
work	will	focus	on	key	questions	such	as	what	are	the	precise	retrotransposons	that	
can	mimic	viruses	once	active,	whether	they	can	simulate	RNA	or	DNA	sensing	or		
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Figure	40	Epigenetic	regulators	protect	cells	from	an	unwanted	innate	immune	
response.	
DNA	methylation	and	potentially	 also	H3K9me3	play	 a	 crucial	 role	 in	protecting	differentiated	 cells	
from	innate	immune	activation	elicited	through	viral	mimicry.	Here,	we	have	identified	MPP8	and	to	a	
lesser	extent	KAP1	as	gatekeepers	preventing	 immune	reactivity.	We	also	show	that	KAP1,	SETDB1,	
the	 HUSH	 complex	 and	 DNA	 methylation	 act	 on	 some	 of	 the	 same	 retrotransposon	 sequences	
including	on	HERVK14C.	ERVs	may	serve	as	PAMPs	through	their	potential	bidirectional	transcription	
and	 production	 of	 double-stranded	 RNA	 and	 /	 or	 their	 cDNA	 synthesis	 through	 potential	 reverse	
transcription.	 Such	PAMPs	 are	well-known	 to	 trigger	 RNA	and	DNA	 sensors.	 Therefore,	 this	 nucleic	
acid	 sensing	mimics	 a	 viral	 infection,	 which	 can	 trigger	 an	 innate	 and	 potentially	 also	 an	 adaptive	
immune	 response.	 We	 have	 detected	 the	 initial	 events	 of	 this	 response	 when	 we	 deplete	 MPP8,	
which	involves	classical	type	I	IFN	signalling.		
	 167	
both	and	whether	MPP8	prevents	viral	mimicry	through	the	maintenance	of	histone	
or	DNA	methylation	or	both?	Finally,	it	is	not	clear	if	retrotransposon	PAMPs	play	a	
role	 in	 the	 normal	 functioning	 of	 the	 immune	 system	 through	 beneficial	 innate	
immune	activation	in	certain	contexts.	
Importantly,	 our	 data	 indicate	 that	 5-Aza	 is	 not	 specific	 to	 cancer	 cells	
because	 it	 affects	 retrotransposons	 and	 ISGs	 in	 both	 cancer	 cell	 lines	 and	 primary	
PBMCs.	Interestingly,	it	has	previously	been	reported	that	the	drug	can	also	be	used	
to	 induce	 regulatory	 T	 cells	 to	 inhibit	 autoimmune	 encephalomyelitis	 (Chan	 et	 al.,	
2014).	Although	we	observed	both	SVA	D	and	HERVK14C	to	be	upregulated	following	
5-Aza	treatment,	it	is	unclear	if	either	serve	as	PAMPs	in	the	ISG	response.	Previous	
studies	 suggest	 that	 dsRNA	 from	 ERVs	 is	 central	 to	 ISG	 induction	 but	 the	 authors	
failed	 to	 directly	 show	 this	 relationship	 and	 it	 is	 possible	 that	 the	 upregulation	 of	
ERVs	 simply	 reflects	 the	 consequence	 of	 an	 inflammatory	 response	 in	 cancer	 cells	
(Chiappinelli	et	al.,	2015;	Roulois	et	al.,	2015).		
During	 viral	 infection,	 characteristic	 viral	 dsRNAs	 or	 5ʹ-triphosphate-ssRNAs	
(Jensen	 and	 Thomsen,	 2012)	 act	 as	 PAMPs	 for	 RNA	 sensors.	 ERV	 transcripts,	 in	
contrast	are	transcribed	and	modified	like	cellular	mRNAs.	However,	TEs	can	still	give	
rise	 to	 dsRNA	 through	 different	 mechanisms.	 Firstly,	 some	 TEs	 have	 bidirectional	
promoters	 and	 can	 therefore	 produce	 dsRNAs	 (Sokol	 et	 al.,	 2015;	 Uesaka	 et	 al.,	
2014)	 as	 proposed	 (Chiappinelli	 et	 al.,	 2015;	 Roulois	 et	 al.,	 2015).	 Secondly,	 stem-	
loop	 structures	 within	 the	 RNA	 transcripts	 (potentially	 from	 SVAs)	 have	 been	
demonstrated	to	induce	innate	immune	responses	(Pichlmair	et	al.,	2009;	Sharma	et	
al.,	2011).	The	RNA	editing	protein,	ADAR1,	mediates	the	adenosine-to-inosine	(A-to-
I)	 editing	 of	 RNA	 transcripts	 and	 prevents	 the	 formation	 of	 stem	 loop	 structures	
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within	 endogenous	 transcripts	 in	 healthy	 cells	 (Aktas	 et	 al.,	 2017;	 Liddicoat	 et	 al.,	
2015).	 During	 DNA	 demethylation,	 an	 increase	 in	 ERV	 transcripts	 may	 potentially	
overwhelm	 the	 activity	 of	 ADAR1	 leading	 to	 an	 accumulation	 of	 dsRNA	 and	
activation	of	RNA	sensors.		
The	 HDAC	 inhibitor,	 TSA,	 or	 KAP1	 knockdown	 could	 not	 phenocopy	 the	
effects	 of	 5-Aza	 and	 this	 may	 be	 because	 KAP1	 knockout	 only	 significantly	
upregulates	 three	 families	 of	 ERVs,	 while	 5-Aza	 treatment,	 affects	 more	 ERVs	
(Chiappinelli	 et	 al.,	 2015;	 Roulois	 et	 al.,	 2015),	 including	 SVAs.	 Similarly,	 TSA	
treatment	 might	 be	 insufficient	 in	 resurrecting	 most	 TEs	 due	 to	 the	 presence	 of	
repressive	histone	marks	and	DNA	methylation	as	previously	reported	(Lynch	et	al.,	
2002;	Svensson	et	al.,	1998).		
The	 lack	 of	 a	 synergistic	 or	 addictive	 effect	 of	 KAP1	 knockdown	 and	 drug	
treatment	 suggests	 that	 KAP1	 exerts	 partial	 redundancy	 with	 other	 epigenetic	
pathways	and	that	the	level	of	redundancy	at	individual	ERV	integrants	may	relate	to	
multiple	parameters	 including	 their	evolutionary	age,	 local	 chromatin	environment	
and	nuclear	position	(Barklis	et	al.,	1986;	Jacobs	et	al.,	2014;	Reddy	et	al.,	2008).		
MPP8	 is	 central	 to	 immune	 reactivity	 because	 its	 depletion	 does	
phenocopied	 5-Aza	 treated	 cells	 and	 this	 is	 in	 line	 with	 the	 notion	 that	 many	
epigenetic	 regulators	 exert	 cross-talk	with	DNA	methylation	 including	 SETDB1	 and	
MPP8	(Chang	et	al.,	2011;	Karimi	et	al.,	2011;	Lee	and	Bieniasz,	2007).	Overall	in	this	
chapter,	we	have	shown	that:	
i) Inhibiting	 DNMTs	 activates	 HERVK14C	 and	 SVA	 D	 elements	 while	
inhibiting	HDACs	activates	HERVK14C	and	LIPA4	
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ii) KAP1	knockdown	can	induce	several	chemokines	but	5-Aza	induces	global	
ISGs	in	cancer	cells	and	primary	cells,	potentially	through	SVAs	
iii) MPP8	 knockdown	 phenocopies	 5-Aza	 in	 ISG	 induction	 that	 proceeds	
through	a	classical	IRF3	and	JAK/STAT-dependent	pathway	
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Chapter	6:	Epilogue	and	future	directions	
My	 thesis	 has	 covered	 research	 into	 the	 role	of	 KAP1	 in	 regulating	 ERVs	 in	
differentiated	 cells,	 challenging	 the	 notion	 that	 the	 KZNF/KAP1	 pathway	 is	
redundant	in	regulating	ERVs	beyond	development.	I	will	discuss	my	data	in	light	of	
recent	 publications	 and	 speculate	 on	 the	 potential	 future	 developments	 of	 the	
project	and	field.		
6.1	Significance	of	this	thesis		
My	 first	 aim	 (Chapters	 3	 and	 4)	 was	 to	 investigate	 the	 ability	 of	 KAP1	 to	
initiate	and	maintain	ERV	repression	in	differentiated	cells.	Most	existing	work	in	this	
field	has	been	done	in	ES	cells	(Jacobs	et	al.,	2014;	Rowe	et	al.,	2010;	Turelli	et	al.,	
2014),	 whereas	 our	 data	 and	 parallel	 advancements	 in	 the	 field	 have	 all	
demonstrated	 a	 continuous	 role	 of	 KZNFs	 and	 KAP1	 in	 the	 regulation	 of	 ERVs	 in	
diverse	 cell	 types	 (Brattas	 et	 al.,	 2017;	 Collins	 et	 al.,	 2015;	 Ecco	 et	 al.,	 2016).	 In	
support	of	a	broad	role	for	KAP1	in	ERV	regulation	in	adult	tissues,	we	found	KZNFs	
to	be	widely	expressed,	albeit	at	low	levels.	We	have	demonstrated	here	that	these	
low	 levels	 are	 sufficient	 to	 induce	 de	 novo	 ERV	 repression	 both	 in	 cell	 lines	 and	
primary	cells.	KZNFs	may	be	only	lowly	expressed	due	to	lower	activity	of	their	target	
ERVs	 in	 somatic	 tissues.	 Alternatively,	 this	 observation	 might	 tie	 together	 with	 a	
recent	 report	 showing	 that	 ZFP809	 (and	 potentially	 other	 KZNFs)	 are	 subject	 to	
protein	degradation	in	differentiated	cells	(Wang	and	Goff,	2017).	I	hypothesise	that	
KZNFs	 may	 function	 as	 restriction	 factors	 inhibiting	 endogenous	 as	 well	 as	
exogenous	 retroviruses	and	 their	 expression	might	be	 induced	 in	adult	 tissues,	 for	
example	upon	viral	infection.	
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I	 anticipate	 more	 studies	 revealing	 the	 connection	 between	 ERVs	 and	
transcriptional	 regulation,	 particularly	 in	 the	 context	 of	 cancer,	will	 be	 revealed	 in	
the	 coming	 years.	 With	 improvements	 in	 techniques	 used	 to	 study	 chromatin	
structure,	 more	 information	 will	 be	 uncovered	 on	 the	 role	 of	 ERVs	 in	 nuclear	
organisation	 too.	Considering	 that	ERV	protein	products	 can	be	expressed	 in	 adult	
tissues,	 I	 anticipate	 that	 another	 new	 area	 of	 research	 will	 involve	 mapping	 ERV	
interactomes.	
In	Chapter	5,	I	explored	the	link	between	ERVs	and	immune	sensing.	I	showed	
that	 epigenetic	 factors,	 particularly	 MPP8,	 can	 protect	 the	 host	 from	 aberrant	
immune	 activation.	 Consistent	with	 recent	 publications	 showing	 the	 ability	 of	 ERV	
transcripts	to	stimulate	 innate	 immune	responses	(Chiappinelli	et	al.,	2015;	Roulois	
et	al.,	2015;	Zeng	et	al.,	2014),	my	data	point	to	a	possible	role	of	KAP1	and	MPP8	
epigenetic	 pathways	 in	 protecting	 immune	 integrity.	 These	 findings	 may	 lay	 the	
groundwork	 for	 further	 investigations	 on	 the	 interplay	 between	 epigenetics	 and	
innate	immunity.	ERVs	likely	play	a	broad	role	in	the	efficacy	of	cancer	drugs	through	
innate	signalling	(Chiappinelli	et	al.,	2015;	Goel	et	al.,	2017;	Roulois	et	al.,	2015)	and	
a	better	understanding	of	the	mechanisms	at	play	will	be	pivotal	to	the	discovery	of	
new	drug	targets	for	cancer	treatments.	
	
6.2	Future	directions		
Following	my	work,	the	next	steps	will	be	to	explore	the	epigenetic	changes	
at	 KAP1-regulated	 ERVs	 following	 KAP1-depletion	 in	 differentiated	 cells.	 Do	 these	
loci	lose	repressive	histone	marks	or	DNA	methylation	or	both	and	gain	active	marks	
prior	to	their	reactivation?	I	think	it	would	also	be	interesting	to	test	the	hypothesis	
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that	KZNFs	function	as	restriction	factors	and	dissect	their	potential	role	during	viral	
infections.	In	addition,	I	would	further	investigate	the	mechanism	responsible	for	the	
ISG	response	observed	in	Chapter	5.	The	primary	questions	that	remain	here	are:	
	
i) What	 is	 the	 PAMP	 in	 5-Aza	 treated,	 KAP1-depleted	 and	MPP8-depleted	
cells?	One	potential	candidate	is	SVA	elements	because	of	the	secondary	
structure	of	their	RNA.		
ii) What	 is	 the	 type	of	PAMP	e.g.	 dsRNA,	or	 cytoplasmic	DNA	or	both	and	
which	PRRs	are	involved?		
iii) Does	MPP8	depletion	induce	an	antiviral	state	that	is	sufficient	to	restrict	
infections	from	exogenous	viruses?	
		
Understanding	the	link	between	the	immune	system	and	ERVs	is	particularly	
relevant	 to	 cancer	 therapy	where	 patients	 are	 under	 5-Aza-based	 treatments	 and	
can	add	an	extra	piece	to	the	puzzle	of	ERV	expression	in	patients	with	autoimmune	
diseases.	
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Appendix	A		 	
Epigenetic control of retrotransposons in adult tissues:
implications for immune regulation
Christopher HC Tie and Helen M Rowe
Retrotransposons tune immune reactivity in differentiated cells
because when they are transcribed, their nucleic acids can be
viewed as non-self leading to innate immune sensing. Most
retrotransposons, however, are subject to transcriptional
regulation by a multitude of epigenetic pathways, which have
coevolved with them for millions of years. While a lot is known
about the epigenetic control of retrotransposons in germ cells
and early embryos, surprisingly little is understood about these
pathways in adult tissues, particularly in human cells. Recent
evidence suggests that retrotransposon repression persists in
differentiated cells and is dynamic. Future insight into this topic
may teach us how to reactivate or silence specific
retrotransposon families, to promote anti-tumor immunity or
dampen autoimmunity through epigenetic modulation.
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Introduction
Transposable elements (TEs) are mobile genetic ele-
ments aptly named ‘controlling elements’ by Barbara
McClintock in the 1950s because of their ability to control
cellular genes [1]. Since their discovery, the advancement
of genome sequencing and bioinformatics technologies
has led to the identification of a huge number of TE
families, the functions of which are now being unraveled.
Retrotransposons are particularly relevant TEs because
they can replicate through an RNA intermediate, allow-
ing them to insert new DNA copies of themselves into the
genome. This has enabled them to accumulate over
millions of years and they now comprise more than half
of the human genome [2]. Over time, deleterious inser-
tions are negatively selected while those beneficial to the
host become co-opted and fixed in the genome [3]. Co-
opted retrotransposons are often from the endogenous
retrovirus (ERV) class, which dates back hundreds of
millions of years [4]. Although retrotransposons can be
beneficial as a driving force behind the evolution of new
genes and non-coding DNA [5,6], they can also compro-
mise genome and transcriptome integrity [7]. A multitude
of epigenetic pathways, therefore, act in early develop-
ment to constrain their transcription and some of these
strategies remain active in differentiated cells.
Epigenetics refers to modifications on chromatin, rather
than DNA sequence alterations, which lead to heritable
effects on gene expression. Chromatin is subject to histone
modifications and cytosine methylation and distinct epi-
genetic marks are associated with an active and silent gene
expression state. For example, acetylation of histone 3 at
the lysine residue at position 27 (H3K27ac) is a chromatin
signature associated with active genes and enhancers [8],
whereas trimethylation of histone 3 at the lysine at posi-
tion 9 (H3K9me3) correlates with heterochromatin and
gene silencing [9–11]. Retrotransposons direct both ge-
netic and epigenetic heritable traits because they can
integrate into our genome in the germ line and orchestrate
epigenetic alterations through the recruitment of tran-
scription factors to their regulatory elements [12].
Since half of the human genome is derived from retro-
transposons, it can be viewed as ‘non-self’ because of its
viral origin. Although most human retrotransposons are no
longer mobile, expression of their nucleic acids and
proteins can lead to the formation of pathogen-associated
molecular patterns (PAMPs) and antigens that we refer to
here as ‘neo-antigens’ that could potentially elicit an
immunological response. Retrotransposons, are therefore
situated at the interface of immune reactivity; when
enriched in silent chromatin they are transcriptionally
inactive and immune masked, whereas when expressed
they may trigger innate and adaptive immunity
[13!!,14!!,15]. In this review, we will discuss the mecha-
nisms in place to maintain retrotransposons silent in
differentiated cells and the implications of these path-
ways. We will focus here on chromatin readers, writers
and erasers and the KAP1 and KRAB-ZNF system. The
role of small RNAs, while important, is beyond the scope
of this review and we direct the reader to a recent review
covering this topic [16].
Epigenetic pathways constraining
retrotransposons
Epigenetic silencing of retrotransposons takes place in
early embryos and in differentiated tissues, epigenetic
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states link back to patterns established during develop-
ment [17!]. The identification of factors that maintain
repression in postembryonic tissues and how dynamic
chromatin marks are in differentiated cell types is a
fascinating and emerging area of research. Moreover,
existing work relies largely on mouse models so it will
be crucial to establish parallels in human cells, where the
precise retrotransposons, their activity and their coevolu-
tion patterns with genes are distinct [18].
Chromatin readers, writers and erasers
Chromatin-associated proteins induce epigenetic changes
to either histones or DNA and mediate downstream
biological functions. Promoter cytosine methylation
occurs at ERVs and is associated with gene repression
[19,20], whereas intragenic methylation prevents spurious
transcription initiation [21]. Interestingly, human ERV-K
(HERV-K) genomic sequences have undergone selection
to mutate CpG dinucleotides, presumably to escape
repression through DNA methylation [22]. De novo meth-
ylation is carried out by DNMT3A, DNMT3B, the newly
discovered rodent-specific DNMT3C, and the cofactor
DNMT3L [23!,24–26] and maintained by DNMT1
through cell divisions [27,28]. Defective DNMT1 leads
to DNA hypomethylation and ERV overexpression and
plays a causative role in the onset of cancer and autoim-
mune disease [29,30]. Interestingly, the reactivation of
ERVs observed following treatment of cells with DNA-
demethylating agents, such as 5-azacytidine (5-AZA) [31]
has been proposed to be responsible for driving anti-
tumor immunity in cancer patients treated with these
drugs through innate sensing of ERV nucleic acids
[13!!,14!!]. 5-AZA drugs are thought to target mainly
DNMT3A and DNMT3B, which can be increased in
expression upon differentiation [32], in contrast to
DNMT3L, which is not expressed in differentiated cells
[33].
Histone methyltransferases (HMTs) including SETDB1
(also known as ESET), SUV39h and G9a (also known as
EHMT2) mediate retrotransposon repression through
histone methylation [9,10,34]. The most relevant to this
review is SETDB1 because it is required for retrotran-
sposon repression in postembryonic tissues [35!!,36].
Indeed, the finding that SETDB1 represses ERVs in
committed mouse B-lineage cells, has led to a new para-
digm that SETDB1 and potentially other histone modi-
fiers remain important in differentiated cells [35!!].
Interestingly, loss of silent chromatin at SETDB1-regu-
lated ERVs is not sufficient for their activation and the
precise panel of ERVs reactivated in specific cell types
depends on the transcription factors available [35!!]. HP1
too, which interacts with H3K9me3 [37,38] and partici-
pates in heterochromatin spreading [39] has been impli-
cated in silencing of ERVs including in differentiated
cells [40,41].
The KAP1 and KRAB-ZNF repertoire
The KAP1 and KRAB-ZNF (KRAB-zinc finger protein)
system silences retrotransposons in early embryos and
embryonic stem cells (ESCs) [12,42,43]. It has likely
evolved in response to retrotransposon  invasions [44]
because KRAB-ZNF transcription factors are largely
specific for transposon sequences [45–47] but now this
pathway also participates in gene regulation [45,48!,49].
KAP1 is recruited to transposons through the interaction
of its RING, B-box and coiled-coil (RBCC) domain with
the KRAB domain of KRAB-ZNFs. Transcriptional
repression is mediated through co-factors such as
SETDB1 [50–52], which prevents binding of transcrip-
tional activators [53,54]. There are several hundred
KRAB-ZNFs [55], which can be viewed as a panel of
effector proteins specific for foreign DNA in the same
way that an antibody repertoire is specific for foreign
antigens. While many KRAB-ZNFs have recently been
matched to their target sequences through chromatin
immunoprecipitation experiments [45–47], only a few
have been functionally characterized. These include
human ZNF91 and ZNF93, which recognize specific
SVA and LINE1 subfamily sequences, respectively
[56!]. The KAP1 and KRAB-ZNF pathway is functional
in human and mouse ESCs and neural progenitor cells
[42,57–59] but little is known about its role in differen-
tiated cells. However, one study showed that KAP1
binds to certain ERV-K elements in human primary
CD4+ T cells [59]. It was also reported that KAP1
and KRAB-ZFPs bind to several ERVs in mouse liver.
Interestingly, while KAP1 knockout in the liver had
little impact on the expression of these ERVs, several
co-regulated cellular genes were affected [48!]. This
suggests that redundant mechanisms may converge to
silence ERVs in differentiated cells [48!]. Surprisingly,
HSP90 has recently been implicated in the formation of
a KAP1 repressor complex at ERVs [60!]. Like KAP1,
HSP90 is necessary to maintain silent chromatin at
ERVs and prevent aberrant transcription of genes close
to the ERVs that it regulates [49,60!]. Most interesting-
ly, this is true not only in ESCs but also in differentiated
macrophages [60!]. The nucleosomal and remodeling
deacetylase (NuRD) complex, which interacts with
KAP1 has also been implicated in retrotransposon re-
pression in differentiated cells [61].
Of note, not all ERV-derived sequences are subject to
epigenetic silencing as some have been co-opted because
their non-coding DNA regulatory elements, nucleic
acids or even gene products benefit their hosts
[5,6,62!!,63!!]. Whether co-opted ERVs are subject to
spatial or temporal repression by KAP1 remains an open
question. However, certain KRAB-ZNFs have been
found to bind to co-opted ERVs and to recruit transcrip-
tional activators and pioneer factors, suggesting that
these ZNFs function to switch on rather then switch
off certain gene networks [45,47].
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Implications for immune regulation
ERVs have been implicated in multiple cancers and
autoimmune diseases, including ovarian and breast can-
cer, systemic lupus erythematosus and multiple sclerosis
[64,65]. There is some convincing evidence that ERVs
can play a causative role in cancer when their LTRs
escape epigenetic repression [66] and interestingly, this
involves mainly primate-specific ERVs [67]. For example,
cryptic enhancers and promoters that reside within ERVs
can drive expression of oncogenes [66,68!].
ERVs regulate the immune system in several ways. For
example, double stranded RNA (dsRNA) produced from
retrotransposons, following treatment of cancer cells with
DNA methyltransferase inhibitors activates interferon
through MDA5, MAVS and IRF7 [13!!,14!!]. Cyto-
plasmic DNA resulting from reverse transcription also
serves as an additional PAMP because it is detected
by the cytosolic DNA sensor cGAS to activate type I
interferon through STING [63!!,69–72]. Likewise, Toll-
like receptors contribute to ERV nucleic acid sensing
[73]. Mutations within genes involved in nucleic acid
metabolism including TREX1 are associated with auto-
immune diseases [74], although such factors block classes
of retrotransposons that are constitutively transcribed
rather than those embedded within silent chromatin. In
addition to innate immunity, ERVs can stimulate adap-
tive immunity too because their encoded gene products,
which are necessary for their mobilization are subject to
standard antigen processing and presentation pathways.
For example, tumor-associated antigens (TAAs) can be
derived from HERV-K envelope protein [75]. Such neo-
antigens can evoke adaptive T cell and antibody
responses [76], both of which have been demonstrated
to regulate ERVs [15,75].
Overall, ERV regulatory sequences including solo LTRs
have been described to contribute to cancer by driving
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Epigenetic factors repress retrotransposons in differentiated tissues, preventing transcription and sensing of nucleic acids derived from endogenous
viruses, which we refer to as ‘non-self’. In differentiated cells, epigenetic silencing of retrotransposons is maintained by incompletely characterized
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factors are depicted in blue to illustrate that this is an emerging area of research. The addition of 5-AZA-based drugs results in the generation of
dsRNA from retrotransposons and potentially cDNA as well through reverse transcription, both of which lead to innate immune activation.
Current Opinion in Virology 2017, 25:28–33 www.sciencedirect.com
oncogenes, whereas longer ERVs if resurrected (e.g.
through 5-AZA treatment) may promote anti-tumor im-
munity through their nucleic acids and proteins. Exactly
how sensing of ERV nucleic acids leads to anti-tumor
immunity is not fully understood but remarkably, it has
been shown that if cancer initiating cells are pretreated
with 5-AZA drugs before their injection into mice, they
form less tumors and this phenotype is dependent on
MAVS [13!!,14!!,68!]. Likewise, if B16 melanoma cells
are pretreated with 5-AZA before their injection into mice
that receive anti-CTLA-4, they can stimulate complete
tumor clearance [13!!]. Furthermore, interferon-respon-
sive genes are upregulated in cancer patients treated with
5-AZA [77!]. Interferon signaling is important presum-
ably to promote apoptosis of cancer cells and to help to
recruit cytotoxic T cells recognizing neo-antigens and
other immune effectors to clear the tumor. It has also
been shown that cytosolic RNA and DNA sensing of
ERVs is necessary to induce T-independent B cell
responses in mice [63!!]. This latter work illustrates that
ERVs have coevolved with their hosts to play a natural
role in modulating the immune system. Overall, ERVs lie
at the intersection of innate and adaptive immunity, due
to their intrinsic immunogenicity.
Concluding remarks
While it was previously thought that histone marks are
primarily required to silence retrotransposons only early
in development [10,50,78,79], where DNA methylation is
reprogrammed [80,81], recent evidence has led to a new
paradigm whereby diverse epigenetic modifiers exert
continuous roles in adult tissues. Here we discuss evi-
dence that SETDB1, DNMTs, HP1, HSP90, the NuRD
complex and potentially KAP1 and KRAB-ZNFs are
some of these factors (Figure 1). Importantly, most of
these regulators have only been studied in mouse models
so far. A future understanding of the pathways operating
in adult human tissues is essential for the development of
innovative drugs. Targeted epigenetic modulation might
prove a potent tool in the future to reactivate certain
retrotransposons so that their nucleic acids and proteins
could serve as natural PAMPs to signal danger to their
host. Such drugs may be valuable to stimulate immuno-
surveillance in cancer patients in which immune activa-
tion pathways may be subdued or could be used in
conjunction with standard vaccines in place of an adju-
vant. Caution should be applied, however, to prevent
unwanted effects of reactivated ERVs on the genome or
transcriptome.
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Abstract	
Endogenous	 retroviruses	 (ERVs)	 have	 accumulated	 in	 vertebrate	 genomes	 and	
contribute	 to	 the	 complexity	 of	 gene	 regulation.	 KAP1	 represses	 ERVs	 during	
development	 by	 its	 recruitment	 to	 their	 repetitive	 sequences	 through	 Krüppel-
associated	 box	 domain-zinc	 finger	 proteins	 (KZNFs),	 but	 little	 is	 known	 about	 the	
regulation	 of	 ERVs	 in	 differentiated	 cells.	 We	 observed	 that	 KAP1	 repression	 of	
HERVK14C	 was	 conserved	 in	 differentiated	 human	 cells	 and	 performed	 KAP1	
knockout	and	mRNA-sequencing	to	obtain	an	overview	of	KAP1	function.	Our	results	
show	that	KAP1	represses	ERVs	and	ZNFs,	both	of	which	overlap	with	KAP1	binding	
sites	and	silent	chromatin	marks	in	multiple	cell	types.	Furthermore,	this	pathway	is	
functionally	 conserved	 in	 primary	 human	 peripheral	 blood	 mononuclear	 cells	
(PBMCs).	 Finally,	we	 reveal	 that	 cytosine	methylation	 that	 acts	 on	 KAP1-regulated	
loci	 is	 necessary	 to	 prevent	 innate	 immune	 reactivity	 of	 ERVs	 and	 other	
retrotransposons,	which	can	mimic	viruses	by	producing	immunostimulatory	nucleic	
acids.	 These	 data	 indicate	 that	 the	 KAP1-KZNF	 pathway	 has	 evolved	 to	 play	 an	
important	 functional	 role	 in	 genome	 stability	 and	 the	 control	 of	 viral	 mimicry	 in	
differentiated	human	cells.		
	
	
Keywords:	epigenetic	control	/	human	differentiated	cells	/	endogenous	retroviruses	
(ERVs)	/	nucleic	acid	sensing	/	KAP1	(KRAB-associated	protein	1)	
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Introduction	
	
Retrotransposons	are	genetic	elements	capable	of	amplifying	their	copy	number	 in	
the	genome	by	replicating	through	an	RNA	intermediate.	They	now	occupy	at	 least	
half	of	the	human	genome	and	individual	loci	reflect	the	genetic	conflict	experienced	
by	 the	 host	 throughout	 evolution[1,	 2].	 Retrotransposons	 are	 divided	 into	 two	
groups,	 those	 with	 long	 terminal	 repeats	 (LTR)	 and	 those	 without	 (non-LTR).	 LTR	
retrotransposons	 are	 known	 as	 endogenous	 retroviruses	 (ERVs)	 because	 their	
genetic	make-up	is	like	that	of	exogenous	retroviruses	from	which	they	are	derived.	
ERVs	 constitute	 around	 9%	 of	 the	 human	 genome[3,	 4]	 and	 are	 a	 class	 of	
retrotransposons	with	 important	 roles	 in	 human	health	 and	 disease.	 For	 example,	
LTRs	of	 the	primate-specific	 retrovirus,	MER41,	have	been	 co-opted	 to	 function	as	
natural	 poised	 enhancers	 for	 a	 network	 of	 interferon-induced	 genes[5].	 The	 co-
option	of	ERVs	into	normal	processes	such	as	development	and	immune	function	is	
the	 result	 of	 co-evolution	 of	 ERVs	 and	 their	 regulatory	DNA	 sequences,	which	 are	
scattered	across	the	genome,	with	their	hosts	over	millions	of	years[6].	
	
ERVs	 are	 subject	 to	 epigenetic	 repression	 in	 adult	 tissues	 involving	 mechanisms	
including	 their	 transcriptional	 repression	 through	 cytosine	methylation	 [7].	 This	 is	
critical	 to	 prevent	 expression	 of	 their	 nucleic	 acids	 and	 proteins,	 which	 could	
potentially	 trigger	 an	 autoimmune	 response.	 This	 has	 recently	 been	 illustrated	 by	
two	studies	in	which	treatment	of	cancer	cells	with	5-AZA-based	DNA	demethylating	
agents	 led	 to	 the	 reactivation	 of	 ERVs[8,	 9].	 This	 in	 turn	 activated	 interferon-
	 4	
stimulated	genes	(ISGs)	through	MDA-5,	MAVS	and	IRF7	following	sensing	of	double	
stranded	RNA	 transcripts,	 including	 those	derived	 from	ERVs.	The	authors	propose	
that	 this	mechanism	 contributes	 to	 anti-tumour	 immunity	 in	patients	 treated	with	
these	drugs	and	remarkably,	cancer	 initiating	cells	pretreated	with	5-AZA	form	less	
tumours	in	mice	in	a	MAVS-dependent	manner[9].	Like-wise,	reactivation	of	ERVs	in	
differentiated	 cells	 has	 also	 been	 linked	 to	 autoimmune	 diseases	 such	 as	multiple	
sclerosis[10].	Despite	the	presence	and	importance	of	ERV	transcriptional	regulation	
in	adult	tissues,	however,	very	little	is	known	about	the	epigenetic	control	pathways	
in	 operation.	 In	 contrast,	 the	 mechanisms	 in	 place	 to	 restrict	 ERVs	 early	 in	
development	 are	 well-described.	 In	 early	 embryos,	 in	 which	 DNA	 methylation	 is	
erased,	 epigenetic	 complexes	 act	 to	 establish	 histone	 and	 cytosine	 methylation	
patterns	 at	 ERVs[11].	 This	 serves	 to	 protect	 transcriptome	 integrity	 and	 prevent	
vertical	transmission	of	retrotransposition	events.	One	such	pathway	involves	KAP1	
and	 krüppel-associated	 box	 domain-zinc	 finger	 proteins	 (KZNFs)[12-16].	 KZNFs	
(known	as	KZFPs	in	mouse)	interact	with	their	corresponding	DNA	targets,	which	are	
mainly	located	within	repetitive	DNA	[17-19],	and	recruit	KAP1	to	these	loci[20-22].	
Gene	silencing	ensues	when	KAP1	binds	epigenetic	modifiers	including	HP1,	SETDB1	
and	DNMTs	[23-25].		
	
KAP1	has	been	shown	to	bind	to	certain	ERVs	in	human	CD4+	T	cells[13]	and	plays	a	
functional	role	in	ERV	regulation	in	human	neural	progenitor	cells,	although	it	is	not	
clear	 if	 this	 is	 the	 case	 in	 differentiated	 neurons[26].	 KAP1	 has	 been	 depleted	 in	
several	 differentiated	 murine	 cell	 types	 with	 little	 effect	 on	 ERVs[27,	 28].	
Interestingly,	 however,	 its	 ablation	 in	mouse	 liver	 results	 in	 the	 overexpression	 of	
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several	 cellular	 genes	 close	 to	 KAP1-bound	 ERVs,	 although	 the	 ERVs	 themselves	
remain	 repressed[27].	 In	 contrast,	 SETDB1,	which	 is	 a	binding	partner	of	KAP1	has	
been	shown	to	be	necessary	for	the	silencing	of	ERVs	in	mouse	B	lymphocytes[29].		
	
Therefore,	 the	 potential	 role	 and	 relevance	 of	 KAP1	 in	 differentiated	 cells,	
particularly	in	humans,	 is	a	fundamental	and	open	question.	We	set	out	to	address	
this	 question	 by	 employing	 CRISPR/Cas9-mediated	 KAP1	 knockout	 in	 human	
differentiated	cells	 followed	by	mRNA-sequencing	and	correlated	our	 findings	with	
KAP1	binding	data.	We	report	here	that	KAP1	binds	to	and	represses	ERVs	and	ZNFs	
in	differentiated	human	cells.	We	demonstrate	using	reporters	that	KAP1	can	induce	
de	novo	ERV	repression	even	in	primary	human	peripheral	blood	mononuclear	cells	
(PBMCs).	 Finally,	 we	 show	 evidence	 that	 KAP1	 is	 one	 epigenetic	 regulator	 that	
controls	retrotransposon	nucleic	acid	sensing	and	activation	of	interferon-stimulated	
genes.	 These	 results	 reveal	 the	 widespread	 importance	 of	 the	 KAP1	 pathway	 in	
genome	 stability	 and	 the	 regulation	of	 viral	mimicry	 in	 differentiated	human	 cells.	
This	 work	 also	 illustrates	 that	 cell	 lines	 could	 be	 used	 to	 dissect	 the	 functions	 of	
KAP1-recruiting	 KZNFs	 in	 human	 gene	 regulation	 through	 their	 targeted	 gene	
knockout.	
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Results	
	
The	 human	 retrovirus	 HERVK14C	 is	 repressed	 by	 KAP1	 in	 undifferentiated	 and	
differentiated	cells	
KAP1	 is	 known	 to	 regulate	 the	 human	 ERV	 (HERV)	 lineage	 HERVK14C	 in	
undifferentiated	 human	 embryonic	 stem	 cells	 (ESCs)[13].	 We	 therefore	 selected	
HERVK-14C	 as	 a	 tool	 to	 explore	 KAP1	 function	 in	 other	 cell	 types.	 HERVK14C	 is	
restricted	 to	 Great	 Apes	 and	 Old	 World	 Monkeys	 (Figure	 1a)	 and	 is	 a	 low	 copy	
number	 ERV	 making	 it	 relatively	 easy	 to	 study.	 We	 first	 identified	 all	 loci	 that	
included	 internal	 regions	 (Figure	 1b)	 because	 KAP1	 has	 been	 documented	 to	
frequently	 target	 internal	ERV	sites	 for	 repression	 including	 sequences	overlapping	
the	 primer	 binding	 site	 (PBS),	 GAG	 and	 ENV[15,	 27,	 30].	We	 designed	 two	 primer	
sets	to	detect	specific	HERVK14C	loci	(Figure	1c)	and	employed	qRT-PCR	to	confirm	
that	 KAP1	 represses	 these	 ERVs	 in	 undifferentiated	 Oct4-expressing	 embryonic	
NTERA-2	cells	(Figure	1d	and	Figure	S1a).	We	then	focused	on	two	differentiated	cell	
lines,	HeLa	and	293T	cells	and	generated	KAP1	knockout	clones	using	CRISPR/Cas9	
genome	 editing.	 We	 validated	 KAP1	 knockout	 and	 complementation	 functionally	
using	described	KAP1-KZNF	 reporters[14,	16]	 (Figure	S1bc)	and	we	discovered	 that	
like	 in	 undifferentiated	 cells,	 KAP1	 represses	 HERVK14C	 in	 differentiated	 cell	 lines	
(Figure	1ef).	The	phenotype	was	consistent	between	clones,	although	the	magnitude	
of	 the	 effect	was	 variable	 and	we	 also	 observed	 differences	 between	primer	 sets,	
which	 recognize	overlapping	as	well	 as	distinct	 loci	 (Figure	1cef).	 Two	other	KAP1-
regulated	retrotransposons,	L1PA4	(a	LINE1	subfamily)	and	SVA	D	(a	SVA	subfamily),	
in	contrast,	were	only	modestly	affected	by	KAP1	depletion	in	both	undifferentiated	
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and	 differentiated	 cells	 (Figure	 1def).	 This	 may	 reflect	 redundant	 silencing	
mechanisms	at	these	elements	and	in	line	with	this,	we	found	SVA	elements	to	often	
be	enriched	for	cytosine	methylation	(Figure	S1d).	
	
A	common	role	for	KAP1	in	repressing	ERVs	and	ZNFs	
Studies	exploring	KAP1	function	have	been	hindered	by	the	fact	that	complete	KAP1	
knockout	 is	 usually	 lethal,	 while	 knockdown	 may	 not	 be	 sufficient	 to	 reveal	 a	
phenotype	 in	all	cell	 types	 [12,	13,	31].	Since	here	we	could	obtain	KAP1	knockout	
HeLa	 cell	 clones	 (Figure	 1),	 we	 employed	 mRNA-sequencing	 to	 gain	 a	 systematic	
overview	 of	 the	 role	 of	 KAP1	 in	 these	 differentiated	 cells.	 Sequencing	 reads	were	
mapped	 to	 the	human	genome	and	 to	RepBase	 to	 assess	 the	 global	 expression	of	
genes	and	 repetitive	elements	 respectively,	and	we	 focused	on	significant	 changes	
(where	 differential	 effects	 were	 >	 2-fold	 with	 p-values	 <0.05).	 Results	 reveal	 that	
KAP1-knockout	 induces	 a	 very	 specific	 and	 modest	 phenotype	 involving	
overexpression	of	ERVs	and	ZNFs	(Figure	2).	HERVs	(HERV-T,	HERV-S	and	HERVK14C)	
were	 the	 only	 class	 of	 repetitive	 elements	 overexpressed	 in	 knockout	 HeLa	 cells	
(Figure	2a	and	Spreadsheet	1)	and	as	expected,	these	ERV	families	were	also	bound	
by	KAP1	according	to	ENCODE	data	(Figure	2a	and	S2a).	Intriguingly,	these	ERVs	are	
present	 in	 diverse	 primates	 and	 other	 mammals	 (Figure	 2b).	 Of	 note,	 several	
retrotransposons	were	downregulated	 in	knockout	 cells	 (Figure	S2b).	The	 fact	 that	
few	 ERVs	 were	 reactivated	 may	 relate	 to	 the	 low	 number	 of	 active	 ERV	
transcriptional	units	in	the	human	compared	to	the	mouse	genome[4].		Interrogation	
of	 the	 transcriptome	 showed	 that	 KAP1	 knockout	 also	 affects	 several	 hundred	
cellular	genes	(Figure	S3ab,	Spreadsheet	2).	When	we	focused	on	upregulated	genes	
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(>2fold	where	padj=<0.05),	we	found	that	strikingly,	ZNFs,	of	which	there	were	13	(9	
of	which	were	KZNFs)	are	the	class	of	cellular	genes	most	significantly	overexpressed	
(Figure	2c).	All	 of	 these	KZNFs	are	also	direct	KAP1-binding	 targets	 (using	ENCODE	
data)(Figure	 S3c),	 illustrating	 that	 KAP1	 plays	 a	 functional	 role	 in	 regulating	 these	
sites,	a	notion	that	was	previously	inferred	only	from	binding	rather	than	functional	
data[32,	33].		
Since	KAP1	repression	of	ERVs	and	ZNFs	is	a	phenotype	that	has	also	been	observed	
in	embryonic	cells[12,	13],	we	hypothesized	 that	KAP1	may	bind	ERVs	and	ZNFs	at	
common	 sites	 in	 both	 undifferentiated	 and	 differentiated	 cells.	 To	 address	 this	
question,	we	determined	 if	any	KAP1	binding	sites	were	common	between	human	
ESCs	and	differentiated	cells	(293T	cells)	using	public	ChIP-seq	data	([13]and	ENCODE	
data	and	 identified	614	common	peaks	 (Figure	S3d	and	Spreadsheet	3).	We	 found	
these	 loci	 to	 be	 highly	 enriched	 for	 ERVs	 compared	 to	 their	 abundance	 in	 the	
genome	 (Figure	 2d).	We	 determined	 the	 nearest	 gene	 to	 each	 of	 these	 sites	 and	
interestingly,	 gene	 ontology	 analysis	 showed	 that	 the	most	 common	 gene	 cluster	
was	 ZNFs,	 (of	which	 there	were	 61,	 including	 40	KZNFs)	 (Figure	 2e),	mirroring	our	
functional	 data	 for	 the	 upregulated	 genes	 (Figure	 2c).	 Finally,	 examining	 the	
occurrence	of	LINE1	elements	and	ERVs	within	KAP1	binding	sites	in	(i)	human	ESCs	
or	 in	 (ii)	 293T	 cells	 or	 (iii)	 within	 common	 sites	 revealed	 a	 similar	 pattern	 of	
distribution,	except	 that	ERV1	elements	were	slightly	enriched	within	 the	common	
sites	(Figure	2f).	This	suggests	that	the	 landscape	of	KAP1	binding	does	not	change	
dramatically	between	these	cell	types.	The	614	common	peaks	are	likely	particularly	
strong	 KAP1-binding	 targets	 allowing	 their	 consistent	 identification.	 Overall,	 these	
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results	illustrate	that	ERVs	and	ZNFs	are	repressed	by	KAP1	through	direct	binding	in	
undifferentiated	and	differentiated	cells.		
	
KAP1	common	binding	sites	are	enriched	for	repressive	histone	marks	in	multiple	
cell	types	and	overlap	KZNF	ERV	targets	
We	hypothesized	that	KAP1	repression	of	key	ERV	and	ZNF	 loci	may	be	a	common	
feature	in	multiple	cell	types.	To	address	this	question,	we	probed	ENCODE	data	of	
epigenetic	marks	in	undifferentiated,	differentiated	and	primary	cell	types	and	asked	
if	 the	 common	 KAP1	 binding	 sites	 we	 identified	 (Figure	 S3d)	 overlapped	 silent	
chromatin	marks	(Figure	3).	We	found	indeed	that	these	loci	correlate	with	KAP1	and	
SETDB1	 binding	 and	 repressive	 H3K9me3	 in	 multiple	 cell	 types	 (Figure	 3a).	 In	
comparison,	 we	 did	 not	 observe	 a	 correlation	 with	 the	 active	 chromatin	 marks,	
H3K4me1	and	H3K27ac	 (Figure	3a)	as	expected.	KAP1	 is	 recruited	to	genomic	sites	
through	KZNFs[14,	16,	32],	which	we	show	here	to	be	maintained	at	low	expression	
levels	through	KAP1	binding	(Figure	2).	We	reasoned	that	a	subset	of	KZNFs	must	be	
widely	 expressed	 and	 at	 a	 sufficient	 level	 to	 recruit	 KAP1	 to	 common	 sites.	 We	
therefore	identified	the	top	one	hundred	most	highly	expressed	KZNFs	in	293T	cells	
using	mRNA-sequencing	data[34],	verified	them	to	be	expressed	at	the	protein	level	
(the	 human	 protein	 atlas[35])	 and	 recorded	 their	 targets	 where	 known[17,	 19]	
(Figure	 3b	 and	 Spreadsheet	 4).	 Many	 of	 these	 KZNFs	 bind	 to	 ERVs	 (Figure	 3b),	
reflecting	KAP1	binding	at	common	loci	(Figure	3c)	and	interestingly,	the	ERV-binding	
KZNFs	 are	 widely	 conserved	 among	 primates	 or	 mammals	 and	 recognize	 ERVL	 or	
ERV1	sequences	(Figure	3d).	These	data	show	that	KAP1	and	KZNFs	repress	ERVs	and	
ZNFs	in	multiple	cell	types	and	suggest	that	core	interactions	may	even	be	conserved	
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between	species.		
	
KAP1	restricts	incoming	ERVs	through	the	primer	binding	site	sequence	
We	next	asked	if	differentiated	cells	were	equipped	with	high	enough	levels	of	KAP1	
and	 its	 associated	 epigenetic	machinery	 to	 induce	de	novo	 repression	of	 incoming	
ERV	 sequences.	 KAP1	 is	 known	 to	 target	 several	 retroviruses	 including	 HERVK	
through	the	primer	binding	site	(PBS)	[13,	15,	36]	as	well	as	other	sites[27,	30].	We	
selected	the	KAP1-bound	and	repressed	HERVK14C	integrant	on	chromosome	15	as	
a	 model	 to	 measure	 de	 novo	 KAP1	 repression	 in	 a	 reporter	 assay.	 It	 contains	 a	
variant	 lysine	 PBS	 sequence	 (PBSChr15),	 which	 we	 cloned	 upstream	 of	 the	
HERVK14C	LTR	in	a	vector	(termed	PBSChr15-LTR-GFP)	and	tested	alongside	a	vector	
containing	 the	 consensus	 PBS-lys1,2	 sequence	 (PBS-LTR-GFP)	 or	 a	 control	 vector	
with	no	PBS	(LTR-GFP)	(Figure	4a).	Using	this	system,	we	could	demonstrate	that	the	
HERVK14C	 chromosome	 15	 PBS	 sequence	 and	 the	 consensus	 PBS	 sequence	 could	
induce	KAP1-dependent	repression	in	both	undifferentiated	and	differentiated	cells	
(Figure	 4bc).	 In	 contrast,	 the	 control	 vector	 was	 not	 subject	 to	 significant	 KAP1	
repression	(Figure	4bc).	
	
PBS-dependent	de	novo	repression	of	ERVs	is	conserved	in	primary	cells	
A	 key	 question	 is	 whether	 the	 KAP1	 pathway	 is	 conserved	 and	 functional	 in	
repressing	 ERVs	 in	 differentiated	 primary	 human	 cells.	 Existing	 data	 suggests	 that	
KAP1	 binding	 is	 conserved	 at	 specific	 ERVs	 in	 primary	 CD4+	 T	 cells[13].	 Here,	 we	
were	 interested	 in	 the	 relevance	of	 the	 KAP1	pathway	 in	 controlling	 the	 potential	
immune	response	elicited	by	uncontrolled	ERV	expression	so	we	focused	on	PBMCs	
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as	a	model	because	they	participate	in	innate	and	adaptive	immunity.	We	found	that	
KAP1	 depletion	 in	 PBMCs	 leads	 to	 overexpression	 of	 HERVK14C	 and	 other	 KAP1-
repressed	retrotransposons	(Figure	5a	and	S4a),	consistent	with	the	overlap	of	KAP1	
binding	 and	 silent	 chromatin	 at	 ERVs	 in	 PBMCs	 (Figure	 3).	 Parallel	 experiments	 in	
activated	CD4+	T	cells	 induced	a	more	modest	effect	(Figure	S4bc),	suggesting	that	
the	 KAP1	 pathway	 may	 be	 partly	 redundant	 with	 other	 epigenetic	 pathways	 in	
primary	cells.	Indeed,	we	could	detect	cytosine	methylation	at	the	HERVK14C	LTR	in	
CD4+	 T	 cells	 (Figure	 S4d).	 In	 HeLa	 cells,	 interestingly,	 cytosine	 methylation	 was	
reduced	at	HERVK14C	by	KAP1	knockout	suggesting	 that	KAP1	maintains	 this	mark	
(Figure	S4e).	It	is	possible	that	sustained	KAP1	knockout	in	primary	cells	would	lead	
to	more	pronounced	overexpression	of	ERVs	and	a	decrease	in	cytosine	methylation	
but	we	were	unable	to	generate	stable	KAP1-depleted	primary	cells	due	to	toxicity.	
To	 overcome	 this	 problem,	 we	 used	 our	 HERVK	 reporters	 (Figure	 4),	 which	 are	
themselves	 unmethylated	 to	 transduce	 PBMCs	 and	measure	 the	 establishment	 of	
repression.	Results	showed	that	the	PBS-containing	vector	was	repressed	relative	to	
the	 control	 vector	 (Figure	 5b),	while	 both	were	 integrated	 at	 similar	 proviral	 copy	
numbers.	 This	 data	 demonstrates	 that	 de	 novo	 KAP1-mediated	 transcriptional	
repression	is	intact	in	PBMCs.	
We	hypothesized	that	a	core	set	of	KZNFs	must	be	expressed	in	PBMCs	as	well	as	in	
other	 cell	 types	 to	 mediate	 KAP1	 repression	 of	 key	 sequences.	 To	 explore	 this	
possibility,	 we	 used	mRNA-sequencing	 data	 (see	methods	 for	 accession	 numbers)	
and	selected	all	KZNFs	that	are	expressed	within	a	given	cell	type	and	looked	at	the	
overlap	of	these	KZNFs	between	cell	 types.	Results	show	that	seventy-seven	KZNFs	
are	 widely	 expressed	 at	 the	 mRNA	 level	 (Figure	 5c,	 Spreadsheet	 5).	 Finally,	 we	
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verified	 that	 several	of	 these	KZNFs	are	also	expressed	at	 the	protein	 level	 (Figure	
5d)	and	we	checked	that	the	top	one	hundred	KZNFs	 in	293T	cells	 (Spreadsheet	4)	
have	been	described	to	be	expressed	at	the	protein	level[35].		
	
Cytosine	methylation	acts	on	KAP1-regulated	retrotransposons	and	prevents	viral	
mimicry	and	innate	immune	activation	
ERVs	are	subject	to	epigenetic	repression	 in	cancer	cells	and	disruption	of	cytosine	
methylation	 with	 5-AZA-based	 drugs	 leads	 to	 the	 activation	 of	 ISGs	 through	 ERV-
derived	nucleic	acid	sensing	[8,	9].	However,	while	the	signaling	pathways	that	5-AZA	
affects	 are	well-established,	 the	 identities	of	 the	epigenetic	 factors	 that	 repress	5-
AZA-modulated	ERVs	are	unknown.	It’s	also	unclear	whether	5-AZA	acts	specifically	
on	 cancer	 cells	 or	 if	 it	 can	 reactivate	 ERVs	 in	 normal	 differentiated	 cells	 too.	We	
reasoned	 that	 KAP1	 may	 be	 one	 epigenetic	 player	 relevant	 to	 the	 5-AZA	 affect	
because	 (i)	 it	 represses	 ERVs	 in	 differentiated	 cells	 and	 (ii)	 it	 recruits	 SETDB1,	
H3K9me3	and	DNA	methylation	 [13,	24,	25,	37,	38].	To	explore	 this	possibility,	we	
performed	experiments	in	cell	lines	and	PBMCs	where	we	depleted	KAP1	or	treated	
cells	 with	 5-AZA	 and	 measured	 derepression	 of	 ERVs	 and	 induction	 of	 ISGs.	 We	
found	 that	 depletion	of	 KAP1	 alone	 leads	not	 only	 to	 ERV	 reactivation	but	 also	 to	
activation	of	 the	 interferon-stimulated	 chemokines,	 CCL5	 and	CXCL10	 in	Hela	 cells	
but	 not	 in	 PBMCs	 (Figure	 6a	 and	 Figure	 S5a-c).	 Importantly,	 these	 genes	 are	 not	
direct	 KAP1	 binding	 targets	 (ENCODE).	 This	 suggests	 that	 the	 KAP1	 pathway	 is	
necessary	to	prevent	ERV	immune	activation	in	certain	cell	contexts,	although	it	may	
exert	 part	 redundancy	with	 other	 epigenetic	 factors.	 In	 contrast,	 5-AZA	 treatment	
potently	 activated	 ISGs	 in	 HeLa	 cells,	 293T	 cells	 and	 primary	 cells	 showing	 that	 in	
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both	cancer	and	normal	cells,	cytosine	methylation	acts	to	prevent	viral	mimicry	and	
immune	 activation	 (Figure	 6b).	 Note	 that	 these	 ISG	 promoters	 are	 not	 subject	 to	
direct	 DNA	 methylation	 regulation	 (ENCODE	 RRBS	 data)	 and	 rather	 that	 ISG	
activation	has	been	shown	to	be	dependent	on	MAVS	signaling[8,	9].	Importantly,	5-
AZA	treatment	affects	some	of	the	same	loci	as	KAP1-depletion	including	the	specific	
copies	of	HERVK14C	that	are	detected	with	our	primers	(Figure	6).	No	further	effect	
was	 observed	 from	 combined	 KAP1-depletion	 and	 5-AZA	 treatment	 (Figure	 S5d).	
Once	ISGs	are	activated,	negative	regulation	of	the	interferon	response	ensures	that	
these	 genes	 are	 switched	 off	 in	 a	 timely	 manner	 to	 prevent	 chronic	 immune	
activation[39].	Interestingly,	we	found	that	12	immune	response	genes	(Spreadsheet	
6)	were	downregulated	in	stable	KAP1	knockout	HeLa	cell	clones,	suggesting	that	the	
reactivated	 ERVs	 in	 these	 cells	 had	 played	 a	 role	 in	 modulating	 immune	 genes.	
Overall,	these	results	show	that	KAP1	and	cytosine	methylation	repress	some	of	the	
same	retrotransposon	targets	to	prevent	innate	immune	activation.	This	is	relevant	
to	the	mode	of	action	of	5-AZA-based	drugs,	which	are	used	in	the	clinic.	Since	KAP1	
depletion	 alone	 is	 not	 sufficient	 for	 global	 ISG	 induction,	 additional	 epigenetic	
factors	likely	contribute	to	retrotransposon	repression	in	differentiated	cells.		
	
Discussion	
	
The	present	work	highlights	the	previously	unknown	role	for	KAP1	in	repressing	ERVs	
and	 ZNFs	 (and	 particularly	 KZNFs)	 in	 differentiated	 human	 cells.	 KAP1	 therefore	
represents	one	epigenetic	pathway	necessary	for	preventing	autoimmunity	that	can	
be	triggered	by	ERV-derived	nucleic	acids	and	proteins.	KAP1	is	also	relevant	to	the	
	 14	
mode	of	action	of	5-AZA-based	drugs	since	KAP1	and	cytosine	methylation	repress	
some	of	the	same	ERVs	(see	Figure	7	for	a	model).	The	fact	that	KAP1	co-regulates	
ERVs	 and	 KZNFs,	 the	 latter	 which	 themselves	 recruit	 KAP1	 to	 ERV	 repetitive	 DNA	
sites	 suggests	 that	 this	 mechanism	 may	 serve	 to	 fine-tune	 KZNF	 expression	 and	
maintain	ERV	repression.	KAP1	constraint	of	KZNF	transcription	has	been	proposed	
before	 from	 binding	 data[32,	 33],	 a	 notion	 which	 we	 now	 support	 here	 with	
functional	data.	Note	that	KAP1	knockout	 in	differentiated	cells	 impacts	on	cellular	
genes	only	modestly	compared	to	the	more	pronounced	effects	observed	following	
KAP1	 knockout	 in	mouse	or	human	ESCs[13,	 28].	 This	may	 relate	 to	 the	 increased	
requirement	for	KAP1	in	early	development	or	an	increased	number	of	KAP1	binding	
sites	 and	 /	 or	 different	 configuration	 of	 chromatin	 in	 embryonic	 cells,	 where	
heterochromatin	spreads	from	repeats	to	genes[13,	28,	40].		
	
Consistent	with	the	presence	of	KAP1	and	silent	chromatin	marks	at	certain	ERV	loci	
in	multiple	 cell	 types,	 our	 data	 also	 reveal	 that	 a	 cohort	 of	 KZNFs	 exert	 a	 diverse	
mRNA	 and	 protein	 expression	 profile.	 These	 factors	 may	 function	 to	 regulate	
heterochromatin	 at	 a	 subset	 of	 the	 genome	 and	 to	 restrict	 infections	 from	
exogenous	 retroviruses.	 This	 is	 supported	 by	 our	 reporter	 experiments	 that	
demonstrate	that	KAP1	can	mediate	sequence-specific	 repression	against	 incoming	
retroviruses.	 The	 fact	 that	 KAP1-repression	 is	 modest	 in	 differentiated	 cells	 may	
relate	to	the	low	expression	levels	of	KZNFs.	Intriguingly,	the	mouse	KZFP,	Zfp809	is	
rapidly	 degraded	 at	 the	 protein	 level	 in	 differentiated	 cells,	 restricting	 its	 potency	
mainly	 to	 embryonic	 cells	 [41].	 An	open	question	 is	whether	 KZNFs	 could	become	
augmented	 in	 their	expression	 in	 response	to	viral	 infections,	 interferon	treatment	
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or	 other	 stimuli	 to	 make	 them	 more	 potent	 in	 differentiated	 cells.	 Finally,	 it’s	
possible	 that	 KAP1	 repression	 of	 common	 loci	 is	 dynamic	 and	 KAP1-bound	 ERV	
regulatory	sequences	may	have	been	co-opted	to	activate	cellular	gene	networks	or	
downstream	 processes	 in	 specific	 contexts,	 a	 hypothesis	 worth	 exploring	 in	 the	
future.	 Interestingly,	 we	 found	 here	 that	 KAP1	 regulates	 HERV-T	 and	 HERVK14C,	
both	 of	 which	 show	 evidence	 of	 co-option[42,	 43].	 KAP1	 is	 often	 enriched	 at	
regulatory	hubs	together	with	other	transcription	factors	(Figure	S2),	suggesting	that	
these	 loci	are	active	under	specific	conditions	and	once	activated,	 the	ERV-derived	
nucleic	acids	may	help	to	trigger	an	immune	response.	Intriguingly,	ERVs	have	been	
proposed	to	play	a	role	in	stimulating	T-independent	B	cell	responses[44].		
	
Like	 KAP1	 depletion,	 treatment	 of	 differentiated	 cells	 with	 5-AZA	 results	 in	 the	
reactivation	of	KAP1-regulated	retrotransposons	including	HERVK14C	and	to	a	lesser	
extent	SVA	D	elements.	However,	depletion	of	KAP1	alone	is	not	sufficient	to	broadly	
activate	 ISGs	 presumably	 because	 the	 effect	 on	 immuno-stimulatory	
retrotransposons	 is	only	modest.	We	propose	 that	KAP1	exerts	partial	 redundancy	
with	other	epigenetic	pathways	and	that	 the	 level	of	 redundancy	at	 individual	ERV	
integrants	may	relate	to	multiple	parameters	including	their	evolutionary	age,	 local	
chromatin	 environment	 and	 nuclear	 position[14,	 45,	 46].	 Future	 work	 will	 be	
necessary	to	determine	exactly	which	factors	act	in	addition	to	KAP1	to	maintain	ERV	
silencing	in	differentiated	cells.	Many	epigenetic	regulators	exert	cross-talk	with	DNA	
methylation	 including	 SETDB1[47],	which	 can	act	 independently	or	 in	 concert	with	
KAP1[48].	 Other	 questions	 are	 the	 identities	 of	 the	 immuno-stimulatory	
retrotransposons	 and	 the	 nature	 of	 the	 signaling	 pathways	 they	 activate	 in	 vivo.	
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ERVs	with	bidirectional	promoters	can	generate	double	stranded	RNA	recognized	by	
MDA-5[8,	 9]	 but	 we	 show	 that	 KAP1	 and	 5-AZA	 also	 repress	 other	 classes	 of	
retrotransposons	in	differentiated	cells	such	as	SVAs,	and	these	may	produce	more	
potent	pathogen	associated	molecular	patterns	(PAMPs).	
	
Hundreds	of	KZNFs	have	recently	been	described	to	target	specific	sequences	within	
repetitive	DNA,	including	ERVs[17-19].	The	relevance	of	such	interactions,	however,	
remains	unknown.	Our	work	illustrates	that	cell	lines	rather	than	ESCs	could	be	used	
to	 determine	 the	 individual	 functions	 of	 a	 core	 set	 of	 KZNFs	 that	 are	 widely	
expressed	through	their	targeted	gene	knockout.	This	would	serve	as	an	economical	
and	 easy	 screening	 method	 to	 assess	 the	 initial	 effects	 of	 KZNF	 knockout	 on	 the	
human	genome	before	 following	up	on	promising	 candidates	 further	 in	 vivo.	Most	
interestingly,	KAP1	and	core	KZNFs	in	combination	with	other	epigenetic	factors	may	
become	new	drug	targets	for	cancer	with	the	aim	to	reactivate	subsets	of	ERVs	and	
other	 retrotransposons	 and	 harness	 their	 natural	 ability	 to	 trigger	 innate	 and	
adaptive	anti-tumour	immunity.		
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Methods	
	
Cell	culture	
Human	teratoma-derived	NTERA-2	cells	(kind	gift	from	Peter	Andrews,	University	of	
Sheffield)	were	cultured	in	Dulbecco's	modified	Eagle's	medium	(DMEM,	Gibco)	high	
glucose,	 supplemented	with	2mM	L-Glutamine,	 10%	 fetal	 calf	 serum	 (FCS)	 and	1%	
Penicillin/Streptomycin	 (P/S).	 They	 were	 split	 1:2	 or	 1:3	 every	 3-4	 days	 by	 cell	
scraping.	HEK293T	(293T)	and	HeLa	cells	were	grown	in	standard	DMEM	+	10%	FCS	
and	P/S	and	split	1:4	every	2	days	using	trypsin.	Human	primary	CD4+	T	cells	were	
grown	in	Roswell	Park	Memorial	Institute	medium	(RPMI,	Gibco)	supplemented	with	
10%	human	serum	and	10	U/ml	of	recombinant	 IL-2	and	activated	using	αCD3	and	
αCD28	pre-coated	flasks	 for	72	hours	during	which	time	 IL-2	was	 increased	to	25U	
/ml.	Peripheral	blood	mononuclear	cells	(PBMCs)	were	grown	in	RPMI	supplemented	
with	20%	FCS	and	10U/ml	of	IL-2	and	activated	using	3ug/ml	of	Phytohemagglutinin-
M	(PHA)	for	72	hours.	
	
KAP1	knockout	through	CRISPR/Cas9	genome	editing	
Guide	 RNAs	 (sgRNAs)	 specific	 to	 several	 different	 exons	 were	 designed	 using	 the	
website:	http://crispr.mit.edu/	and	cloned	into	the	PX459	plasmid	(Addgene),	which	
was	 then	 transfected	 into	HeLa	and	HEK293	T	 cells.	After	24	hours,	 the	 cells	were	
subjected	to	puromycin	selection	for	24	hours	or	until	control	cells	had	completely	
died.	 The	 bulk	 population	 was	 then	 used	 for	 single	 cell	 cloning.	 Knockout	 was	
assessed	 across	 a	 panel	 of	 clones	 by	 Western	 Blotting	 using	 the	 KAP1	 antibody,	
MAB3662	(Millipore)	and	validated	functionally	using	KAP1-KZNF	reporter	assays.	
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Primary	cell	isolation		
PBMCs	were	 isolated	 from	 a	 buffy	 coat	 or	 from	 fresh	 blood	 from	 healthy	 donors	
using	lymphoprep	(Axis-Shield).	CD4+	T	cells	were	obtained	from	the	isolated	PBMCs	
using	 the	 CD4+	 T	 cell	 Isolation	 Kit	 (Miltenyl	 Biotec)	 according	 to	 manufacturer’s	
instructions.	 The	 purity	 of	 the	 cells	 was	 verified	 by	 flow	 cytometry	 following	
antibody	staining.	Antibodies	used	are	shown	in	Table	1.	
	
	Western	blotting	
1-2	 x	 106	 cells	 were	 washed	 with	 PBS	 and	 lysed	 in	 NuPAGE	 LDS	 sample	 buffer	
(Thermo	Fisher)	with	5%	β-mercaptoethanol.	Samples	were	sonicated	for	90	seconds	
at	20Hz	and	heated	at	95o	C	for	5	minutes.	Lysates	were	then	loaded	onto	handcast	
10%	 SDS-polyacrylamide	 gels	 in	 tris/glycine/SDS	 buffer	 and	 mini-PROTEAN	 tanks	
(Biorad),	 followed	 by	 wet	 transfers	 onto	 Polyvinylidene	 Difluoride	 (PVDF)	
membranes.	 Antibodies	 used	 for	 blotting	 the	membrane	 are	 listed	 in	 Table	 1.	 All	
secondary	antibodies	were	horseradish	peroxidase-conjugated	 (GE	healthcare)	and	
membranes	 were	 developed	 using	 ECL	 kits	 (ECL,	 Prime	 or	 Select	 kits	 from	
Amersham).		
	
Actin	 Chemicon,	MAB1501	 mouse	monoclonal	
KAP1	 Millipore,	MAB3662	 mouse	monoclonal	
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PCNA	 Millipore,	clone	PC10	 mouse	monoclonal	
OCT3/4	 Santa	Cruz,	sc-5279	 mouse	monoclonal	
PE-Cγ	5	CD3	(ε-chain)			 BD	Bioscience,	555341	 mouse	
FITC	-	CD4	
	 BD	Bioscience,	345768	
mouse	
PE	-	OCT3/4	
	
eBioscience,	12-5841-80	 rat	
FITC	IgG1	(κ	Isotype	Control)	 BD	Bioscience,	555909	 mouse	
PE-Cγ	5	IgG2a	(κ	Isotype	Control)	 BD	Bioscience,	555575	 mouse	
PE	IgG2a	(κ	Isotype	Control)	 eBioscience,	12-4321-80	 rat	
Table	1.	List	of	antibodies	used.	
	
shRNA	lentiviral	vectors	and	transduction	
Hairpin	sequences	against	human	mRNAs	were	designed	using	 the	Clonetech	RNAi	
designer	 website	 (http://bioinfo.clontech.com/rnaidesigner/)	 and	 annealed	 into	
oligo	duplexes.	The	duplexes	were	then	cloned	into	HIV	SIREN	into	BamHI-EcoRI	sites	
and	the	products	were	checked	by	sequencing.	VSV-G-pseudotyped	lentiviral	vectors	
were	produced	by	co-transfecting	293T	cells	in	10cm	plates	with	1.5µg	of	the	shRNA	
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plasmid,	1µg	p8.91	and	1µg	pMDG2	encoding	VSV-G.	The	supernatant	was	harvested	
on	two	consecutive	days	(from	48h	post-transfection)	and	used	neat	or	concentrated	
via	 ultracentrifugation	 (20,000	×	 g	 for	 2h	 at	 4°C).	 Two	days	 post	 transduction,	 the	
cells	were	selected	with	puromycin	(2.5ug/ml)	for	48	hours	(or	until	control	cells	had	
completely	died)	prior	to	experiments.		
	
RNA	extraction	and	quantification	
Total	 RNA	 was	 extracted	 using	 an	 RNeasy	 mini	 kit	 (Qiagen)	 and	 DNase	 (Ambion	
AM1907)	treated.	500ng	of	RNA	was	used	for	cDNA	production	using	SuperScript	II	
Reverse	 Transcriptase	 (ThermoFisher)	 and	 random	 primers	 following	 the	
manufacturer’s	 instructions.	 mRNA	 expression	 levels	 were	 quantified	 using	
quantitative	 reverse	 transcription	PCR	 (qRT-PCR)	using	an	ABI	 7500	Real	 Time	PCR	
System	 (Applied	 Biosystems).	 SYBR	 green	 Fast	 PCR	 mastermix	 (Life	 Technologies)	
was	used.	CT	values	 for	 the	test	genes	were	normalized	against	 those	of	Gapdh	or	
B2M	 using	 the	 –ΔΔCt	 method	 to	 calculate	 fold	 change.	 See	 Table	 1	 for	 primer	
sequences.	 Data	 are	 shown	 as	 means	 +/-	 standard	 deviation	 with	 the	 number	 of	
replicates	stated	in	figure	legends.	
	
DNA	methylation	analysis	
DNA	was	harvested	using	a	DNeasy	Blood	&	Tissue	Kit	(Qiagen)	and	1µg	of	DNA	was	
used	 for	 bisulfite	 conversion	 using	 an	 EpiTect	 Bisulfite	 Kit	 (Qiagen)	 following	 the	
manufacturer’s	 protocol.	 4µl	 of	 converted	 DNA	 was	 then	 amplified	 through	 PCR	
using	 the	 primer	 pairs	 described	 in	 the	 supplementary	 primer	 table	 (Table	 1).	
Primers	were	designed	using	the	site:	http://urogene.org/methprimer/	and	the	PCR	
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products	were	cloned	using	the	TOPO	TA-Cloning	Kit	(Thermo	Fisher	Scientific)	and	
the	T7P	primer	was	used	to	sequence	the	products.	DNA	methylation	status	of	the	
TOPO	clones	was	measured	using	the	QUMA	online	tool	 (http://quma.cdb.riken.jp)	
by	the	Riken	Institute.	
	
GFP	reporter	assay	
The	HERVK14C	LTR	was	cloned	into	a	PGK-GFP	plasmid	in	place	of	the	PGK	promoter	
at	XhoI-BamHI	sites.	The	consensus	lysine	PBS	sequence	was	cloned	upstream	of	the	
LTR	 via	 an	 oligo-duplex	 strategy	 into	 the	 XhoI	 site	 while	 the	 Chromosome	 15	
HERVK14C	specific	lysine	PBS	was	cloned	into	the	backbone	through	a	PCR	strategy	
into	the	XhoI-BamHI	sites.	The	final	products	were	verified	via	sequencing.		
Cells	were	plated	at	a	concentration	of	105	cells/ml	in	24	well	plates.	After	6	hours,	
wells	 were	 transduced	 with	 VSV-pseudotyped	 GFP	 vectors	 at	 increasing	 doses	
(normalized	 between	 vectors	 by	 the	 number	 of	 transducing	 units,	 which	 were	
calculated	by	first	titering	vectors	on	kap1	knockout	293T	cells)	and	fresh	media	was	
replenished	after	24	hours.	After	a	further	48	hours,	the	cells	were	fixed	in	1%	PFA,	
washed	in	PBS	and	GFP	was	read	using	flow	cytometry.		
	
Intracellular	Oct4	staining	
1x106	 cells	 per	 condition	were	 fixed	 and	 permeabilized	 using	 intracellular	 staining	
buffers.	The	cells	were	then	stained	with	Oct4-PE	or	isotype	control	antibodies	(see	
Table	1),	washed	and	analyzed	by	flow	cytometry.	
	
Luciferase	reporter	assay	
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Luciferase	 assays	 were	 conducted	 according	 to	 the	 Promega	 dual-Luciferase	 kit	
instructions.	293T	cells	were	plated	6	hours	before	transfection	at	a	concentration	of	
105	 cells/ml	 in	24	well	plates.	 Following	 ratios	defined	before[14],	200	ng	of	KRAB	
ZNF	 plasmid	 DNA,	 20	 ng	 of	 Luciferase	 reporter	 plasmid	 DNA	 and	 2	 ng	 of	 pRT-
TK_Renilla	 control	 plasmid	 were	 co-transfected	 (10:1:0.1	 ratio)	 using	 1.5	 μl	 of	
Fugene	6	(Promega)	and	30	μl	of	Opti-MEM	(Gibco).	48	hours	post-transfection,	cells	
were	 lysed	 and	 luciferase	 was	 measured	 using	 the	 Dual	 Luciferase®	 assay	 kit	
(Promega,	 E1910)	 in	 an	 opti-plate	 using	 a	 Glomax	 96	 microplate	 Luminometer’s	
(Promega)	Dual	Glow	program.	The	Renilla-encoding	plasmid	was	used	as	an	internal	
control	 for	 transfection	 efficiency	 normalization.	 Firefly	 to	 Renilla	 ratio	 was	 then	
further	 normalized	 against	 the	 empty	 vector	 or	 negative	 control	 as	 repression	
readouts	and	expressed	in	percentages	where	the	control	is	set	to	100%.	
	
mRNA-sequencing	and	analysis	
Total	 RNA	 Samples	 were	 processed	 using	 Illuminas	 TruSeq	 Stranded	 mRNA	 LT	
sample	preparation	kit	(RS-122-2101)	according	to	manufacturer’s	instructions	with	
some	 deviations:	 Libraries	 to	 be	 multiplexed	 in	 the	 same	 run	 were	 pooled	 in	
equimolar	 quantities,	 calculated	 from	 Qubit	 and	 Bioanalyser	 fragment	 analysis.	
Samples	 were	 sequenced	 on	 a	 NextSeq	 500	 instrument	 (Illumina,	 San	 Diego,	 US)	
using	a	43bp	paired	end	run	resulting	in	>15million	reads	per	sample.	Run	data	were	
demultiplexed	 and	 converted	 to	 fastq	 files	 using	 Illumina’	 s	 bcl2fastq	 Conversion	
Software	v2.16.	Fastq	files	were	then	aligned	to	the	human	genome	NCBI	build	37.2	
using	Tophat	2.014	then	deduplicated	using	Picard	Tools	1.79.	Reads	per	transcript	
were	 counted	 using	 HTSeq	 and	 differential	 expression	 was	 estimated	 using	 the	
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BioConductor	package	DESeq2.	P-values	were	adjusted	for	multiple	testing	with	the	
Benjamini-Hochberg	 false-discovery-rate	 (FDR)	 procedure.	 Genes	 were	 considered	
up	or	downregulated	where	differential	affects	were	>	2	fold	and	where	adjusted	p	
values	were	<0.05.	 For	 analysis	 of	 repeats,	 TrimGalore	 v0.4.0	was	used	 to	 remove	
adaptors	and	trim	read	ends	using	default	parameters.	Reads	were	mapped	against	
the	RepBase	v20.06	human	library	using	Bowtie2v2.2.4.	The	samtools	v.1.19	idxstat	
utility	 was	 used	 to	 extract	 the	 number	 of	 mapped	 reads	 per	 repeat,	 that	 were	
inputted	 to	 DESeq2	 to	 identify	 differentially	 expressed	 repeats.	 P-values	 were	
adjusted	for	multiple	testing	with	the	Benjamini-Hochberg	false-discovery-rate	(FDR)	
procedure.	 Gene	 ontology	 analysis	 was	 conducted	 using	 the	 DAVID	 website:	
https://david-d.ncifcrf.gov/[49,	 50].	 Public	 mRNA-sequencing	 data	 was	 used	 to	
determine	 if	 KZNFs	 were	 expressed	 in	 different	 cell	 types	 (see	 data	 access	 for	
accession	numbers).	A	gene	was	considered	to	be	expressed	if	it	had	an	rpkm	value	
of	 >0.5.	 The	 top	 100	 KZNFs	 expressed	 in	 293T	 cells	 were	 determined	 by	 sorting	
mRNA-sequencing	data	on	rpkm	values.	
	
ChIP-sequencing	analysis	
Chromatin-immunoprecipitation-sequencing	 data	 for	 human	 ESCs	 and	 293T	 cells	
were	 downloaded	 from	 NCBI	 Gene	 Expression	 Omnibus	 (GEO)	 under	 accession	
numbers	GSE57989	 (HuESC)	 and	GSE27929	 (293T).	 TrimGalore	 v0.4.0	was	 used	 to	
remove	 adaptors	 and	 trim	 read	 ends,	 and	 reads	were	mapped	 against	 the	human	
genome	(hg19	assembly)	using	Bowtie2	v2.2.4.	Peaks	were	called	 in	each	replicate	
using	Macs2	v	 2.1.1,	 and	 the	 bioconductor	 package	 DiffBind	
(https://bioconductor.org/packages/DiffBind)	was	used	to	construct	Venn	diagrams	
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and	 identify	 overlapping	 ESC	 and	 293T	 peaks.	 Human	 repeat	 and	 gene	 locations	
were	downloaded	from	the	UCSC	browser	(RepeatMasker	and	RefGene	tables)	and	
the	 repeats	 and	 genes	 closest	 to	 the	 overlapping	 ESC/293T	 peaks	 were	 identified	
using	bedtools-2-17-0.	 Chip-sequencing	 correlations	were	 analysed	using	 the	Chip-
Cor	website:	http://ccg.vital-it.ch/chipseq/chip_cor.php.	
	
Statistical	analysis	
All	 data	 in	 the	 figures	 are	 presented	 as	 the	 standard	 deviation	 (where	 there	 are	
three	or	more	samples)	assessed	by	using	two	tailed,	unpaired	Student	t	tests	(see	
figure	legends	for	details).	A	P-value	of	<	0.05	was	considered	statistically	significant	
(***=p<0.001,	**=p<0.01	and	*=p<0.05).	
	
Ethics	statement	
Healthy	adult	blood	donors	provided	written	 informed	consent.	Culture	of	primary	
peripheral	 blood	 mononuclear	 cells	 from	 blood	 donors	 has	 been	 reviewed	 and	
granted	ethical	permission	by	the	National	Research	Ethics	Service	through	The	Joint	
UCL/UCLH	 Committees	 on	 the	 Ethics	 of	 Human	 Research	 (Committee	 Alpha)	 2	
December	2009;	reference	number	06/q0502/92.	
	
Data	access	
mRNA-sequencing	data	are	being	submitted	to	the	NCBI	Gene	Expression	Omnibus	
(GEO)	(http://www.ncbi.nlm.nih.gov/geo/)	database	and	other	data	are	 included	 in	
the	article	and	its	supplementary	information	files.	Accession	numbers	for	the	public	
data	are	as	follows:	293T:	GSE27929	(Chip-seq),	HuESC:	GSE57989	(Chip-seq),	293T:	
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GSE44267	 (mRNA-seq),	 HeLa:	 this	 study	 (mRNA-seq),	 Macrophages:	 GSE36952	
(mRNA-seq),	CD4+	T	cells:	GSE69549	(mRNA-seq),	HuESC	(mRNA-seq).	
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Figure	Legends	
Figure	 1.	HERVK14C	 is	 repressed	 by	 KAP1	 in	 undifferentiated	 and	 differentiated	
cells	
(A)	Schematic	diagram	showing	the	age	of	HERVK14C.	(B)	Chromosome	map	showing	
the	HERVK14C	loci	with	at	least	one	internal	open	reading	frame	and	long	terminal	
repeats.	 Note	 that	 many	 copies	 are	 present	 on	 the	 Y	 chromosome	 so	 are	 not	
relevant	in	female	cells.	(C)	Venn	diagram	showing	the	chromosome	copies	detected	
by	 the	 two	 primer	 sets.	 (D)	 qRT-PCR	 expression	 of	 endogenous	 repeats	 following	
shRNA-mediated	 KAP1	 depletion	 in	 NTERA-2	 cells.	 Results	 were	 normalized	 to	 β2	
microglobulin	(B2M).	KAP1	expression	levels	were	verified	by	qRT-PCR	and	Western	
blot.	A	representative	experiment	of	2	experiments	is	shown.	Two-tailed	unpaired	t	
tests	were	done	(HERVK14C_2	p-value	=	0.002300).	(E	and	F)	qRT-PCR	expression	of	
endogenous	repeats	following	KAP1	knockout	in	HeLa	(E)	and	293T	cells	(F).	Results	
were	normalized	to	β2	microglobulin	(B2M).	KAP1	expression	levels	were	verified	by	
qRT-PCR	and	Western	blot.	Two-tailed	unpaired	t	tests	were	done	and	p-values	are:	
(E)	 HERVK14C_1:	 0.0017,	 HERVK14C_2:	 0.0044,	 SVA	 D	 VNTR:	 0.0243	 (F)	
HERVK14C_2:	 <0.0001.	 Clones	 8,	 12	 and	 15	 (from	 E)	 were	 selected	 for	 mRNA-
sequencing.	
	
Figure	2.	A	common	role	for	KAP1	in	repressing	ERVs	and	ZNFs	
(A)	 Boxplots	 showing	 repeats	 significantly	 upregulated	 (>2	 fold	where	 p=<0.05)	 in	
knockout	compared	to	wildtype	HeLa	cells	based	on	mRNA-sequencing	data.	HERV-T	
and	 HERV-S	 but	 not	 HERVK14C	 also	 reached	 significance	 when	 only	 adjusted	 p-
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values	were	considered,	where	differences	are	compared	to	the	whole	of	 repbase.	
KAP1	binds	to	these	ERVs	(ENCODE	data)	and	binding	data	is	shown	in	Figure	S2a.	(B)	
Evolutionary	 tree	showing	 the	age	of	KAP1-repressed	HERVs	 identified	 in	A).	Here,	
HERV-K	refers	to	HERVK14C.	Estimated	ages	of	stated	lineages	are	given	and	marked	
with	a	star.	Myr:	million	years	(C)	The	38	upregulated	genes	identified	(>2	fold	where	
padj=<0.05)	 were	 converted	 to	 DAVID	 IDs	 and	 used	 for	 gene	 ontology	 analysis.	 3	
gene	 clusters	were	 significantly	 enriched	 (p-value	 =	 <0.05,	 drawn	on	 the	 plot	 as	 a	
dotted	line)	in	the	data	set:	zinc	finger	proteins	(p=2.2	x	10-7),	negative	regulators	of	
metabolic	processes	 (p=0.0036)	and	angiogenesis	 (p=0.011).	Venn	diagrams	on	the	
right	show	numbers	of	upregulated	genes,	ZNFs	and	KZNFs	and	the	overlap.	(D)	The	
nature	 of	 conserved	 KAP1	 binding	 sites	 between	 human	 ESCs[13]	 and	 293Ts	
(ENCODE)	(see	Figure	S3d)	is	shown	(left	pie	chart).	ERVs	are	enriched	compared	to	
their	relative	abundance	in	the	genome	(right	pie	chart).	(E)	The	614	KAP1	common	
binding	sites	(see	Figure	S3d)	were	interrogated	for	their	nearest	gene	and	this	gene	
list	was	converted	to	DAVID	IDs	and	used	for	gene	ontology	analysis.	4	gene	clusters	
were	significantly	enriched	(p-value	<0.05,	drawn	on	the	plot	as	a	dotted	line):	zinc	
finger	 proteins	 (p=1.1	 x	 10-19),	 fibronectin	 folding	 (p=0.016),	 protein	 phosphatase	
(p=0.033),	 and	 synapse	 (p=0.047).	 Venn	 diagrams	 on	 the	 right	 show	 numbers	 of	
KAP1-bound	loci,	ZNFs	and	KZNFs	and	the	overlap.	(F)	Comparison	of	the	distribution	
of	 KAP1-bound	 ERVs	 and	 LINE1	 elements	 between	 undifferentiated	 cells	 (human	
ESCs),	differentiated	cells	(293Ts)	and	KAP1	common	sites	(sites	conserved	between	
human	ESCs	and	293Ts).	
	
Figure	3.	KAP1	common	binding	sites	are	enriched	for	repressive	histone	marks	in	
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multiple	cell	types	and	overlap	KZNF	ERV	targets	
(A)	 Genomic	 coordinates	 of	 the	 common	 KAP1	 sites	 identified	 in	 Figure	 S3D	
(conserved	 between	 ESCs	 and	 293Ts)	 were	 subjected	 to	 ChIP-seq	 correlation	
analyses	using	ChIP-Cor	software	(see	methods).	Each	plot	shows	duplicate	ChIP-seq	
experiments	 from	 ENCODE.	 (B)	 	 The	 binding	 sites	 (where	 known[17,	 19])	 within	
repeats	and	genes	of	the	top	100	most	highly	expressed	(defined	by	RNAseq	rpkm)	
KZNFs	in	293T	cells.	These	KZNFs	were	also	confirmed	to	be	expressed	at	the	protein	
level	 (http://www.proteinatlas.org/cell).	 (C)	 The	 binding	 sites	 within	 repeats	 and	
genes	 of	 KAP1	 at	 common	 KAP1	 sites.	 (D)	 KZNFs	 within	 the	 top	 100	 most	 highly	
expressed	group	that	are	known	to	bind	ERVs	were	assessed	for	their	age	and	type	
of	ERV	that	they	bind	to.	
	
Figure	4.	KAP1	restricts	incoming	ERVs	through	the	primer	binding	site	sequence	
(A)	Schematic	diagram	showing	reporter	constructs	used.	The	18-bp	PBS	sequence	
was	 cloned	 upstream	 of	 the	 HERVK14C	 LTR	 promoter	 (which	 is	 identical	 in	 all	
vectors)	in	an	antisense	orientation.	(B)	NTERA-2	cells	were	transduced	with	either	
an	empty	 vector	 (WT)	or	 the	 same	vector	 containing	an	 shRNA	against	KAP1	 (KD)	
prior	to	puromycin	selection	and	transduction	with	increasing	doses	of	GFP	reporter	
vectors.	 GFP	 expression	 was	 analysed	 72	 hours	 post	 reporter	 transduction.	 A	
representative	experiment	of	2	experiments	is	shown.	Two-tailed	unpaired	t	test	p-
values:	PBS-LTR-GFP:	0.0148;	PBSChr15-LTR-GFP:	0.0377	(C)	The	same	as	(B)	except	
that	 here	 KAP1	wildtype	 (WT)	 and	 knockout	 (KO)	 293T	 cells	were	 used.	 P-values:	
PBS-LTR-GFP:	0.0044;	PBSChr15-LTR-GFP:	0.0077.	
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Figure	5.	PBS-dependent	de	novo	repression	of	ERVs	is	conserved	in	primary	cells	
	(A)	 qRT-PCR	 expression	 of	 endogenous	 repeats	 following	 shRNA-mediated	 KAP1	
depletion	in	PBMCs.	Results	were	normalized	to	β2	microglobulin	(B2M).	(B)	PBMCs	
were	 transduced	 with	 increasing	 doses	 of	 GFP	 reporter	 vectors	 (vectors	 were	
normalized	to	the	same	number	of	infectious	units	after	titering	them	on	permissive	
cells),	 left	plot.	PBS-repression	was	verified	 to	be	not	due	 to	 lack	of	 integration	as	
vectors	were	integrated	at	similar	relative	levels	as	measured	by	GFP	Taqman	qPCR,	
right	plot.	A	293T	cell	line	with	a	single	vector	copy	integrant	(PGK-GFP)	was	used	as	
a	control	to	estimate	the	absolute	copy	numbers.	A	representative	experiment	of	3	
experiments	 is	 shown	here.	Two-tailed	unpaired	 t	 test	p-value	0.0288	 (dose	3).	 (C)	
The	 expression	 of	 340	 KZNFs	 was	 assessed	 in	 multiple	 cell	 types	 using	 public	
mRNAsequencing	data	and	venn	diagrams	show	the	overlap	 in	expression	profiles.	
(D)	Western	 blots	 showing	 the	 protein	 expression	 levels	 of	 ZNF37A,	 ZNF33A,	 and	
ZNF320	in	HeLa	cells,	293T	cells,	and	NTERA-2	cells.		
	
Figure	 6.	 Cytosine	 methylation	 acts	 on	 KAP1-regulated	 retrotransposons	 and	
prevents	viral	mimicry	and	innate	immune	activation	
(A)	 qRT-PCR	 expression	 of	 endogenous	 repeats	 (left)	 and	 ISGs	 (right)	 following	
shRNA-mediated	KAP1	depletion	in	HeLa	cells.	n=2	and	two-tailed	unpaired	t	test	p-
values	are:	HERVK14C:	0.025,	0.003;	SVA	VNTR:	0.00027,	0.01;	 ISG56:	0.002;	CCL5:	
0.007,	0.00003;	CXCL10:	0.0008;	Mxa:	0.011;	IKba:	0.008,	0.01.	See	also	Figure	S5	for	
ISG	 expression	 in	 KAP1-depleted	 PBMCs.	 (B)	 qRT-PCR	 expression	 of	 endogenous	
repeats	(left)	and	ISGs	(right)	following	5-AZA	treatment	of	293T	cells,	HeLa	cells	and	
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PBMCs.	 A	 representative	 experiment	 of	 two	 is	 shown	 in	 each	 case.	 Two-tailed	
unpaired	t	tests	were	performed.	293T	cell	p-values:	HERVK14C:	0.018;	SVA	D	VNTR:	
0.005;	 CCL5:	 0.004;	 CXCL10:	 0.003;	Mxa:	 0.00006;	 IKba:	 0.007.	 HeLa	 cell	 p-values:	
ISG56:	 0.005;	 CCL5:	 0.0006;	 CXCL10:	 0.0007;	 Mxa:	 0.0001;	 IFNb:	 0.02.	 PBMC	 p-
values:	 HERVK14C:	 0.1;	 SVA	 D	 VNTR:	 0.003;	 ISG56:	 0.001;	 CCL5:	 0.012;	 CXCL10:	
0.012;	Mxa:	 0.02;	 IKba:	 0.08.	 Results	were	 normalized	 to	Gapdh	 and	 B2M	 (Gapdh	
results	shown).	
	
Figure	7:	Model	
KAP1	 controls	 ERVs	 and	 ZNFs	 in	 differentiated	 human	 cells.	 KAP1	 and	 SETDB1	
binding	are	detected	at	ERVs	and	ZNFs	 in	differentiated	cells	and	overlap	with	 the	
silent	chromatin	mark	H3K9me3	as	well	as	cytosine	methylation,	which	we	detect	at	
HERVK14C	and	SVAs.	The	KAP1-KZNF	pathway	is	functionally	intact	in	differentiated	
cells	 including	 PBMCs.	 5-AZA	 treatment	 leads	 to	 the	 inhibition	 of	 cytosine	
methylation	 at	 KAP1-regulated	 retrotransposons	 including	 ERVs,	 inducing	
reactivation	 of	 ERV	 and	 SVA	 transcription.	 These	 retrotransposons	 induce	 viral	
mimicry	because	they	can	produce	double	stranded	RNA,	and	ERVs	can	potentially	
also	produce	DNA	through	reverse	transcription.	Viral	mimicry	results	in	nucleic	acid	
sensing	 and	 induction	 of	 ISGs.	 KAP1	 depletion	 is	 not	 sufficient	 for	 global	 ISG	
induction	 suggesting	 it	 exerts	 partial	 redundancy	 at	 repressing	 ERVs	 with	 other	
epigenetic	regulators	in	differentiated	human	cells.	
	
Figure	S1.	Validation	of	cell	types	and	functional	validation	of	KAP1	knockout.	
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(A)	NTERA-2	and	293T	cells	were	stained	for	Oct4	intracellularly	and	were	subjected	
to	 flow	 cytometry	 analysis.	 A	 PE	 isotype	 control	 antibody	was	 used	 as	 a	 negative	
control.	 (B)	 KAP1	 knockout	 HeLa	 cells	 were	 validated	 using	 a	 known	 KAP1-KZFP	
target	 sequence[15,	 16]:	 Wildtype	 HeLa	 cells,	 KAP1	 knockout	 cells	 and	 KAP1	
reconstituted	 knockout	 cells	 (KAP1	 expression	 levels	 are	 shown	 by	Western	 blot)	
were	doubly	transduced	with	a	PBS-Pro-GFP	reporter	vector	(from	[12])	and	a	vector	
expressing	 either	 the	 cognate	 ZFP,	 Zfp809	 or	 a	 control	 ZFP,	 Zfp819.	 In	 MOCK	
controls,	 the	 ZFP-expression	 vectors	 were	 replaced	 with	 same	 volume	 of	 media.	
Two-tailed	 unpaired	 t	 test	 p-values	 are:	 HeLa	 wildtype:	 0.033;	 KAP1	 KO	 clone_1:	
0.3185;	KAP1	KO	clone_2:	0.0036.	(C)	KAP1	knockout	293T	cells	were	validated	using	
known	 KAP1-KZNF	 target	 sequences	 (constructs	 were	 a	 kind	 gift	 from	 David	
Haussler)	[14].	KAP1	wildtype	and	knockout	293T	cells	were	co-transfected	with	the	
luciferase	 reporter	 construct,	 a	 renilla	 control	 plasmid	 and	 constructs	 expressing	
either	ZNF91	or	ZNF93	 (see	methods).	Two-tailed	unpaired	 t	 test	p-values	are:	WT	
SVA_ZNF91:	 <0.0001;	 WT	 LINE1_ZNF93:	 0.0001;	 KO	 SVA_ZNF91:	 0.6008;	 KO	
LINE1_ZNF93:	0.0841.	(D)	DNA	methylation	analysis	of	endogenous	SVA	D	VNTRs	in	
293T	 cells.	 Primers	 were	 designed	 on	 a	 SVA	 D	 VNTR	 copy	 on	 chromosome	 7	 but	
primers	 recognize	 219	 copies	 of	 SVAs,	 some	 of	 which	 exhibit	 CpG	 deletions	 or	
mutations	(shown	by	“x”	on	the	CpG	map).	PCR	for	the	Oct4	gene	body	was	used	as	
a	positive	endogenous	control	for	cytosine	methylation.	
	
Figure	S2.	Examples	of	KAP1-regulated	repeat	elements.	
(A)	Examples	of	ERV	 loci	 that	are	bound	by	KAP1	and	potentially	act	as	 regulatory	
hubs	through	multiple	transcription	factor	interactions	as	revealed	by	ENCODE	data.	
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(B)	Repeats	significantly	downregulated	in	KAP1	knockout	HeLa	clones	compared	to	
control	cells	based	on	mRNA	sequencing	data.	
	
Figure	S3.	Cellular	genes	are	among	the	targets	of	KAP1	regulation.	
(A)	Examples	of	cellular	genes	upregulated	or	downregulated	upon	KAP1	knockout	in	
HeLa	cells	based	on	mRNA-sequencing	data.	BigWig	files	were	uploaded	to	the	UCSC	
genome	browser	as	URL	links	and	the	same	scale	applied	to	all	samples	(B)	The	top	
100	most	significantly	downregulated	genes	(>2	fold	with	a	padj	value	of	<0.05)	were	
converted	to	DAVID	IDs	and	used	for	gene	ontology	analysis.	All	shown	gene	clusters	
were	significantly	enriched	(p-values	=	<0.05)	in	the	data	set:	signal	peptide	(p=8.9	x	
10-19),	glycoprotein	(p=3.6	x	10-19),	cell	adhesion	(p=2.5x	10-10),	extracellular	matrix	
(p=1.6x	 10-8),	 EGF-like	 region	 (p=0.000004),	 wounding	 response	 (p=0.000006),	
plasma	 membrane	 (p=0.000029),	 cell-cell	 adhesion	 (p=0.000160),	 and	 innate	
immune	response	(p=0.000780).	(C)	Table	showing	that	all	upregulated	KZNFs	(from	
Figure	2c)	are	KAP1-bound	according	 to	ENCODE	data.	 (D)	Venn	diagrams	showing	
that	some	KAP1	binding	sites	are	common	between	human	ESCs	and	293T	cells.	614	
common	 binding	 sites	 were	 identified	 based	 on	 their	 presence	 in	 duplicate	 KAP1	
ChIP-sequencing	 experiments	 in	 human	 ESCs	 as	 well	 as	 in	 duplicate	 KAP1	 ChIP-
sequencing	experiments	in	293T	cells.	Data	are	from[13]	and	ENCODE	(293T	cells).	
	
Figure	S4.	A	role	for	KAP1	in	repression	of	ERVs	in	primary	cells	
(A)	Shows	an	independent	PBMC	experiment	with	a	different	donor	to	that	shown	in	
Figure	5a.	(B	and	C)	Primary	CD4+	T	cells	were	activated	and	transduced	with	KAP1	
knockdown	or	control	vectors.	Cells	were	harvested	at	different	time	points	for	(B)	
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Western	blot	and	(C)	qRT-PCR.	 (D	and	E)	DNA	methylation	status	of	the	HERVK14C	
LTR	region	on	Chromosome	15	in	CD4+	T	cells	(D)	and	KAP1	wildtype	and	knockout	
Hela	cells	(E)	as	tested	using	bisulphite	sequencing.	
	
Figure	S5.	KAP1	depletion	is	not	sufficient	for	global	ISG	induction	
(A	 and	 B)	 PBMCs	 depleted	 for	 KAP1	 as	 shown	 in	 Figure	 5a	 and	 Figure	 S4a	 were	
assessed	for	induction	of	ISGs	by	qRT-PCR.	(C)	A	repeat	independent	experiment	to	
that	shown	in	Figure	6a	is	shown	here.	Two-tailed	unpaired	t	tests	were	performed	
and	p-values	are:	L1PA4:	0.009,	0.003;	HERVK14C:	0.006,	0.004;	SVA	D	VNTR:	0.012;	
CCL5:	 0.005,	 0.007.	 (D)	 qRTPCR	 expression	 of	 endogenous	 repeats	 (left)	 and	 ISGs	
(right)	 following	 shRNA-mediated	 KAP1	 depletion	 or	 5-AZA	 treatment	 or	 a	
combination	 of	 both	 in	 293T	 cells,	 n=2.	 Two-tailed	 unpaired	 t	 test	 p-values	 are:	
HERVK14C:	0.00012,	0.0007;	SVA	VNTR:	0.0017;	ISG56:	0.0016,	0.02,	0.00097;	CCL5:	
0.0003,	0.00006;	CXCL10:	0.0001,	0.0007;	MxA:	0.005,	0.0009,	0.00034;	Ikba:	0.012,	
0.0077.	
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“Now,  here,  you see,  i t  takes a l l  the running you can 
do,  to keep in the same p lace.  I f  you want to get  
somewhere e lse,  you must  run at  least  tw ice as fast  as 
that !”  
	
―	Lewis	Carroll,	Alice	Through	the	Looking	Glass					
